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RNA interference (RNAi) is a powerful tool to knock down specific message RNA expression 
levels in cells by exploiting a natural intracellular regulatory phenomenon in mammalian species. 
Gene silencing using short interfering RNAs (siRNAs) has many potential therapeutic applications. 
Local or topical siRNA therapeutics have been most actively investigated.  
Osteoporosis is rapidly becoming a global healthcare crisis worldwide. Most osteoporotic 
fractures require surgical intervention, reduction and stabilization, and various fixation devices are 
used as implants to improve fracture healing, necessitating the development of new treatment 
options for this condition. After orthopedic fixation device implantation, large numbers of osteoclast 
precursors recruited into the peri-implant tissue can rapidly differentiate into osteoclasts which 
accelerate bone loss and cause aseptic loosening and finally prosthetic failure. Injectable bone 
cements are clinically used to improve mechanical properties to improve fixation as bone 
augmentation biomaterials in osteoporosis, with several FDA-approved calcium phosphate 
cements (CPC) products in clinical use. Compared to nondegradable polymethylmethacrylate 
bone cement, CPC has several unique properties for bone, including intrinsic osteoconductivity, 
osteoinductivity and acceptable biocompatibility. Significantly, calcium-based bone cements in 
bone augmentation use provide a potential depot for local drug delivery directly to bone sites in 
osteoporosis. 
 iv 
The objective of this dissertation research was to investigate a new strategy to deliver siRNA 
locally to bone to inhibit osteoclast formation and function in improving osteoporotic bone healing. 
Our initial siRNA delivery data showed successful use of siRNA against receptor activator of 
nuclear factor-kappa B (RANK) and farnesyl pyrophosphate synthase (FPPS), resulting in 
knockdown of RANK in both osteoclast precursor and osteoclast cultures and knockdown of FPPS 
in both osteoclasts and osteoblasts, supporting a proof-of-concept to deliver siRNA to bone. In 
order to deliver siRNA to osteoclasts locally, resorbable poly(lactic-co-glycolic acid) (PLGA) 
microparticles were utilized as protective carriers. Cell-specific phagocytosis was achieved by 
PLGA particle size-cell phagocyte discrimination and selective uptake by bone phagocytes. 
PLGA-siRNA particles were dispersed equally into clinical-grade injectable CPC to serve as the 
delivery carrier and facilitate further active and passive in vivo degradation of cement and 
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RNA THERAPEUTICS TARGETING OSTEOCLAST-MEDIATED  
EXCESSIVE BONE RESORPTION 
Abstract 
 This chapter describes the diversity of molecular targets suitable for RNA interference 
(RNAi)-based gene knockdown in osteoclasts to control osteoclast-mediated excessive bone 
resorption. We identify strategies for developing targeted short interfering RNA (siRNA) delivery 
and efficient gene silencing, and describe opportunities and challenges of introducing siRNA as a 
therapeutic approach to hard and connective tissue disorders.  
Introduction 
 Current treatments for osteoporosis can be divided into two categories: antiresorptive 
modulators and anabolic therapies. Estrogen, estrogen receptor modulators, calcitonin and 
bisphosphonates fall into the first category. Only one anabolic agent—teriparatide—is clinically 
approved, administrated by daily injection.1 The limited number of options in antiresorptive therapy 
reflects inadequate efficacy, severe side effects, high dosing frequency or low patient 
compliance:1-6 estrogen treatment exhibits known side effects on breast and uterus inappropriate 
for long-term use; long-term calcitonin treatment can induce tolerance since more than half of the 
patients produce circulating antibodies to calcitonin.7 Bisphosphonates, the most common current 
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osteoporosis treatment, exhibit general side effects including gastrointestinal irritation, bone/joint 
pain and jaw osteonecrosis.8-10 The latter two adverse effects can persist and even spread to new 
areas of unaffected bone after bisphosphonate therapy is discontinued. Because of 
bisphosphonate’s long half-life, e.g., alendronate’s half-life in bone is 10.9 years,11 drug can 
remain active in bone for long periods after drug therapy is discontinued. Severe suppression of 
bone turnover has also been noted.12, 13 Long-term bisphosphonate therapy increases fracture risk, 
including atypical fractures first reported in 2005.14, 15 Recently, oral bisphosphonates were 
associated with 23 cases of esophageal cancer.16 Therefore, maximum treatment duration for 
bisphosphonates is suggested to be 5 years.17 Bisphosphonates are consequently 
counter-indicated in the context of fragility fracture healing. This enduring drug bioactivity presents 
substantial challenges for treatment of osteoporosis. Moreover, clinical studies of systemic 
bisphosphonate administration in combination with implants for 6 months or 2 years showed 
significant bone loss in the peri-implant area within 3 months postoperation.18, 19 Similarly, in total 
hip arthroplasty, up to 14% bone loss was reported during the first 3 months postsurgery.20  
 Human clinical experience indicates that improved therapeutic strategies are needed in the 
context of osteoclastic bone resorption therapies. In 2010, denosumab (ProliaTM, Amgen), a fully 
humanized monoclonal antibody targeting receptor activator of nuclear factor-kappa B ligand 
(RANKL), was approved by the FDA as a twice-yearly subcutaneous injection for treating 
postmenopausal osteoporosis. This antibody therapeutic appears well-tolerated and superior to 
the common bisphosphonate drug, aldendronate, in preserving bone mineral density in several 
clinical trials to date.21, 22 Additional new therapeutics are actively under investigation to meet the 
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requirements of this fast-growing patient population worldwide. 
RNA interference and siRNA delivery as a new therapeutic approach 
 RNA interference (RNAi) is a sequence-specific posttranscriptional gene silencing tool.23 The 
process of gene-specific silencing through destruction of its message RNA transcript can be 
triggered by endogenous or exogenous small interfering RNAs (siRNAs).24 Long double-stranded 
mRNAs derived from endogenous gene transcription or transfected transgene plasmids present in 
the cytoplasm can trigger the cleavage activity of the intracellular enzyme, Dicer, to cut mRNA into 
19-nucleotide pairs with two nucleotide overhangs at both 3’-ends, called small interfering RNA 
(siRNA).25 These double-stranded siRNA pieces then incorporate into RNA-induced silencing 
complexes (RISCs) which have a catalytic core comprising Argonaute (Ago) family proteins.26, 27 
Ago-2 then cleaves and removes the siRNA sense strand and thereafter RISC becomes activated 
with the remaining antisense siRNA strand. The antisense siRNA strand guides RISC activity in 
the cytoplasm to cleave its targeted complementary mRNA molecules, resulting in down-regulation 
of the targeted gene and corresponding protein expression. First introduced in 2001, RNAi has 
been exploited for its highly specific mechanism of mRNA transcript targeting, and as a target 
screening and validation tool for cell signaling studies of many types. RNAi is used for 
investigating and elucidating mammalian gene function as an alternative to knockout techniques. 
Specifically, siRNA also shows great potential for future targeted therapeutics for gene-associated 
diseases. Gene silencing using siRNA has several advantages intrinsic to RNAi, such as its high 
specificity, intrinsic biological response 28 and more efficient and specific silencing effects with 
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lower dosing requirements, compared to antisense-based gene silencing.29  
 However, as polyanions, synthetic or in situ transcribed siRNAs do not readily or reliably enter 
mammalian cells. The main challenge in developing siRNA therapies, like other nucleic acid 
therapeutics, is to deliver them specifically into targeted tissues or cells. Viral and nonviral vectors 
have been employed to address siRNA cell transfection inefficiency, and nonviral delivery is 
typically achieved by cationic lipoplexing reagents.24, 30 Viral vector-based delivery is consistently 
associated with vector-based short hairpin RNA (shRNA) production systems, a DNA-based 
strategy to encode and obtain host-synthesized shRNAs in situ. These shRNAs can be further 
intracellularly processed into siRNA by Dicer. Both methods have their advantages and 
disadvantages. Nonviral delivery uses siRNA directly to generate potent silencing effects; 
therefore, it is simple and controllable. However, single-dose siRNA silencing effects are transient 
(up to 5 days in dividing cells),24 and lipid-based siRNA delivery complexes can be removed from 
circulation by the liver rapidly, and lack tissue/cell specificity. The viral vector-based shRNA 
strategy has the potential of being able to provide stable, enduring gene silencing. Gene therapy 
can in principle continuously generate siRNA. The major bottleneck of the viral vector is its 
well-known safety issues.24 Nevertheless, while nonviral delivery avoids the pitfalls of viral vector 
delivery, including high viral toxicity, possible carcinogenicity, proven immunogenicity and 
significant cost limitations,31 it is extremely inefficient in targeting, transfection and expression. 
Because of the substantial challenges with reliable systemic siRNA delivery and targeting, almost 
all current clinical foci for siRNA-based therapeutics are based on local or topical siRNA 
therapeutics. Successful siRNA delivery approaches currently include ocular, respiratory, central 
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nervous system, dermal and vaginal delivery where local dosing accesses target cell populations 
directly.32-36 One largely unexplored delivery route is via implantable combination devices 
facilitating local siRNA delivery directly from medical implants to adjacent tissue sites.37 
RNAi applications in new osteoporosis therapies 
 As a nucleic acid therapeutic precedent, DNA-based gene therapy has developed rapidly for 
musculoskeletal applications in the last two decades. The therapeutic approach has been 
introduced to various disease categories: osteogenesis imperfecta,38 lysosomal storage 
disorders,39 rheumatoid arthritis,40, 41 osteoarthritis,42 and osteoporosis.43-45 Specific to 
osteoporosis, gene transfer strategies deliver genetic material, either using intravenous injection of 
viral vectors carrying osteoprotegerin (OPG) cDNA44, 45 or local injection of interleukin-1 receptor 
antagonist cDNA-transduced cells.43 Due to desirable short-term transgene expression without the 
need to closely regulate transgene expression, DNA-based gene therapy has recently produced 
progress in musculoskeletal tissue healing. In a rat critical size defect model in femurs, BMP-2 
cDNA-transduced cells seeded into collagenous scaffolds showed better healing compared with 
use of recombinant BMP-2 protein directly.46 The feasibility of intralesional injection of viruses 
carrying cDNA encoding osteoinductive genes has been demonstrated in both rabbit and rat 
segmental defect models.47, 48 Gene transfer strategies have been developed for many 
applications for musculoskeletal healing, such as spine fusion, articular cartilage and meniscus, 
intervertebral disc, ligament and tendon.49 DNA-based transgene therapies continue to 
demonstrate the potential for treating musculoskeletal diseases, providing a solid foundation for 
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developing siRNA-based approaches in this field. 
 Applications of RNAi to musculoskeletal therapies can target a large and increasing number 
of signaling cascades in several tissue types, primarily bone and cartilage. In addition, RNAi can 
be utilized in several therapeutic categories: inflammation, degeneration and regeneration. RNAi 
use in the context of treating rheumatoid arthritis has been actively investigated to date.50 
Osteoporosis is less studied but represents a particularly interesting application for RNAi 
therapeutics, targeting a diverse number of possible pathways achieved by local delivery to 
fragility sites via bone augmentation strategies. Instead of complete gene knockout, both 
site-specific and temporally selective control over cellular signaling activity are perhaps more 
appealing for developing new osteoporosis therapies. FDA-approved denosumab demonstrates 
precedent success in this regard. The transient efficacy of siRNA means it can be turned off and 
on, facilitating this transient programmed benefit. Notably, siRNAs have new targets distinct from 
other drug classes, with their own unique characteristics: they interrupt intrinsic cellular pathways 
with high targeting specificity.   
Osteoclastogenesis and osteoclastic bone resorption 
 Normal bone is constantly replaced by resorption of old bone by osteoclasts and deposition of 
new bone by osteoblasts. Continuous bone turnover results in the adult human skeleton being 
completely replaced every 10 years.51 This balance of bone turnover is tightly regulated in healthy 
individuals. Osteoclasts residing at or near the bone surface are multinucleated phagocytic cells 
formed by the fusion of monocyte macrophage precursor cells.52 They are responsible for 
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resorbing bone, working together with osteoblasts (bone producing cells) and playing a central role 
in normal bone remodeling. Two cytokines – nuclear factor kappa B (NF-κB) RANK ligand (RANKL, 
also called TRANCE/OPGL/ODF) and macrophage colony-stimulating factor (M-CSF) 53, 54 – are 
essential to this process.55-57 Previously published evidence shows that osteoclast formation can 
be stimulated in vitro using cocultures of bone marrow cells and stromal cells/osteoblasts 
expressing those two cytokines.58-60 M-CSF interacting with its c-fms receptor provides signals 
necessary for precursor cell survival and proliferation by receptor binding on early osteoclast 
precursor cells.61 RANKL is the key cytokine for promoting osteoclastogenesis. Interactions 
between soluble RANKL and RANK receptor on the surface of osteoclast precursors are essential 
for expression of osteoclast-specific genes,62 bone resorption and survival of mature osteoclasts.63 
Furthermore, osteoclastogenesis is negatively regulated by OPG (or osteoclastogenesis inhibitory 
factor, OCIF), also expressed by stromal cells and osteoblasts.64 OPG is a decoy receptor that 
competes with RANK for binding RANKL.65 Osteoclast production can be blocked by 
over-expression of OPG, resulting in osteopetrosis in mice.64, 66 In this RANKL/RANK/OPG 
regulatory axis, positive regulator RANKL and negative regulator OPG are coordinated through 
interaction with RANK to regulate normal bone formation and degradation.  
 RANK is therefore a central factor in this bone metabolic regulatory pathway. It is central to 
much of the osteoclast functional phenotype and to bone metabolic balance. Therefore, RANK 
was chosen as the knockdown target to suppress osteoclast-mediated bone resorption.67 
Selective knockdown of RANK in mouse bone marrow cells can significantly block formation of 
Tartrate Resistant Acid Phosphatase (TRAP)-positive cells with RANKL and M-CSF in vitro. 
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Cell-cell fusion can be inhibited in RANK siRNA-transfected osteoclasts, consistent with the fact 
that RANKL stimulation is critical for cell fusion to osteoclasts.68 Successful transfections have 
been seen in mature osteoclasts, and osteoclast-mediated bone resorption was dramatically 
inhibited by RANK siRNA using the pit formation assay in vitro.67  
 Activation of RANK by RANKL not only induces osteoclast differentiation and survival, but 
also leads to activation of bone resorption by mature osteoclasts. Once activated, differentiated 
osteoclasts move to the target matrix and attach to the bone surface. After attachment, an isolated 
extracellular microenvironment, called the sealing zone, formed between the interface of the 
underlying bone with osteoclast membranes, is actively generated by osteoclasts.69 Osteoclasts 
polarize themselves to form a ruffled membrane adjacent to the bone surface which is their 
resorptive organelle in the sealing zone. Osteoclasts then acidify and dissolve the underlying bone 
matrix by pumping hydrogen ions mediated by a vacuolar H+-adenosine triphosphatase 
(H+-ATPase) through the ruffled membrane into the sealing zone. Osteoclast intracellular pH is 
maintained by HCO3-/Cl- exchange across cell surfaces other than the ruffled membrane area.70 
These ion transporting events result in an acidic pH of ~4.5 only within the resorptive 
microenvironment.71 The mineral phase of bone is first digested under this acidic milieu, followed 
by degradation of the collagen-rich demineralized organic component of bone by released 
hydrolytic enzymes.72 Bone matrix degradation proteins are taken up by osteoclasts through the 
ruffled membrane from the resorption lacuna and released through the basolateral membrane into 
the extracellular space.73 After local bone resorption is complete at this site, osteoclasts detach 
from the bone matrix and migrate to a new site to begin the next functional cycle. Because of this 
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central role in bone processing, osteoclasts are naturally a major target for most studies seeking to 
suppress bone resorption. In this review, siRNA targets for osteoporosis are sorted into three 
categories: osteoclastogenesis, osteoclastic bone resorption activity and osteoclast survival, 
including other potential associated targets identified to date. In addition, progress in developing 
efficient target silencing, delivery issues and emerging opportunities and challenges to exploit 
siRNA for therapeutic purposes are discussed. 
Targets for siRNA in Osteoporosis and Bone Metabolism 
Osteoclastogenesis 
 Transcription factors essential for osteoclastogenesis, including NF-κB downstream of 
RANK,74 mediate osteoclast differentiation and inflammatory osteolysis.75 Osteoclast 
differentiation failure is reported to be caused by mutant NF-κB in mice.76 Its upstream regulator, 
IκB kinase (IKK) complex, contains IKKα and IKKβ as catalytic subunits and IKKγ as a regulatory 
subunit.77, 78 IKKα and IKKβ are required for normal bone homeostasis. IKKβ is essential for 
osteoclastogenesis and osteoclast survival since deletion of IKKβ impairs osteoclast differentiation 
in vitro and in vivo.79, 80 IKK alpha(-/-) mice did not show overall skeletal defects, but IKK alpha(-/-) 
hematopoietic cells failed to differentiate into multinucleated osteoclasts.81 Nonetheless, the role of 
IKKγ is unclear. Recently, transient transfection of siRNA to inhibit IKKγ in bone marrow-derived 
osteoclast precursors was reported using a retroviral delivery approach.82 When IKKγ was 
knocked down, formation of multinucleated osteoclasts was reduced 83% compared with controls. 
In addition, the role of IKKγ was confirmed through observation that RANKL-induced osteolysis 
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was impeded by preventing oligomerization of IKKγ monomers using peptides in mice.82 The study 
suggested that IKKγ is essential for osteoclastogenesis, and thus, all three IKK subunits could be 
potential targets for inhibiting osteoclastogenesis and osteolysis using siRNA. 
 Interactions between RANKL and RANK are essential for osteoclastogenesis. RANK has 
three TNF receptor-associated factor 6 (TRAF6) binding sites and recruits TRAF6 to activate the 
transcription factors NF-κB and activator protein-1 (AP-1).83, 84 Nuclear factor of activated T cells 
(NFATc1) has been demonstrated as the transcription factor most strongly induced by NF-κB 
activation.85 NFATc1 is also known to be important in immune response and also play an essential 
role in osteoclastogenesis.85, 86 Therefore, siRNA targeting NFATc1 in both RAW264.7 cells and 
RAW-induced osteoclasts under LPS stimulation was examined.87 Specific knockdown of NFATc1 
led to reduced formation of mature osteoclasts and significantly decreased osteoclast-specific 
gene expression, including TRAP and cathepsin K, both responsible for effective osteoclastic bone 
resorption. 
 Once RANK is activated by its ligand, several signaling cascades are induced during 
osteoclast formation or activation, resulting in activation of several transcription factors mediated 
by protein kinases,88 such as c-Fos, NF-κB, c-Jun, and NFATc1.84 Transcription factor c-Jun has 
recently shown its essential role in osteoclastogenesis.89 Interaction between RANK and RANKL 
can stimulate JNK and activate c-Jun which complexes with c-Fos downstream to form AP-1.84 
Moreover, c-Jun was reported to regulate osteoclastogenic activities of NFATc-1: 
dominant-negative c-Jun transgenic mice were unable to form osteoclasts due to arrested 
activation and expression of the NFAT family proteins.90 Recently, using a proteomic approach, a 
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member of a family of growth regulatory genes, schlafen2 (Slfn2), was found to be highly induced 
by RANKL activation and capable of regulating c-Jun activation.91 Using RNA silencing technology, 
knockdown of Slfn2 resulted in significantly reduced expression of c-Jun and NFATc1 and 50% 
less TRAP-positive multinucleated cells compared with control. Furthermore, over-expression of 
Slfn2 enhanced c-Jun phosphorylation. Slfn2 therefore functions downstream of RANK/RANKL 
signaling and upstream of c-Jun and NFATc1 in osteoclastogenic regulation. 
 Dendritic cell-specific transmembrane protein (DC-STAMP), a seven subunit-transmembrane 
protein originally found in dendritic cells 92 is highly expressed in osteoclasts but not in 
macrophages.93 Expression levels of DC-STAMP can be rapidly up-regulated under 
RANKL-mediated osteoclastogenesis in osteoclast precursors.94 Using siRNA to specifically knock 
down its expression in RAW-D cells completely abrogated the formation of multinucleated 
osteoclast-like cells stimulated with RANKL and TNF-α in vitro.94 Consistent with this, 
osteoclastogenesis can also be enhanced by over-expression of DC-STAMP and  vice versa.94 In 
addition, DC-STAMP has been further proven essential for both osteoclast and foreign body giant 
cell fusion.93 No multinuclear osteoclasts were observed in bone sections from 
DC-STAMP-deficient mice, and their mononuclear cells were unable to differentiate to multinuclear 
osteoclasts under stimulation with RANKL and M-CSF in vitro, remaining mononuclear, 
TRAP-positive cells.93 These cells are able to resorb bone, but with much lower efficiency, 
exhibiting the pathogenesis of moderate osteopetrosis.93 Consistent with these results, bone 
mineral density and bone volume per tissue volume in DC-STAMP-/- mice increased compared 




 A novel gene bearing significant similarity to the DC-STAMP family, called osteoclast 
stimulatory transmembrane protein (OC-STAMP), was identified in both primary bone marrow cells 
and RAW264.7 cells in 2007.95 It is strongly up-regulated in response to RANKL stimulation as a 
multiple transmembrane protein in osteoclasts. Blocking OC-STAMP expression by either RNA 
interference or OC-STAMP antibodies showed similar results as blocked DC-STAMP: 
mononuclear, TRAP-positive cells.95 The results suggest that both DC-STAMP and OC-STAMP 
are responsible for cell fusion and each of them can not compensate for the other since 
knockdown of only one of them impaired osteoclast multinucleation. 
 A study aimed at protecting biomaterials by inhibiting macrophage fusion at implant sites 
showed that using siRNA targeting Rac1 can limit fusion without limiting phagocytosis.96 As the 
study attempted to find the fusion target shared by foreign body giant cells formed by monocyte 
fusion and also by osteoclasts, osteoclast formation theoretically should be inhibited as well. 
Further study is required to confirm the effect of Rac1 silencing on monocyte fusion to osteoclasts. 
 A membrane glycoprotein, CD9, one of the tetraspanins, has been reported to play an 
important role in cell fusion during osteoclastogenesis.97 CD9 has been reported to be involved in 
cell-cell fusion and cell motility in different cells.98, 99 In RAW264.7 cells, CD9 locates to the cell 
membrane and its expression is up-regulated by RANKL stimulation.97 Targeted inhibition of CD9 
using siRNA is able to significantly inhibit the formation of RAW264.7 differentiated osteoclasts by 
inhibiting cell fusion in cultures. Over-expression of CD9, interestingly, can promote cell fusion in 
RAW264.7 cultures without RANKL stimulation, but fused cells are TRAP-negative. In the same 
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study, CD9 is confirmed to be expressed in osteoclasts in vivo by immunohistochemical analysis of 
tissue sections from mouse femoral bone. 
 During the osteoclastogenesis cell-cell fusion process, sialic acid which is involved in a 
number of biologic responses, was hypothesized to play a role in this process.100 Takahata et al.101 
found that alpha (2,6)-linked-sialic acid degraded during osteoclast differentiation and desialylated 
cells only could form mononuclear TRAP+ cells with normal expression of osteoclast markers. 
Using siRNA to knock down alpha (2,6)-sialyltransferase produced significant inhibition of 
osteoclast multinucleation, which suggests a role for alpha (2,6)-linked-sialic acid in cell-cell fusion 
processes during osteoclastogenesis.  
 A novel gene, nha-oc/NHA2 is significantly upregulated in RANKL-stimulated osteoclast 
precursors.102 As the murine orthologue of the human gene HsNHA2,103 encoding a cation-proton 
antiporter (CPA) localized on the mitochondria, it is proposed to regulate proton concentration in 
osteoclast mitochondria. NHA-oc/NHA2 selectively expressed in differentiated osteoclasts 
regulates Na+-dependent mitochondrial pH changes and mitochondrial passive swelling. 
Importantly, nha-oc/NHA2 siRNA inhibits TRAP-positive multinucleated cell formation and 
resorption activity under RANKL stimulation. This reduction partially resulted from apoptosis 
induced from the loss of inhibition of caspase-9 activation by NHA-oc/NHA2. Therefore, 
NHA-oc/NHA2 is integrally involved in osteoclast formation, resorption and survival. 
 Ovarian cancer G-protein-coupled receptor 1 (OGR1) is a histidine-enriched proton-sensor. 
The OGR1 gene was found to be 7-fold up-regulated in the long bone of CSF-1-null osteopetrotic 
rats after CSF-1 injections compared to untreated mutants.104 Expression of OGR1 can also be 
14 
 
induced in RAW264.7 cells under RANKL stimulation during osteoclast differentiation. Specifically 
knocking down OGR1 expression by siRNA (>1µg/ml) produced almost 50% inhibition of 
osteoclast formation in both mouse bone marrow mononuclear and RAW264.7 cells without 
significant cell death. Concomitant with confirming OGR1’s role in regulating osteoclastogenesis, 
the expression and function of the regulators of G-protein signaling (RGS) proteins of 
osteoclastogenic RANKL signaling cascades were investigated. RGS proteins have been 
suggested to physiologically regulate G-protein cycles and G-protein signaling in hematopoietic 
cells.105, 106 In this protein family, RGS18, specifically expressed in hematopoietic cells, showed 
consistent decreases in mRNA expression levels during RANKL stimulated osteoclastogenesis.107, 
108
 Target-specific knockdown of RGS18 in RAW264.7 cells using siRNA resulted in enhanced 
osteoclast formation under RANKL induction. Additionally, antibodies against OGR1 with Zn2+ ion 
addition (antagonist of OGR1)109 significantly reversed the effects of RGS18 siRNA. These 
observations suggest that the ability of RGS18 to suppress osteoclastogenesis depends on the 
OGR1 signaling pathway and inhibition of OGR1-mediated cell signaling.108 
 Another RGS member, RGS12, is reported to be significantly upregulated after RANKL 
stimulation, with its expression being dose-dependent on RANKL.110 Using vector-based RNAi 
technology, stable RGS12-silenced RAW264.7 cells showed 18.7 times lower numbers of 
TRAP-positive multinucleated cells under RANKL stimulation compared with control groups. The 
mechanism of completely blocking osteoclast differentiation was suggested to lie in regulation of 
intracellular Ca2+ oscillations in the NFAT2 pathway during differentiation. Such Ca2+ oscillations 
can be completely blocked and the expression of NFAT2 simultaneously significantly inhibited in 
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RGS12-silenced cells.110   
 Triggering receptor expressed in myeloid cells-1 (TREM2) is produced in myeloid cells in 
bone marrow, and locates to these cell surfaces. Interactions between TREM2 and DAP12 
produced from the TYROBP gene transmit signals to activate the cells. Osteoclast precursor cells 
harvested from DAP12-/- mice only form mononuclear TRAP-positive cells under stimulation with 
RANKL and M-CSF. These cells exhibit only 50% ability to resorb bone compared with wildtype 
cells.111 siRNA against TREM2-transfected RAW264.7 cells largely reduces numbers of 
TRAP-positive cells, and most were small (<10 nuclei) or mononucleated cells. Thus, 
TREM2/DAP12 signaling plays an important role in osteoclast differentiation under RANKL 
stimulation.112 The same study blocked TREM2 in murine primary cell-induced osteoclasts using 
antibodies and showed decreased bone resorption, providing evidence that the TREM2/DAP12 
signal also regulates osteoclast function. 
 Extended space flight can cause severe bone loss in astronauts due to microgravity. 
Compared with normal gravity, microgravity can accelerate osteoclastogenesis about 2-fold.113 
Gene expression profiling of RAW264.7 cells under microgravity conditions has shown increased 
expression of the calcium-binding protein A8/calgranulin A (S100A8). siRNA knockdown of 
S100A8 in RAW264.7 cells significantly suppressed osteoclastogenesis under microgravity 
conditions. S100A8 can be a therapeutic target to prevent bone loss during extended space flights.  
 Retinoblastoma protein-interacting zinc finger 1 (RIZ1) protein also participates in 
RANKL-induced osteoclastogenesis,114 binding with both retinoblastoma protein and estrogen 
receptors and reportedly involved in osteosarcoma.115-117 RIZ1 expression increases under RANKL 
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induction at 24 hours, and RIZ1 siRNA-transfected RAW264.7 cells showed significantly inhibited 
NFATc1 activation 3 days post-RANKL and M-CSF treatment, but with no significant influence on 
TRAF6 expression. Thus, RIZ1 is suggested to positively regulate NFAT-1 activity at the last 
stages of osteoclastogenesis. RAW264.7 cells with reduced RIZ1 expression exhibited 
substantially reduced ability to form TRAP-positive multinucleated osteoclast-like cells under 
RANKL and M-CSF stimulation. Recently, c-Abl SH3 domain-binding protein-2 (3BP2) has been 
recognized as a key regulator of RANKL-induced osteoclastogenesis.118 3BP2 regulates several 
immunoreceptor signaling pathways in immune cells, such as T, B, and NK cells, and was reported 
to promote activation of NFAT in T and B cells.119-123 Knockdown of 3BP2 in RAW264.7 cells 
decreased expression of NFATc1 and completely suppressed RANKL-induced TRAP-positive 
multinucleate cell formation.118 
 The family of disintegrin and metalloproteinases (ADAM) peptides are cell surface proteins 
involved in cell adhesion and cell fusion.124 ADAM8 is a transmembrane glycoprotein expressed in 
monocytes and significantly up-regulated during osteoclastogenesis.125, 126 Recently, ADAM8 has 
been shown to promote osteoclastogenesis whereby vitamin 1,25-(OH)D3-stimulated osteoclast 
formation was inhibited by ADAM8 antisense treatment.126 Its direct effect on osteoclastogenesis 
was also investigated using siRNA.127 Silencing ADAM8 in RAW264.7 cells decreased osteoclast 
formation and cell size compared with controls, and modestly decreased osteoclast marker mRNA 
levels when stimulated with RANKL. In contrast, transfection of ADAM8 into RAW264.7 cultures 
increased osteoclast marker mRNA expression levels and increased the number of TRAP-positive 
cells. The study also showed that ADAM8 was highly expressed in rheumatoid arthritis (RA) 
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pannus macrophages and multinucleated cells adjacent to eroded cartilage. Therefore, ADAM8 
was a recommended target for suppressing RA progression by preventing osteoclast formation.  
 Epidermal growth factor receptor (EGFR) has been the focus of increasing attention in 
osteoclastic bone resorption, shown to promote bone resorption in vitro.128 Its inhibition in vitro 
resulted in suppression of bone marrow stromal cell induced osteoclast differentiation.129 Yi et 
al.130 investigated EGFR function in osteoclast formation and survival, and found that EGFR 
expression was highly up-regulated by RANKL. Knockdown of EGFR in bone marrow monocytes 
using lentivirus expressing shRNA completely suppressed osteoclastogenesis with RANKL and 
M-CSF. In addition, EGFR siRNA blocked NFATc1 expression completely under RANKL 
stimulation. This study also showed that EGFR co-immunoprecipitated with RANK and Gab2 
which mediates the RANK signaling cascade. These data imply that EGFR may couple with RANK 
via the signaling mediator Gab2 to regulate RANK-stimulated downstream pathways, playing an 
important role in osteoclastogenesis. 
 Multinucleated osteoclasts are formed by fusion of monocyte macrophages. Therefore, the 
role of integrins important for trafficking monocytes in osteoclastogenesis has been assessed 
using siRNA. Only two integrin pairs are found on pre-osteoclast monocytes: CD11a/CD18 (LFA-1), 
and CD11b/CD18 (Mac-1) which is considered the premier marker of pre-osteoclasts.131, 132 
Antibodies against CD11b and CD18 to block Mac-1 both in RAW264.7 and primary cell culture 
can significantly inhibit osteoclastogenesis, but not antibodies against CD11a.133 Specific 
knockdown of CD11b using siRNA in RAW264.7 cells, yielding a 50% decrease in CD11b 
expression, resulted in ~50% reduction in osteoclast area. This inhibition was suggested to occur 
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in the early stages of cell differentiation since it was accompanied by a 3-fold increase in the 
mRNA expression level of NFATc1, a major regulator of osteoclastogenesis.133 Taken together, 
integrin Mac-1 is suggested to play an important role in early stage osteoclast differentiation via 
pre-osteoclast cell-cell interactions.  
 A new member of the TNF family that induces cell apoptosis, called TNF-related 
apoptosis-inducing ligand (TRAIL), shares a 25% amino acid homology with RANKL134 and is 
reported to inhibit osteoclastogenesis in both human peripheral blood mononuclear cells (PBMC) 
and RAW264.7 cells, possibly by inhibiting the p38/MAPK pathway.135 It is also involved in human 
osteoclast apoptosis.136 More recently, TRAIL has been found to inhibit the accumulation of 
RANKL-dependent p27Kip1 in PBMC.137 p27Kip1 is a cyclin-dependent kinase inhibitor shown to be 
progressively upregulated to play an important role in mediating RANKL-induced murine 
osteoclastogenesis.138, 139 Addition of TRAIL into pre-osteoclast cultures incubated with RANKL 
and M-CSF resulted in the 6-fold decrease in formation of TRAP-positive cells and significant 
reduction in the expression of p27Kip1.137 Using siRNA to specifically knock down p27Kip1 in PBMC 
culture dramatically reduces formation of TRAP-positive cells induced by RANKL and M-CSF, 
consistent with the results of p27Kip1-deficient mice.139 Taken together, p27Kip1 function alone 
appears essential for RANKL-mediated osteoclastogenesis. 
Bone resorption targets 
 After osteoclasts mobilize the bone mineral phase, several hydrolytic enzymes degrade the 
organic bone component. The principal protease involved in this process is cathepsin K,72, 140 a 
19 
 
lysosomal protease mainly expressed in osteoclasts and released from the ruffled membrane to 
the resorption lacunae in the sealed zone. Cathepsin K mRNA and protein expression levels are 
stimulated by RANKL in a time- and dose-dependent manner, and increase with osteoclast 
differentiation and activation.141-143 Cathepsin K efficiently degrades type I and II collagen, and 
gene mutation can cause osteopetrosis and exhibit features of pycnodystosis.140, 144, 145 Specific 
down-regulation of cathepsin K mRNA expression decreased both the number and area of bone 
pits more than 50% without significantly changing cell viability.146 The unchanged osteoclast 
number may benefit maintenance of bone homeostasis since osteoclast and osteoblast activities 
are closely correlated, and disruption of this communication may cause other issues.147 In mature 
osteoclasts, cathepsin K expression is increased by RANKL, both in vitro and in vivo.141 
RANK-RANKL binding activates at least five distinct downstream signaling pathways.148 TRAF6 
acts as a critical adaptor in binding with the cytoplasmic domain of RANK; its mutations cause 
osteopetrosis.149, 150 Activation of transcription factor AP-1 has been suggested to result from 
TRAF6 signaling.143 AP-1 is a heterodimeric protein composed of Jun (c-Jun, JunB or JunD) and 
Fos.151 Transfecting RAW264.7 cells with either the dominant negative form of c-fos or siRNA 
against either c-jun or junB down-regulated RANKL-mediated cathepsin K gene expression. Both 
transfections inhibited CTSK promoter activity, suggesting that AP-1 stimulated the cathepsin K 
promoter.143 In addition, c-Fos is known to play a critical role in osteoclastogenesis: 
over-expression of c-Fos rescues RANKL-induced osteoclast formation previously blocked by 
N,N-dimethyl-d-erythro-sphingosine treatment.152  
 H+-ATPase in the osteoclast ruffled membrane is responsible for reducing and maintaining the 
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low pH in the sealed resorption lacuna during the process of osteoclast-mediated extracellular 
acidification. The ATPases have multiple subunits. One subunit isoform located in the ruffled 
membrane, subunit a3, is reported to be highly expressed and essential to osteoclast resorption 
function. Defects in this subunit of the vacuolar proton pump induce severe osteopetrosis.153, 154 
Hu et al.155 showed successful carrier-free a3 siRNA transfection of primary rat osteoclast cultures, 
reporting that actin ring structures characteristic of actively resorbing osteoclasts were reduced to 
20% of controls after siRNA transfection, but re-emerge after halting transfections. Bone resorption 
pits were significantly reduced 48 hours after transfections and type I collagen C-terminal 
cross-linked telopeptides in the culture media were decreased more than 50% compared to 
controls or nontargeting siRNA-treated groups. H+-ATPase knockdown is similar with cathepsin K 
knockdown: specific gene down-regulation reduces osteoclastic resorption activity without 
inducing cell death.  
 H+-ATPases have two domains: V1 located on the cytoplasm side and V0 bound within the 
membrane.156 ATP-hydrolytic domain V1 has 8 individual subunits, A-H.157, 158 Subunit C in murine 
H+-ATPase has three isoforms: Atp6v1c1 (C1), Atp6v1c2a (C2a), and Atp6v1c2b (C2b).159 Only 
C1 is highly expressed in osteoclasts compared to the other two, and is highly up-regulated after 
RANKL and M-CSF stimulation during differentiation.160 Feng et al.160 depleted C1 expression in 
murine bone marrow macrophages with no significant difference in numbers of TRAP-positive 
multinucleated cells compared with untreated cultures. However, osteoclastic ability to actively 
produce H+ to acidify the extracellular sealing zone environment was largely impaired, and areas 
of resorption pits on dentin slices by siRNA-treated osteoclasts were 0.5~0.75% of control cultures. 
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Co-immunoprecipitation studies showed that C1 interacted with another essential ruffled border 
H+-ATPase subunit a3 and colocalizes with microtubules, but distinct from a3 deficiency,62 C1 
depletion was able to impair F-actin ring formation.160 C1 was therefore suggested to be a 
regulator of F-actin sealing ring formation during osteoclast activation. Taken together, C1 
knockdown does not affect osteoclastogenesis, but inhibits osteoclastic bone resorption.  
 Electrostatic neutralization of the membrane potential gradient during osteoclast acid 
secretion is maintained by Cl- ion channels on the osteoclast’s ruffled border.161 CIC-7 Cl- channels 
are highly expressed in osteoclasts and localize to the ruffled border membrane. Disruption of 
CIC-7 in both humans and mice produced severe osteopetrosis.161 With the exception of CIC-7, 
CIC-3 in the CLC family of channels was identified in osteoclasts as the functional Cl- ion-specific 
channel in intracellular organelles, such as endosomes and lysosomes.162 Both organelle acidity 
and bone resorption activity are reduced using siRNA against CIC-3. Okamoto et al. concluded 
that observed osteoclastic bone resorption relied on such internal organelle acidification, since 
CIC-3 only locates to intracellular organelles, influencing this organelle acidity exclusively. 
However, bone resorption activity remains in the absence of CIC-3 activity in osteoclasts, 
attributed to the role of CIC-7 or other redundant Cl- ion channels.162, 163 Since CIC-7 causes 
severe osteopetrosis in chloride channel-deficient mice,161 the functional role of K+/Cl- 
cotransporters (KCCs) in mouse osteoclast-mediated bone resorption has been a focus. KCCs 
exist in many tissues and cells, transporting K+ and Cl- ions each driven by their respective 
individual chemical gradients.164, 165 A previous study showed that both CIC-7 and KCC1 mRNA 
was expressed in murine osteoclasts, with KCC1 locating to the cell membrane.163 The KCC 
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inhibitor, R(+)-butylindazone (DIOA) was able to increase the intracellular concentration of both Cl- 
and H+ in resorbing osteoclasts. Thus, inhibiting KCCs can suppress Cl- secretion in resorbing 
osteoclasts, which eventually produces reduced H+ pumping activity. Transfecting bone marrow 
cell-induced osteoclasts with siRNA against KCC1 dramatically reduces of the area of bone 
resorption pits compared with controls and these results are similar, but slightly less potent, to 
those from CIC-7 inhibition.163 
 The Na+/Ca2+ ion exchanger (NCX) is a bidirectional membrane transporter regulating Ca2+ 
homeostasis in many tissues on cell plasma membrane.166 The NCX family comprises 
homologous proteins: NCX 1, NCX 2, NCX 3.167, 168 In murine osteoclasts, three splice variants of 
NCX1 and NCX3, called NCX1.3, NCX1.41 and NCX3.2, were detected.169 NCX mediates both 
Ca2+ efflux and influx and is predicted to locate to the ruffled border and control Ca2+ influx in 
resorbing osteoclasts.169 SiRNA delivered against each NCX1.3, NCX1.41 and NCX3.2 at 100nM 
in mouse bone marrow cell-induced osteoclasts all significantly reduced the area of bone 
resorption pits per osteoclast approximately 50%.169 These data support the essential role of these 
three NCX in Ca2+ transport and their important role in regulating bone resorption. 
 The c-Src gene, encoding a cytosolic protein tyrosine kinase (PTK), 170 is also essential for 
osteoclast activity. Lack of c-Src expression in mice resulted in osteopetrosis characterized by 
inactive osteoclasts.171 Previous work indicates that c-Src is functional as an adaptor in 
osteoclasts, regulating cell attachment and migration by recruiting essential signaling proteins.172 
Strong c-Src PTK activity has been found in ruffled borders in active osteoclasts.173 
Osteoclast-mediated bone resorption can be abolished both in vivo and in vitro by blocking c-Src 
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PTK activity in osteoclasts.174 Knockdown of Src expression in RAW264.7 cells reduces both size 
and number of actin rings, and decreased cell spreading and fusion rates.175 c-Src PTK activity is 
activated by dephosphorylation, and a structurally unique osteoclast-specific transmembrane 
protein-tyrosine phosphatase (PTP-oc) in osteoclasts is known.176 RAW/C4 osteoclast-like 
precursor cells transfected with PTP-oc siRNA in serum-containing media and showed 
RANKL-mediated suppression of osteoclast differentiation. Both osteoclast number and size was 
significantly reduced by decreasing endogenous PTP-oc mRNA levels.177 In addition, apoptosis 
was induced significantly by PTP-oc siRNA compared to control siRNA. Enhanced apoptosis from 
such knockdown also suggests its role in osteoclasts. Additionally, PTP-oc is  also indicated to be 
involoved in regulating RANKL-mediated osteoclastic differentiation.178 A homologous 
recombination strategy was used to inhibit PTP-oc function in RAW264.7 cell culture. PTP-oc 
knockout cells could not form TRAP-positive multinucleated osteoclast-like cells under RANKL 
treatment after 7 days. Therefore, PTP-oc is a target not only on mature osteoclasts to inhibit bone 
resorption, but also on osteoclast precursors to limit differentiation into osteoclasts. 
 The osteoclast sealing zone requires tight attachment between osteoclasts and the bone 
surface for successful bone resorption179 and this depends upon formation of a dense belt-like 
actin ring surrounding the ruffled membrane.180 These osteoclast actin rings have high 
concentrations of actin filaments assembled locally into dynamic structures as podosomes in bone 
attachment sites. With its significant prerequisite role in osteoclastic bone resorption, actin ring 
formation is a target for inhibiting osteoclasts and has been investigated in many studies. Gelsolin 
is an important actin regulator, necessary for podosome formation but not necessary for actin ring 
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formation, which means that gelsolin-null osteoclasts are able to resorb bone, but with reduced 
potency.181-183 However, Wiscott-Aldrich syndrome protein (WASP) critical for podosome assembly 
exists in the actin ring of gelsolin-null osteoclasts.182 WASP interacts with phosphatidylinositol 
4,5-bisphosphate (PIP2) and Cdc42 in response to integrin ανβ3 signaling, enhancing the sealing 
zone formation and bone resorption.182 Mice without WASP expression exhibited defects in 
formation of podosomes and actin rings in the sealing zone and bone formation.184 Attenuation of 
WASP using siRNA demonstrated the absence of podosome formation of actin rings and reduced 
bone resorption. WASP is activated by the coordinated binding of Cdc42 and PIP2, and full 
activation stimulates the actin-nucleating function of the actin-related protein (Arp)2/3 complex by 
associating with Arp2/3.185-188 The Arp2/3 complex initiates actin nucleation and crosslinking, and 
has been reported to be 3-fold upregulated in RAW264.7 cells in response to RANKL.189, 190 
Knockdown of Arp2 in RANKL-stimulated RAW264.7 cells using siRNA generated an average 
70% protein reduction 30 hours posttransfection.190 Fewer podosome-like structures appeared, 
and compared with control, less than 1% actin rings were observed after knockdown, proving the 
vital role for Arp2/3 in actin ring formation and its potential to be a new target for therapeutic agents. 
Actin nucleation requires phosphorylation of WASP’s C-terminal VCA domain during WASP 
binding to Arp2/3 complex after integrating a number of signals.191-193 The PTP-PEST 
(protein-tyrosine phosphatase-proline, glutamic acid, serine, threonine amino acid sequence) has 
been shown to be involved in WASP and Src phosphorylation and dephosphorylation.194 This 
regulates phosphorylation of proteins associated with WASP and enhances interactions between 
WASP, actin monomers, and the Arp2/3 complex by increasing the WASP conformational 
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stability.194 At the same time, it regulates Src activity through (de)phosphorylation.195 Reducing 
PTP-PEST expression levels using siRNA in osteoclasts eliminated actin rings and significantly 
inhibited formation of the sealing zone, formation of WASP-cortactin-Arp2 complexes195 and bone 
resorption.194 This indicates a direct role of PTP-PEST in the formation of cell-sealing zones while 
interacting with WASP. 
 Simultaneously with WASP, cortactin, a c-Src substrate, binds with Arp2/3 at its N-terminal 
acidic domain to promote Arp2/3-induced actin assembly and stabilize actin filaments by binding to 
their repeat regions.196 Cortactin was not found in hematopoietic cell precursors, but is induced in 
differentiated osteoclasts. Depletion of cortactin in primary mouse osteoclasts using siRNA 
resulted in the absence of podosomes, sealing rings and loss of bone-resorbing ability, suggesting 
an indispensable role for cortactin in osteoclastic bone resorption. Cortactin’s mechanism for 
regulating sealing ring formation has been further studied.197 Instead of inhibiting the initial actin 
aggregate phase, knockdown of cortactin using siRNA suppressed the subsequent sealing zone 
maturation process. 
 Osteoclast ability to attach to bone surfaces is essential for successful bone resorption. An 
intracellular calcium channel, inositol-1,4,5-triphosphate receptor-1 (IP3R1) is involved in the 
regulation of reversible osteoclast attachment.198 IP3R1 can bind an endosomal isoform of 
IP3R-associated cGMP-dependent kinase substrate (IRAG). Using siRNA against IRAG in human 
osteoclasts in vitro reduced cell spreading diameters and displayed distributed podosomes.199 
Loss of podosome ring structures explained reduced cell adhesion. Knockdown of the orphan 
nuclear receptor ERRα in RAW264.7 cells200 generated similar effects as IRAG. Expression of 
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osteopontin and the β3 integrin subunit is down-regulated after silencing ERRα. Transfected cells 
detach from the substrate easily and no podosome belts are observed. Though cell adhesion and 
migration is impaired, their differentiation and precursor cell proliferation are not influenced by 
ERRα knockdown.  
 Given the essential role of actin assembly in osteoclastic bone resorption, the motor protein 
family of myosins responsible for actin-based motility was examined in osteoclasts.201, 202 Myosin X 
(Myo10) maintains low expression levels in most vertebrate tissues,203 binding actin and 
microtubules.204 Assembly of podosomes and sealing zones in osteoclasts depends on a complete 
intact microtubule system.205, 206 RNAi-mediated inhibition of Myo10 in both RAW264.7 and mouse 
bone marrow-derived osteoclasts reduced the sizes of sealing zones and cell perimeters, but did 
not influence cell fusion.202 
 Brain-type creatine kinase (Ckb) exhibits high up-regulation upon osteoclast maturation as 
witnessed with proteomic technology.207 Increased expression occurs in both mice bone marrow 
cells and RAW264.7 cells exposed to RANKL and M-CSF. Ckb regulates ATP distribution and 
supply in cells, required in osteoclast actin formation and maintenance.208, 209 Down-regulation of 
Ckb in cell cultures produced prominent reduction in areas of resorption pits on dentin slices.207 
Reduced resorption ability was suggested to be partially due to impaired actin ring structures 
observed in transfected osteoclasts. In addition, Ckb was also shown to affect V-ATPase 
activity,207 a major proton pump essential for osteoclastic resorption. Normal osteoclasts can 
recover their intracellular pH under challenge with strong acid over about 400 seconds. However, 
the lack of such intercellular pH recovery observed when inhibiting Ckb, infers that Ckb influences 
27 
 
osteoclast bone resorption by affecting V-ATPase. In vitro cell culture data were confirmed in vivo 
through reduced bone surface erosion in ovarectomized Ckb-/- mice. Interestingly, no significant 
differences in numbers of osteoclasts were observed between Ckb-/- and wildtype mice.207 
Therefore, Ckb is a target for altering osteoclast activity, not osteoclastogenesis. 
Osteoclast viability targets 
 In addition to targeting osteoclastogenesis and osteoclastic bone resorption, targeted 
induction of osteoclast apoptosis is also an efficient strategy to suppress excessive bone loss. 
EGFR is a target for regulating osteoclast differentiation (mentioned in Section 4.1). Inhibition of 
EGFR expression was also reported to cause apoptosis of mature osteoclasts through a 
caspase-9/caspase-3-dependent pathway by inhibiting the activation of P13K-Ake/PKB.130 Taken 
together, siRNA against EGFR can not only inhibit osteoclast differentiation, but also suppress 
mature osteoclast survival.  
 RANK siRNA can be similarly characterized, as RANKL/RANK interaction is responsible for 
osteoclast differentiation, bone resorption and mature osteoclast survival as well. Therefore, 
mature osteoclasts transfected with RANK siRNA resulted in cell death.67 Taken together, 
transfection of either osteoclast precursors or mature osteoclasts with RANK siRNA can reduce 
osteoclast-mediated bone resorption by inhibiting osteoclast differentiation, resorption activity and 
osteoclast survival.  
 Bisphosphonates, the most commonly used pharmacological approach for targeting 




 As an alternative, siRNA against alendronate’s (a nitrogen-containing bisphosphonate, N-BP) 
known molecular target,210 farnesyl pyrophosphate synthase (FPPS), was investigated to inhibit 
osteoclasts and promote osteoblast activity simultaneously. FPPS plays an important role in the 
mevalonate pathway which produces lipids essential for cell survival.211 Additionally, N-BPs are 
reported to induce human osteoblast differentiation and mineralization in culture by inhibiting the 
mevalonate pathway.212 siRNA targeting FPPS significantly suppressed osteoclast cell viability 
with a single transfection and significantly increased osteoblast differentiation with effects 
sustained 5 days posttransfection in osteoblasts. However, this treatment does not significantly 
change osteoblast proliferation and mineralization compared to controls.213 Therefore, selective 
knockdown of FPPS expression has the potential to inhibit osteoclasts while at the same time 
promoting osteoblastic activity. 
 Other siRNA targets described above influence osteoclast survival as well. NHA-oc/NHA2, 
mentioned as a target for osteoclastogenesis, inhibits osteoclast resorption activity partially 
because reduced NHA-oc/NHA2 express induces apoptosis by loss of inhibition of caspase-9 
activation;102 significant osteoclast death can also be induced by OGR1 siRNA transfection; siRNA 
against structurally unique osteoclast-specific transmembrane PTP-oc induces significant 
apoptosis in RAW/C4 osteoclast-like precursor cells. In addition, many other general cell apoptosis 
signals are reported. Using siRNA targeting these proteins regulating these pathways, cell-specific 




Other potential osteoporosis targets 
 Recognition of bone by osteoclasts is regulated by cell integrin receptors.214 Integrins, as 
calcium-dependent, heterodimeric transmembrane protein receptors, mediate cell attachment with 
extracellular matrix or with other cells. Four different integrins are actively expressed in 
osteoclasts.215 Among them, ανβ3 is highly expressed in osteoclasts and exhibits an important role 
in facilitating osteoclast attachment to bone and subsequent bone resorptive processes.216 
Osteoclast-mediated bone resorption was shown to be significantly inhibited by anti-ανβ3 antibody 
treatment in vitro 217 and increased skeletal mass, absence of actin rings and abnormal osteoclast 
ruffled membranes were all observed in osteoclasts in ανβ3-deficient mice.216 Integrin ανβ3 
recognizes the extracellular RGD peptide sequence and therefore RGD peptide has been used to 
label and target ανβ3-positive cells in vivo.218 In addition, inhibition of ανβ3 using a soluble RGD 
mimic as a receptor antagonist reduced osteoclastic bone resorption both in vitro and in vivo, 
suggesting that ανβ3 blockade prevents rapid bone loss caused by estrogen withdrawal.219 In a 
study seeking to identify human peripheral blood monocyte subsets differentiating into osteoclasts, 
integrin-β3 subunit siRNA was transfected into human CD16+ monocytes.220 This transfection 
significantly reduced TRAP-positive multinucleated cells in a dose-dependent manner. Silencing 
the β3 subunit in myeloma cells from human patients suppresses bone resorption activity (i.e., 
osteoclast-like activity) of these cells in vitro.221 These data reflect the importance of β3 integrin 
subunit in RANKL-induced osteoclastogenesis. Therefore, ανβ3 could be an attractive target to 
attenuate or modulate osteoclastic bone resorption. 
 The soluble cell signaling protein, p53, is well known to protect cells from malignant tumor 
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transformation by coordinating several intracellular signaling networks.222 The ubiquitin ligase, 
murine double minute 2 (MDM2), regulates p53 activation by controlling p53 half-life.223 Recently, 
a small molecule inhibitor, Nutlin, is reported to competitively bind MDM2 to interrupt p53-MDM2 
interaction and activate the p53 pathway.224, 225 In order to investigate the effect of Nutlin-3 on 
pre-osteoclastic precursor cell survival, proliferation and differentiation, human peripheral blood 
mononuclear cell pre-osteoclasts were transfected with p53 siRNA.226 Results showed that 
Nutlin-3 anti-osteoclastogenesis activity was greatly compromised by p53 siRNA, indicating that 
the inhibitory effects of Nutlin-3 on osteoclast precursors require the p53 activation pathway. Using 
siRNA technology to interrupt p53-MDM2 interactions may therefore have therapeutic implications 
for controlling excessive osteoclastic activity. 
 OGR1 was mentioned (vida supra) as a possible target for controlling osteoclastogenesis. 
This seven-pass transmembrane protein binds protons and exhibits pH-sensing activity.109 Given 
that increased extracellular proton concentrations led to nuclear translocation of NFATc1, a 
downstream mediator of RANKL stimulation in osteoclasts,227 OGR1’s role, while still unclear, 
could be linked to bone pH homeostasis working as a proton sensor in response to external 
acidosis.109 Therefore, further studies investigating OGR1 function in bone resorption sites is 
necessary to validate OGR1 as a target for osteoclast-mediated excessive bone resorption. 
 FPPS has been used as an siRNA target to inhibit osteoclast viability, mimicking the 
pharmacology of N-BPs (vida supra). However, depletion of intracellular geranylgeranyl 
pyrophosphate (GGPP) has also been reported to produce analogous phenotypic effects of 
bisphosphonate treatment on both osteoclasts and osteoblasts.228, 229 Therefore, siRNA inhibition 
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of GGPP synthase may induce apoptosis in osteoclasts while simultaneously promoting 
osteoblastic activities. Using siRNA against GGPP synthase could also potentially suppress 
excessive bone loss by stimulating osteoblastic bone production. 
 As osteoclasts form from cell fusion, cell-to-cell contact is critical for osteoclastogenesis. Cell 
adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), whose expression is 
regulated by intracellular signalling through NF-κB and JNK, is involved in cell-cell contact 
between osteoclast precursors and osteoblasts/stromal cells, or among osteoclast precursors.230, 
231
 ICAM-1 binds to integrin pairs, LFA-1 (CD11a/CD18), blocking interactions between ICAM-1 
and LFA-1, inhibiting osteoclast formation.230 Hidetaka et al. reported that siRNA knockdown of 
LFA-1 in RAW264.7 cells had no effects on osteoclastogenesis. Alternatively, ICAM-1 could be an 
siRNA target to inhibit osteoclasts as ICAM-1 is not only expressed on osteoclast precursors and 
mature osteoclasts, but also on osteoblasts.232, 233 Therefore, cell-specific targeted delivery will be 
essential for the specific bioactivity and siRNA selectivity to osteoclasts as desired.    
siRNA Delivery to Bone 
Challenges and strategies 
 RNAi as a novel therapeutic approach has considerable potential to silence abnormal genes, 
especially for gene targets not effectively targeted by conventional therapeutics (i.e., by small 
molecules, proteins and antibodies). The major obstacle for developing siRNA for therapeutics is 
also its targeted delivery with clinically acceptable formulations and reliable routes of 
administration. This is particularly true of siRNA delivery to bone with its intrinsically poor drug 
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penetration and vascular perfusion. Bone is primarily composed of three cell types: osteoclasts, 
osteoblasts and osteocytes. Bone’s unique extracellular matrix is strongly mineralized with calcium 
phosphate, forming ~70 wt% apatite, a major reservoir of the body’s calcium most actively involved 
with physiological calcium and phosphorus homeostasis. Increasing molecular and cellular 
understanding of bone biology has produced continuous reports of new potential therapeutic 
targets for various bone pathologies. Nonetheless, despite new targets identified as 
osteoclast-specific, targeting methods are not yet reliably tissue-based specifically with requisite 
bone-specificity necessary for these therapeutic agents. Serious complications from 
cross-reactivity with other nontarget tissues or poor efficacy due to low drug target tissue 
concentration require a reliable targeting strategy. Many attempts to improve the targeting of drugs 
to bone mineral fraction (apatite) include drug conjugation with bone-targeting ligands, such as 
tetracycline,234 estradiol, and bisphosphonate.235, 236 Bisphosphonates, especially N-BPs, as 
antiresorptive drugs having intrinsic high affinity to the bone apatite surface, are very attractive for 
delivery of conjugated nonspecific bone therapeutic agents. However, their exploitation as 
bone-targeting agents must consider that free bisphosphonate itself also will increase 
antiresorptive activity. 
 SiRNAs are well known for their very short circulating half-lives in vivo.237 Unmodified naked 
siRNA cannot be directly administered directly in vivo, exhibiting only a 6 min half-life after 
systemic administration to rats due to degradation by serum nucleases.237 Many studies seek to 
overcome the challenges of siRNA delivery by the chemical modification of siRNA nucleotides, 
lipid/liposomal/polymer-based complexes, and collagen (atelocollagen)-based238, 239 formulations 
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for siRNA, as well as viral vectors and polymer-complexed siRNA carriers.240 These methods each 
have their advantages and disadvantages, but nonviral delivery is considered a more clinically 
relevant delivery mechanism, avoiding the known problems of current viral vector delivery: high 
viral toxicity, possible carcinogenicity, proven immunogenicity and significant cost limitations.31 
Delivery of siRNA-targeted specifically to bone is not an entirely new story. To date, in vivo siRNA 
studies in humans have focused on rheumatoid arthritis (RA) by local delivery (intra-articular 
injection241, 242, electroporated siRNA243, topical cream34), or by systemic delivery, each with 
modest effects.244 Delivery of siRNA to bone osteoclasts in vivo, either targeted to or addressing, is 
not yet reported. 
 To improve siRNA stability in vivo, various chemical modifications have been investigated. 
SiRNA stability against nuclease degradation can be improved by introducing a phosphorothioate 
(P=S) backbone linkage or modifying the ribose 2’-hydroxyl position as 2’-OMe or 2’-F, as well as a 
4’-thioribose modification.245 All show significant improvements over unmodified siRNA.246-248 
Combination of 2’- and 4’-thioribose modification results in substantially improved siRNA 
bioactivity and plasma stability.249 This improved siRNA plasma stability facilitates more reliable 
systemic dosing and versatile delivery options. In addition, specific siRNA chemical modifications 
can potentially be used to improve conjugation and targeting as well. Bone-targeting ligands, 
antibodies250 or small molecule drugs (vida supra) can be conjugated with siRNA molecules with 
various chemistries for systemic delivery of siRNA-based bone disease therapeutics. For example, 
bisphosphonates, can be conjugated to ribose hydroxyl groups in siRNA sugars. Modification of 
the ribose 2’-OH at the 3’ end of the guide siRNA strand appears effective for improving siRNA 
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activity.240 In this case, bisphosphonate performs both as a drug and also as a targeting moiety to 
deliver siRNA specifically to bone.  
 Using tissue-specific targeting methods, both locally and systemically delivered siRNA can be 
more reliably dosed by judicious combination of other “homing” molecules. Established drug 
delivery strategies can be utilized for both targeted systemic and local siRNA delivery, including 
siRNA conjugation to cell membrane-targeting ligands, antibodies, water-soluble polymers 251 or 
cell-penetrating peptides. These methods seek to improve amount of siRNA delivered specifically 
to targeted bone cells, and to limit drug off-target effects in cells other than osteoclasts.  
 RANK expressed on osteoclast precursors as well as on mature osteoclasts serves as a 
popular molecular target for osteoporosis therapies. Antibodies against RANK have been tested 
for effective osteoclast targeting by conjugation with calcitonin, an antiresorptive protein drug.252 
The conjugate showed efficacy inhibiting osteoclast formation and bone resorption. The strategy, 
using receptor ligand binding peptides as the targeting moiety, provides a general approach to 
generating an osteoclast-targeting platform for specific drug delivery to osteoclasts. Other 
osteoclast-specific proteins can also be utilized for this purpose, such as cathepsin K and 
NHA-oc/NHA2. In addition, many calcium-binding proteins, recently reviewed,253 including acidic 
proline-rich salivary proteins, osteocalcin, sialoprotein and osteopontin, have the potential as novel 
bone-targeting moieties.253 The hexapeptide (Asp)6 exhibited high affinity to bone and was used as 
bone-targeting moiety conjugated with estradiol in ovariectomized mice. The conjugates 
maintained bone density similarly to unconjugated estradiol, but without displaying increased liver 
and uterus weight.254, 255  
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 In addition to specific chemical modifications, protection of siRNA in plasma is also provided 
by formulating siRNA into nano/macro-sized particles for delivery, as recently reviewed.256-258 Most 
drug delivery strategies to date primarily target the liver, either deliberately or nondiscriminately, a 
natural result of first-pass metabolism and highly efficient liver-based drug and colloidal clearance. 
This is an advantage for liver targeted therapies: for example, hydrodynamic tail-vein injection of 
Fas siRNA successfully protected mice from liver failure and fibrosis.259  However, the liver and 
other reticuloendothelial (MPS/RES) system tissues efficiently filter most drug carrier particles (i.e., 
>90%) despite active targeting to other target tissue sites. To avoid this massive dose removal, 
locally delivered siRNA-particle formulations can be used in bone-targeted therapeutics. 
Specifically to target osteoclast or osteoclast precursors, siRNA delivery can exploit drug carrier 
particle size-selective cell-specific uptake to numerous phagocyte target cells in bone tissue using 
local delivery. In the context of osteoporosis therapy, targeted cells are pre-osteoclastic monocytes 
and osteoclasts -- all naturally phagocytic cells. Phagocytes efficiently take up particles with 
diameters up to 10 µm.260 However, particles with diameters greater than 300 nm are too large to 
penetrate nonphagocytic cell membranes (i.e., osteoblasts, fibroblasts) either passively or by 
endocytosis or pinocytosis.261 Therefore, siRNA-loaded microparticles with controlled sizes could 
be exploited for selective internalization by osteoclastic phagocytic mechanisms, and to target 
siRNA to these cells in new osteoporotic therapeutic strategies without a conjugated targeting 
moiety. These particles could be delivered locally to bone sites in clinical cases, especially in bone 
augmentation and implant surgeries. Additionally, for some bone molecular drug targets 
appropriate both for osteoclasts and osteoblasts, siRNA-containing nanoparticles capable of being 
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taken up by both cell types might be effective for increasing bone mass by inhibiting osteoclasts 
while simultaneously stimulating osteoblasts. Particle opsonisation by host plasma proteins, 
commonly a problem for drug carriers, may confound target cell phagocytosis since opsonisation 
(particularly, nonspecific adsorption of immunoglobulins and complement onto the particles) may 
activate macrophages and T-cells and cause inflammation in surrounding tissues and damage to 
healthy cells.262 
 Currently, local siRNA administration is more efficient than its systemic delivery for short-term 
therapeutic purposes.263 Nonetheless, local delivery must also consider target specificity. For 
example, intra-articular injection of siRNA for RA is not an effective route of administration for 
transfecting osteoclasts located near or on bone surfaces at most common osteoporotic bone sites, 
notably pelvis, vertebrae and wrist.264 To maximize drug availability to specific bone sites and 
obtain a reliable, reproducible and predictable pharmcokinetic profiles, bioactive materials, 
including porous chitosan/collagen scaffolds265 and injectable FDA-approved calcium phosphate 
bone cements (CPC) are being developed as drug carriers for local bone delivery. 
Polymethylmethacrylate (PMMA) bone cements used clinically for implant fixation, kyphoplasty 266 
and bone augmentation,267 exhibit very poor control over entrapped dose release kinetics, often 
leaving up to 40% of the drug trapped in PMMA.268, 269 Injectable CPC exhibits several unique 
properties for bone drug delivery, including peri-operative preparation and drug loading, 
liquid-solid setting in situ, intrinsic osteoconductivity (degradable by osteoclasts), osteoinductivity 
(infiltrated by osteoblasts and replaced with new bone), and acceptable biocompatibility.270-272 
CPC’s self-setting ability at ambient or body temperature within the bone cavity 273 enables 
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injectable formulation, largely expanding its therapeutic utility.274, 275  To date, a large body of 
evidence supports the feasibility and value of using CPC as a local drug carrier in bone 
augmentation. Pharmacologically active molecules are readily dispersed or distributed throughout 
CPC prior to setting and surgical placement, providing a sustainable and controlled drug release 
medium. Several conventional small molecule and protein-based drugs have been delivered using 
CPC in bone, including antibiotics to decrease postsurgical infections,276-279 anticancer drugs to 
reduce tumorogenesis280, 281 and growth factors to promote bone healing.282, 283 Therefore, despite 
its limited mechanical properties, CPC could also be used to deliver siRNA to bone as a local 
delivery matrix. A degradable cationic hydrogel comprising of gelatin and chitosan has been used 
for local delivery of an antisense oligonucleotide targeting murine TNF-α to suppress 
endotoxin-induced osteolysis in mouse calvaria.284 Cationic polymeric chitosan complexes with 
anionic nucleotides and also facilitates cell transfection. Osteoclast numbers and bone resorption 
were significantly suppressed 4 weeks postimplantation. The same idea can also be extended to 
siRNA local delivery to bone. The intrinsically low pH in osteoclast resorption lacuna and in the 
cell lysosome is attractive as a basis for targeting drugs conjugated to carriers containing 
acid-cleavable hydrazone bonds.285 Additionally, various acid-sensitive, cathepsin K-specific and 
MMPs-specific peptide linkages (reviewed recently253) also provide disease- and environmentally 





Nonspecific siRNA-cell bioactivities and off-target side effects 
 The first clinical trials involving siRNA were applied by local intraocular injection in patients 
with choroidal neovascularization (CNV).33, 286 CNV is an age-related eye disorder characterized 
by the choroidal vessel invasion to the retina beneath retinal pigmented epithelium. Naked siRNA 
targeting VEGFA or VEGFR1 showed significant suppression in a laser-injury-induced CNV mice 
model.33, 286 However, in 2008, new data showed that this therapeutic suppression is a general 
siRNA-class effect, independent of siRNA sequence.25 The observed therapy was based on 
interactions between cell-surface (but not endosomal) toll-like receptor 3 (TLR3), a cell membrane 
double-stranded viral RNA sensor found on numerous cell types,287 and siRNA, regardless of RNA 
sequences, target, and internalization. However, to bind TLR3, siRNA of 21 nucleotides or longer 
was required to form a 2:1 TLR3-RNA conjugate. TLR3 plays an indispensable role in the 
TRIF--NF-κB cell signalling cascade where TRIF is the TLR3 adaptor protein.288 This important 
discovery has revealed generic properties of siRNAs on vascular tissues, and improved the global 
understanding of siRNA general bioactivities, both desired and potentially undesired, through 
non-specific signalling pathways.  
 In this regard, primary human choroidal endothelial cells showed decreased survival in 
serum-containing media cultured with serum-stable 2’O-methyl-Lus-siRNA (without transfection 
reagents).25 Such extracellular siRNA-induced cytotoxicity might affect other organs, including 
bone. Osteoclast precursors but not mature osteoclasts express TLR3.59 Poly(I:C)dsRNA, which 
acts as a TLR3 ligand to stimulate cell surface TLR3, produced strong inhibition of osteoclast 
differentiation in both mouse bone marrow cultures and human peripheral blood monocytes at 1 
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µg/ml in a dose-dependent manner under induction by M-CSF and RANKL. TLR stimulation 
induces the production of various proinflammatory cytokines such as TNF-α289 and prompts high 
levels of phagocytic activity in osteoclast precursors,59 indicating an enhanced immune response 
after TLR stimulation in osteoclast precursors. Taken together, both the unanticipated vascular and 
immune-general siRNA-class effects should be carefully considered for siRNA therapies, 
especially when delivered systemically.  
Conclusions 
 Gene silencing using siRNA has many potential therapeutic applications due to several 
advantages intrinsic to RNAi, such as its high target specificity and intrinsic biological response.28 
Effective siRNA delivery and selective targeting to desired tissue sites remains problematic. siRNA 
delivery to bone has developed relatively slowly compared to its delivery to other tissues. In this 
regard, osteoporosis is an increasingly challenging problem globally with a need for improved 
therapeutics. Many new cellular targets in osteoclasts are continually reported and attractive for 
siRNA knockdown. Efficient siRNA delivery methods and selective targeting to bone connective 
tissue and osteoclasts must be developed, improved and optimized. siRNA’s efficacy, 
bioavailability and therapeutic duration in the context of osteoclast-mediated bone resorption are 
largely unexplored, but this strategy has attractive options for development of new therapeutics.  
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SIRNA KNOCKDOWN OF RANK SIGNALING TO CONTROL  
OSTEOCLAST-MEDIATED BONE RESORPTION 
Reprinted with permission from Wang, Y; Grainger, D.W. Pharm Res 2010, 27(7),1273-84. 
Abstract 
This chapter demonstrates the potential for small interfering (si)RNA control of osteoclast 
function. RANK and RANK ligand can act together to activate osteoclast formation and its intrinsic 
bone resorption activities. Suppression of RANK reduces osteoclast-mediated bone resorption in 
vitro. Delivery of siRNA targeting RANK to both RAW264.7 and primary bone marrow cell cultures 
produces short-term repression of RANK expression without off-targeting effects, and significantly 
inhibits both osteoclast formation as determined by tartrate-resistant acid phosphatase (TRAP) 
assay, and subsequent bone resorption by resorption pit assay. 
Introduction 
With mean life expectancy increasing worldwide, degenerative skeletal diseases become 
more significant. Age-related hormonal changes are correlated with enhanced osteoclast activity 
observed in this patient population. Reduced bone density is highly associated clinically with the 
risk of fragility fractures,1-3 decreasing the eligibility for orthopedic implants, significantly impairing 
many patients’ quality of life. The osteoclast is the major cell type responsible for bone resorption. 
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Together with the bone-forming osteoblast, the osteoclast regulates the homeostasis of skeletal 
mass and continual turnover.4 Increased osteoclast function induces excessive 
osteoclast-mediated bone resorption, leading to bone loss-associated diseases, including Paget’s 
disease,5 osteoporosis,6 hypercalcemia 7 and metastatic bone disease.8  
As large multinucleated cells, osteoclasts originate from mononuclear precursors of the 
monocyte-macrophage cell lineage.9 Osteoclastogenesis, cell maintenance and activation involve 
complex pathways with intricate relationships between multiple signaling molecules. Macrophage 
colony-stimulating factor (M-CSF), receptor activator of nuclear factor κB (RANK) and RANK 
ligand (RANKL) are known to be key molecules initiating osteoclast formation. Interaction between 
M-CSF and its receptor, c-Fms, generates signals for osteoclast precursor cell survival and 
proliferation.10  By contrast, osteoclastogenesis is modulated by positive interactions between 
RANK and RANKL and negative interactions between RANKL and osteoprotegerin (OPG). RANK 
is a transmembrane signaling receptor expressed on haematopoietic precursor cells and 
osteoclasts.11 Interaction of RANKL is required for osteoclast formation, activation and calcium 
homeostasis.11, 12 It has also been reported that interaction of RANK and RANKL increases 
survival of the mature osteoclast in vitro and in vivo.13 RANK signals through the key adapter 
molecule, TNF receptor-associated factor (TRAF) 6, and RANK cytoplasmic domains, to regulate 
formation and activation through osteoclast-specific gene expression.11 Mice lacking RANK, TRAF 
6 or RANKL are deficient in osteoclasts and lack osteoclastogenesis.12, 14-16 OPG, a soluble protein 
of the TNF receptor family, secreted by osteoblasts, competitively binds RANKL,11, 17 consequently 
acting as a decoy receptor to block osteoclastogenesis and suppress osteoclast survival.18, 19 Thus, 
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positive regulator RANKL and negative regulator OPG are normally coordinated to modulate bone 
degradation and formation homeostasis by competitive interactions with RANK. RANK is therefore 
a central factor in this bone metabolic regulatory pathway.  
RNA interference (RNAi) 20 is a relatively recent development with increasing utility as a 
sequence-specific posttranscriptional gene silencing tool.21 Because systemic siRNA targeting has 
proven very challenging, local or topical siRNA therapeutics have been most actively investigated.  
Successful delivery approaches include ocular, respiratory, CNS, skin and vaginal sites where 
local siRNA delivery accesses desired cell target populations directly.22-26 To date, siRNA targeting 
of RANK responsible for osteoclast formation and function has not been reported. The purpose of 
this study is to assess the utility of RNA interference (RNAi) methods to target RANK in regulating 
osteoclast formation and function in vitro. Reduction of RANK expression using siRNA specific to 
RANK is expected to suppress bone resorption by osteoclasts, ultimately increasing bone density 
and potentially preventing bone mass loss. In order to determine the efficacy of this 
RANK-targeting siRNA, both RAW and primary cells were evaluated for RANK message and 
protein expression after siRNA delivery. Functional assessments included inhibition of osteoclast 
formation by TRAP assay, and functional suppression of osteoclasts by bone resorption pit assay. 
Results show that osteoclast formation and osteoclast-mediated bone resorption can be 





Materials and Methods 
Cell culture 
 Immortalized murine monocyte-macrophage cell line culture.  A subclonal line of murine 
monocytic pre-osteoclastic RAW264.7 cells, purchased from the American Type Culture Collection 
(ATCC), was cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 
10% heat-inactivated fetal bovine serum (FBS, Hyclone®, UT) and 1% penicillin-streptomycin 
(Gibco), defined for all cell cultures as “complete media”. To induce osteoclast formation in vitro, 
RAW cells (passage number controlled to less than 10) were cultured on 24-well plates in 
complete media at the density of 4×104 cells per well supplemented with 100ng/ml of RANKL. 
Complete media with RANKL was changed every other day.  
 Primary murine cell harvest and differentiation.  C57BL/6 male mice (6-8-week-old, Jackson 
labs) were maintained in a specific pathogen-free facility at the University of Utah. All procedures 
were performed as approved by the Institutional Animal Care and Use Committee of University of 
Utah. Bone marrow cells (BMC) were harvested from murine tibias and femurs of C57BL/6 male 
mice and differentiated into osteoclast precursors using previously described methods.27-29 Briefly, 
BMCs were cultured in α-MEM (Gibco) containing 10% FBS and 1% penicillin-streptomycin 
overnight at a density of 1×106 cells/ml. Nonadherent cells were harvested the next day and 
immediately seeded into 24-well tissue culture plates in complete media with 30 ng/ml M-CSF 
(R&D Systems) at a density of 1×106 cells per well. After 2 days of culture, attached cells were 
used as osteoclast precursors. To generate osteoclasts, precursor cells were incubated in 
200ng/ml RANKL and 30ng/ml M-CSF (R&D Systems) in complete media, refreshed every other 
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day. RANKL working concentrations to reliably generate osteoclasts from both RAW264.7 and 
primary cell cultures in serum media were experimentally determined.  
 sRANKL expression.  A glutathione-S-transferase (GST)-tagged sRANKL construct was 
generated by cloning the murine sRANKL SalI/NotI fragment, coding 470-951 nucleotides, into the 
plasmid pGEX-4T-1 (a generous gift of Dr. M. F. Manolson, University of Toronto). The expressed 
protein was harvested as previously described.29-31 GST-tagged sRANKL was purified by 
Glutathione Sepharose 4B affinity resin (Amersham Pharmacia Biotech), dialyzed against 
phosphate buffered saline (PBS, Gibco) and concentrated using Amicon Ultra centrifuge tubes 
(Millipore). Protein concentration was determined by BCA protein assay kit (Pierce). 
 siRNA transfection of cells.  An siGENOME SMARTpool (Dharmacon) containing four 
different siRNA sequences all designed to target murine RANK, as well as four pure individual 
siRNAs (1, sense 5’-GAGCAGAACUGACUCUAUGUU- 3’, antisense 5’-CAUAGAGUCAGUUC 
UGCUCUU-3’; 2, sense 5’-GCGCAGACUUCACUCCAUAUU-3’, antisense 5’-UAUGGAGUGAAG 
UCUGCGCUU-3’; 3, sense 5’-CCAAGGAGGCCCAGGCUUAUU-3’, antisense 5’-UAAGCCUGGG 
CCUCCUUGGUU-3’; 4, sense 5’-CAAGAAGUGUGUGAAGGUAUU-3’, antisense 5’-UACCUU 
CACACACUUCUUGUU-3’), and a non-targeting control siRNA (sense: 5’-UAGCGACUAAA 
CACAUCAAUU-3’, antisense: 5’-UUAUCGCUGAUUUGUGUAGUU-3’) were purchased from 
Dharmacon. DharmaFECT 4 (DF4, Dharmacon) was used as the cationic lipid cell transfection 
reagent. RAW cells were seeded at a density of 4 × 104 cells per well in 24-well plates in DMEM at 
37°C with 5% CO 2 overnight. Transfection with siRNA/DF4 complexes was then carried out in 
complete media. Primary BMC were seeded at 1 × 106 cells per well in 24-well plates in complete 
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media containing 30ng/ml M-CSF for 2 days. Subsequently, siRNA transfection was immediately 
performed. Transfection reagent DF4 and siRNA were prepared according to manufacturer’s 
instructions (Dharmacon). Final dosing concentrations of all siRNAs provided to each well were 
125 nM in a total volume of 1.0 microliter DF4. Cell uptake of siRNA complexes was performed by 
incubating cells with siRNA complexes in complete media at 37°C with 5% CO 2. In osteoclast 
formation and pit formation assays, cells were transfected by siRNA complexes in complete media 
with 100ng/ml RANKL (RAW cells) or 30 ng/ml M-CSF and 200 ng/ml RANKL (BMC). Nonspecific 
knockdown of DF4 was assessed by using non-targeting siRNA dosed under identical conditions. 
Multiple cell transfections were carried out identically each day over the successive first 3 days, or 
on alternating days, as specified in each figure. In the case of transfection of osteoclast cultures, 
RAW cells and primary BMCs were seeded in 24-well plates and treated as mentioned above to 
generate osteoclasts. Mature osteoclasts were purified essentially as described elsewhere 28, 32 by 
gently washing with PBS without Ca2+ and Mg2+ (Gibco). By tapping the plate, most mononuclear 
cells were detached, while multinucleated osteoclasts remained on the plate. Osteoclasts were 
transfected by incubating with siRNA complexes prepared as above in complete media containing 
100ng/ml RANKL (RAW cells) or 200ng/ml RANKL and 30ng/ml M-CSF (BMC). 
 Reverse transcriptase-polymerase chain reaction (RT-PCR).  Total RNA was isolated 48 
hours after siRNA transfection using an RNeasy Mini Kit (Qiagen). Up to 4 micrograms of RNA 
were used to make cDNA with the SuperScript III 1st strand RT kit for PCR (Invitrogen). PCR 
primers were designed for RANK (5’-AGATGTGGTCTGCAGCTCTTCCAT-3’, 5’- ACACACTTC 
TTGCTGACTGGAGGT-3’) and cyclophilin B (housekeeping control, 5’- AGCGCTTCCCAGATG 
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AGAACTTCA-3’, 5’-GCAATGGCAAAGGGTTTCTCCACT-3’) using Primerquest software 
purchased from Integrated DNA Technologies (IDT). PCR was performed with iTaq DNA 
polymerase (Bio-Rad), 1.5 mM magnesium chloride, 200 µM each of dNTPs, 500 nM of each 
primer and 2 µL of the cDNA. Reactions were performed using the following protocol: 95oC melt, 
60oC anneal and 72oC extension in the iCycler Thermal cycler (Bio-Rad). PCR products were 
analyzed on ethidium bromide-stained TBE-based 2% agarose gels run at 100V for 30 minutes 
and visualized with UV light. 
 Real-time quantitative PCR (qPCR) analysis.  cDNA was prepared as described above. 
Primers for RANK (5’-TAGGACGTCAGGCCAAAGGACAAA-3’, 5’-AGGGCCTACTGC 
CTAAGTGTGTTT-3’, Probe: 56-FAM/TGAAGGTGCCAGGGAAATTCAAGAAAGA/36-TAMSp) 
and cyclophilin B (5’-TCCGGCAAGATCGAAGTGGAGAAA-3’, 5’-AACCTTGTGACTGGCTACCTT 
CGT-3’, Probe: 56-FAM/TCATCCCTCTAAGCAGCTGTCTG TGT/36-TAMSp) were designed using 
Primerquest software purchased from IDT. Experiments were performed using 7900HT Sequence 
Detection System and data were analyzed using SDS RQ manager (Applied Biosystems).  
 RANK Western immunoblot assay.  Cells were lysed in RIPA buffer (Sigma) supplied with 1× 
protease inhibitor cocktail (Pierce) and 1mM phenylmethylsulfonyl fluoride (Sigma).32 Insoluble 
material was removed by centrifuging at 15,000 rpm at 4°C for 5 minutes after 20 minutes on ice. 
Protein concentration was measured with a BCA protein assay kit (Pierce). Heat-denatured 
samples were separated on 4-12% SDS-polyacrylamide gels (Invitrogen) and blotted on PVDF 
filters (Bio-Rad). After blocking with 5% (w/v) dry milk in 0.5% Tween 20 in TBS (TBST), the filter 
was incubated overnight in primary antibody against RANK (BAF692; R&D systems) in 5% 
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BSA/TBST with constant shaking. After three washes with TBST, the membrane was incubated 
with streptravidin-HRP (RPN 1231; Amersham Pharmacia Biotech Ltd). The housekeeping control 
was detected with antibody against cyclophilin B (PA1-027; Affinity BioReagents) and 
HRP-conjugated donkey antirabbit antibody (SA1-200, Affinity BioReagents). Secondary 
antibodies were detected with chemiluminescence reagent (Santa Cruz Biotechnology) and band 
images were captured using a Molecular Imager Gel Doc XR System (Bio-Rad). 
 Tartrate-resistant acid phosphatase (TRAP) assay.  Cells were stained for TRAP using a 
leukocyte acid phosphatase kit (Sigma) according to the instructions. Osteoclasts staining positive 
with at least three nuclei were counted as TRAP-positive cells. 
 Bone resorption pit assay.  Bovine bone was sawed into 0.2-0.3 mm thick slices (a gift from 
Dr. S. Miller, University of Utah) and washed as described 29 before placing small pieces into 
24-well plates. A total of 4×104 RAW cells were plated and cultured on bone slices in DMEM for 12 
hours and then cells were transfected with siRNA in complete media with 100ng/ml RANKL (Day 
1). BMCs were plated on bone slices at a density of 1×106 per well in 30ng/ml M-CSF complete 
media for 2 days. Thereafter, siRNA transfection was performed in 200ng/ml RANKL and 30ng/ml 
M-CSF-containing complete media (Day 1). The media was changed every other day. To observe 
osteoclast-generated bone resorption, slices were stained using a previous described method.29 
Pit numbers per frame were counted from random fields under microscopic observation.  
 Cell imaging.  Live adherent cells, TRAP-stained images and pit images were photographed 
using a Nikon Eclipse TE 2000-U microscope, with Photometrics Coolsnap ES camera (gray scale, 
Roper Scientific) or QImagine RETIGA EXi color 12-bit camera (color, Canda), using MetamorphTM 
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software (Molecular Devices) or QCaptureTM software (QImaging). An average of 15 frames per 
well were taken randomly for TRAP assay analysis and 10 frames were acquired randomly from 
each bone slice for pit formation analysis (except for triple siRNA transfection sequences in 
primary BMC where 5 frames were acquired). 
 Statistical analysis.  Analysis of variance (ANOVA) followed by two-tailed student’s t-test was 
used for statistical analysis. For multiple comparisons, Bonferroni correction was applied. All 
experiments were repeated three times. Error bars represent the standard error of the mean.  
Results 
Transfection in culture of RAW cells 
 Optimization of siRNA transfection in cultures of RAW cells.  DharmaFECT 4 (DF4) was 
chosen as a siRNA transfection reagent since it was appropriate for mouse and rat cell lines based 
on the manufacturer’s instructions. Transfection conditions in serum-containing media were 
optimized using a commercial murine-targeted siRNA pool (SMARTpool). Each siRNA sequence 
was then tested individually for their effectiveness to knock down RANK expression in cells in 
complete media. While qPCR results for sample siRNA-1 and -2 RANK knockdown were 
statistically indistinguishable, siRNA-2 was selected for further study since it produced the greatest 
overall knockdown effect (Figure 2.1A, p=0.009). RANK siRNA-2, therefore, was used for all 
further siRNA transfections of RAW cultures. Nonspecific knockdown of RANK by DF4 evaluated 
using non-targeting siRNA and DF4 demonstrates little effect by PCR analysis, shown in Figure 






Figure 2.1 RANK mRNA expression knockdown in cultured RAW cells. RNA was harvested 
48 hours posttransfection. (A) Four RANK siRNAs were assayed by qPCR analysis for the 
greatest knockdown effects. (ap<0.05, bp<0.01, each compared with controls without treatment). 
(B) DF4 was tested for nonspecific knockdown of RANK using non-targeting siRNA. (C) RANK 
siRNA-2 was used to knock down the RANK gene expression in RAW-derived mature osteoclasts. 
Representative images of (E) RAW-derived osteoclasts (arrows) after a 48-hours knockdown by 
RANK siRNA, compared with (D) controls with no treatment. (10X magnification) (F) RANK mRNA 
expression knockdown in RAW cell culture after multiple serial transfections determined by 




RANK expression in cultures compared with untreated osteoclasts (Figure 2.1C). Additionally, in 
the presence of RANKL, small osteoclasts continued to fuse into larger ones in control cultures 
(Figure 2.1D), while in RANK siRNA-treated cultures (Figure 2.1E), the speed of cell fusion was 
suppressed after treatment, and the osteoclast size was smaller than those in controls. RANK 
expression knockdown by multiple serial RANK and non-targeting siRNA transfections of RAW 
cells were tested using qPCR analysis (Figure 2.1F). Serial transfections were performed every 
other day. mRNA was extracted on Day 3 (single siRNA transfection on Day 1), Day 5 (double 
siRNA transfections on Day 1 and 3), Day 7 (three siRNA transfections on Day 1, 3, and 5) and 
Day 9 (four siRNA transfections on Day 1, 3, 5, and 7), respectively. Compared to control (no 
treatment) groups, RANK siRNA-2 significantly suppressed RANK expression in all four situations 
(p<0.001). There was no significant difference between the control groups and the non-targeting 
siRNA groups on RANK expression for one (p=0.2), two (p=0.49), three (p=0.23), or four (p=0.51) 
serial transfections, indicating that DF4 had no significant effect on expression of RANK in the 
absence of specific siRNA. In addition, compared with non-targeting siRNA transfections, the 
RANK siRNA-2 groups showed significant reduction of RANK expression for all four dosing 
situations: one (p=0.00163), two (p=0.0007), three (p=0.0056), and four (p=0.0049) serial siRNA 
transfections (p<0.01).  RANK protein expression was detected by Western blotting after single 
and multiple transfections, respectively. For a single transfection, RANK protein was at most 
suppressed 3 days posttransfection and then began to recover (Figure 2.2A). Multiple 
transfections were performed in two ways. First, RAW cells were transfected successively daily in 
the first 3 culture days (Day 1 to Day 3). Protein was harvested on Day 5, 6 and 7. RANK 
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knockdown was maintained until Day 6 and then started to return from Day 7 (Figure 2.2B). 
Second, RAW cells were transfected three times serially but on every other day (Day 1, 3 and 5), 
and protein was harvested from Day 7 to Day 9. Figure 2.2C clearly shows that protein knockdown 
effects could be prolonged until Day 9 with serial transfections.  
 Effects of RANK siRNA on osteoclast formation and pit resorption in RAW cells.  RAW cells 
were transfected with RANK siRNA or non-targeting siRNA in complete media with 100ng/ml 
RANKL. For each siRNA, cells were dosed either once (Day 1), or three times serially on alternate 
days (Day 1, 3, and 5). To evaluate osteoclast formation, TRAP assay was performed on Day 7. 
 
Figure 2.2 Western blot analysis of RANK protein knockdown in RAW cell cultures. Western 
blotting analyzed 30µg of cell lysate per sample. (A) Protein was harvested at 3, 4, and 5 days 
after single RANK siRNA-2 transfection. (B) RANK protein expression after three successive 
RANK siRNA-2 transfections. Protein was harvested on Day 5, 6, and 7. (C) RANK protein 
expression after three serial RANK siRNA-2 transfections on Day 1, 3 and 5. Protein was 





Results are summarized in Figure 2.3F. Both controls with no siRNA exposure (Figure 2.3A) and 
cells treated with non-targeting siRNA (single transfection, Figure 2.3B; three transfections, Figure 
2.3C) showed strongly TRAP-positive multinucleate giant cells. Compared to controls, both single- 
(Figure 2.3D, p=0.007) and three-dose transfections with RANK siRNA (Figure 2.3E, p=0.00015) 
showed significant reductions in numbers of TRAP-positive multinucleate cells in culture. There 
was no significant difference in the number of osteoclasts between controls and the single 
non-targeting siRNA transfection groups (p=0.17). Although three serial non-targeting 
transfections exert some influence on osteoclast formation by the transfection reagent (p=0.042), 
comparisons between three serial transfections of non-targeting versus RANK siRNA show that 
osteoclast numbers were significantly reduced in the RANK siRNA-treated groups (p<0.001). The 
same trend exists for comparisons between single transfections of non-targeting versus RANK 
targeting siRNAs (p=0.017). Three-dose RANK siRNA transfection groups showed reduced 
osteoclast numbers compared with single dose groups, but not significantly different (p=0.13). 
Resorption pit assay was performed 6 days postsingle transfection. Formation of resorption pits on 
bone slices was markedly curtailed in the siRNA-treated groups (Figure 2.3G, p=0.02) compared 
to controls (no treatment) that displayed many pits formed by osteoclasts.  
 Effects of siRNA on RANK mRNA and protein expression in primary BMC cultures.  To 
ensure that RANK siRNA-2 retained the most powerful knockdown effects, differences in siRNA 
knockdown for the 4 different RANK siRNAs were tested on primary BMC cultures in serum media. 
RT-PCR results clearly demonstrated that RANK siRNA-2 was the most efficient at 





Figure 2.3  Effects of RANK siRNA and non-targeting siRNA on osteoclast formation 
determined by TRAP assay in RAW cell cultures. Cultures were performed in the presence of 
RANKL (A) with no siRNA treatment for positive controls, (B) transfected with non-targeting siRNA 
once on Day 1, (C) transfected with non-targeting siRNA three times serially every other day, (D) 
transfected with RANK siRNA once on Day 1, (E) three times serially every other day. (F) 
Comparison of the number of TRAP-positive multinucleate cells formed after siRNA dosing. 
(bp<0.01, cp<0.001, RANK siRNA-2 single and three transfection groups vs. controls). (scale bar = 
250µm) Inhibition of osteoclast-mediate bone resorption by RANK siRNA was evaluated by pit 
formation assay. (G) Difference of resorption pit numbers per frame (10X magnification) between 









Figure 2.4 RANK knockdown by RANK siRNA dosing to primary BMC and BMC-derived 
osteoclasts in serum-based culture. RNA was harvested 48 hours posttransfection. Protein was 
harvested 3 days posttransfection, except from the mature osteoclasts, the RNA was 48 hours 
posttransfection. Western blotting analyzed 30µg of cell lysate per sample. (A) Four RANK siRNAs 
were analyzed by RT-PCR for the greatest knockdown effect. (B) Lysates analyzed by Western blot 
for RANK protein expression suppression by a single dose of RANK siRNA. (C) RANK protein 
expression after three serial siRNA transfections on every other day. Protein was harvested on Day 
7, 8, and 9. (D) Inhibition of target RANK gene expression in primary cell-induced osteoclasts at the 
mRNA and protein level as shown by PCR (D) and Western blot (E). Representative images of 
primary BMC-derived osteoclasts (arrows) after 48-hours knockdown by RANK siRNA (G) compared 
with controls (F). (10X magnification) 
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used for subsequent transfections in primary BMCs. Consistently, RANK protein production was 
reduced both by single siRNA transfection (Figure 2.4B) and three serial transfections on alternate 
days (Figure 2.4C). Furthermore, RANK siRNA transfection was also able to suppress RANK 
message expression in primary BMC-induced mature osteoclasts. PCR products showed 
significantly reduced RANK mRNA expression in osteoclast cultures after single transfection  
(Figure 2.4D), as well as reduced RANK protein expression by Western blot assay (Figure 2.4E). 
Similarly to RAW cell cultures, BMC-induced osteoclasts had reduced rates of cell fusion after 
transfection (Figure 2.4G) compared to large osteoclasts formed in control cultures (Figure 2.4F). 
Effects of RANK siRNA in primary BMC cultures 
 TRAP assays were performed on Day 5 cell cultures for single siRNA transfections. 
Compared with controls (Figure 2.5B), significant reductions in numbers of TRAP-positive 
multinucleate giant cells posttransfection (Figure 2.5C, p=0.001) were observed. Results are 
summarized in Figure 2.5A. Primary osteoclast precursor cells were cultured on bovine bone 
slices. Resorption pit assay was performed on Day 5 for single transfections. Controls without 
siRNA treatment produced abundant resorption pits on bone slices as detected by microscopy (4X 
magnification). RANK siRNA treatment inhibited osteoclastic bone resorption with significant 
reductions in resorption pit numbers (Figure 2.5D, p=0.04).  
Discussion 
We provide evidence that siRNA delivered to cells in serum-containing media can 
successfully and specifically inhibit RANK expression both in osteoclast precursors and mature 
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osteoclasts from RAW secondary and primary BMC. This results in suppression of cell-based 
bone resorption mechanisms by reducing the number and activity of osteoclasts in cultures.  
RANK plays an essential role in regulating osteoclastogenesis.33 Activation of RANK by its 
ligand, RANKL, is required for the formation and activation of osteoclasts.12, 15 Similar to RANK, 
OPG can also bind RANKL to act as a competitive inhibitor by blocking RANK interaction.17, 34, 35  
Since the elucidation of the RANK/RANKL/OPG signaling pathways, RANKL and OPG have been 
 
Figure 2.5  Inhibition of primary cell-induced osteoclast formation and activity by RANK 
siRNA. (A) Inhibition of osteoclast formation by a single RANK siRNA dose (Day 1). TRAP assay 
was performed on Day 5 (bp<0.01). Resorption pit assay was performed on same day. 
Representative image of TRAP-stained cells in (B) control groups with no treatment, and (C) 
treated groups with single siRNA dose. (D) Comparison of average pit number for cell-treated 
bovine bone slices per frame (4X magnification) between controls (no treatment) and single dose of 




actively investigated as therapeutic targets. Several OPG-based approaches to regulate bone 
mass and reduce bone resorption have been reported in animal models 17, 18, 36 and in a human 
trial.37 However, reliable delivery of a large protein therapeutic poses several challenges, including 
limited stability, relevant dosing and bioavailability (short half-life), possible host immune 
responses to recombinant products, patient compliance (parenteral requirements) and complex 
formulating issues for sustained protein release.38-40 A fully human monoclonal antibody targeting 
RANKL, denosumab, is currently investigated as a subcutaneous injection in late-stage clinical 
development for bone metabolic therapies.41-43 Possible safety issues of this anti-RANKL antibody 
regard cross-reactions with OPG or RANK-activated endogenous antibodies. Therefore, other 
therapeutic options are necessary. RNAi is an alternative approach to RANK and RANKL control in 
this same context. In this approach, siRNA molecules silence gene expression in a 
sequence-specific manner by causing degradation of corresponding endogenous mRNA.20, 44, 45  
In fact, complete absence of either RANKL or RANK (as shown in RANKL and RANK knockout 
mice) eliminates RANKL-RANK signaling between osteoblasts and immature osteoclasts.12, 15  
This depletes functioning mature osteoclasts, removes intrinsic bone deposition control 
mechanisms and eventually causes osteopetrosis in these knockout mutants.  Therefore, due to 
these concerns as well as other side effects (i.e., targeting undesired cell populations expressing 
RANK, and general nonspecific targeting), site- and temporally selective, as well as reversible 
control over RANK-RANKL activity, rather than its complete, irreversible abolition, is considered 
more appealing for developing new clinical approaches to osteoporosis therapies. In this study, 
siRNA targeting RANK was transfected into serum-based secondary macrophage cultures, 
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primary monocyte-macrophage cultures, and culture-generated osteoclasts to observe RANK 
mRNA knockdown and suppression of protein expression. While RNAi has noted issues with 
mammalian cell delivery efficiency and specific targeting,46 one advantage of siRNA in the context 
of RANK is the transient gene knock-down experienced (5~6 days, depending on the target, cell 
type and frequency of target protein expression typical to that cell) with relatively small amounts of 
siRNA dosed. This provides an alternative control feature for RANK suppression in cells compared 
to mutants completely lacking RANK or protein-based systemic antagonism approaches. 
Additionally, clinical osteoporosis bone augmentation approaches 47, 48 permit local placement of 
siRNA-releasing carriers directly into osteoporotic sites by injection, permitting renewable, local 
siRNA delivery to bone RANK at these sites and avoiding systemic delivery issues. As osteoclasts 
central to both bone metabolic control and RANK presentation derive from fusions of 
haematopoietically sourced circulating cells and tissue-resident differentiated macrophages, 
assessing and comparing the utility of siRNA knockdown effects in both secondary and primary 
macrophage cultures was considered an important milestone. Immortalized commercial 
RAW264.7 monocyte-macrophages are commonly cultured as macrophage surrogates despite 
the general lack of reporting of phenotypic indicators or fidelity to primary macrophages, and their 
relatively high rates of contamination from commercial sources.49 Some limitations with the 
accuracy of RAW cell comparisons to primary macrophages in model assays have already been 
noted.27, 50  Aggressive endocytosis and proliferation rates in RAWs, characteristic of 
tumor-derived cell lines, as well as higher frequency and intensity of both gene up-regulation and 
protein expression, may all alter the intensity and duration of siRNA effects.51 Nevertheless, as 
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RAW264.7 cells have been frequently used for in vitro generation of osteoclasts,32, 52-54 this study 
compared RAW cells to primary BMC for effects of siRNA on osteoclast behavior.  
RANK siRNA-2 provides the highest knockdown of the RANK mRNA for both RAW and 
primary BMC cultures. A dose of 125 nM RANK siRNA and the commercial cationic lipid 
transfection reagent, DF4 demonstrated successful inhibition of the target RANK gene expression 
at the mRNA level 48 hours after transfection in serum-based culture conditions. In addition, 
evidence indicates that RANK message knockdown is not caused by the transfection reagent, as 
there was no significant reduction of RANK mRNA expression in cells transfected with 
non-targeting siRNA/DF4 complexes. Moreover, the accumulating effects of multiple serial 
transfections were evaluated in RAW cells, showing sustained knockdown effects in 
serum-containing culture media. A likely explanation for the similar RANK knockdown effects 
observed with the three and four transfection cycles could be the increasing cell numbers by the 
third and fourth transfection cycles, diluting effects of constant siRNA dosing.  
Protein expression analysis of both cell cultures further confirmed RANK knock-down using 
siRNA. In RAW cell cultures, with single transfections, RANK protein levels were suppressed after 
3 days in culture. Subsequently, RANK protein production began to recover, due possibly to rapid 
cell proliferation and dilution of siRNA within cells. Multiple transfections (i.e., 3 serial doses) were 
performed, successively in the first 3 days or serially every other day throughout the culture period. 
In the latter case, RANK protein expression can be suppressed until Day 9. The same prolonged 
protein suppression was observed in BMCs as well, suggesting that changing the frequency of 
multiple siRNA transfections can extend protein knockdown. Therefore, serial siRNA transfections 
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performed every other day was considered more effective and hence used for multiple 
transfections in subsequent assays. 
Since RANK also resides on mature osteoclasts and positively regulates osteoclast activation 
and survival, it was also important to target RANK on mature osteoclasts. We found that mature 
osteoclasts induced from both RAW and primary BMC cultures can be successfully transfected by 
siRNA, producing significant reductions in both RANK message and protein compared with 
untreated controls. In support of this, we found that in both secondary and primary cultures, after 
osteoclasts were transfected by RANK siRNA, further fusion was suppressed. This corresponds to 
a previous report showing that RANKL stimulation is essential for cell fusion of osteoclasts.55 
Large osteoclasts have much greater bone resorbing capability than small osteoclasts under same 
conditions,32, 56, 57 therefore, the bone resorbing activity of osteoclasts is suppressed after RANK 
siRNA transfection at least in part by controlling osteoclast fusion and size. We further assessed 
RANK siRNA effects on osteoclast formation. In RAW cell cultures, osteoclast numbers were 
reduced significantly in both single and three serial RANK-siRNA treated groups. No significant 
changes were observed in the number of osteoclasts in single non-targeting siRNA-treated 
cultures compared with controls, consistent with minimal apoptosis and cell viability influences 
from transfection. Three serial transfections of non-targeting siRNA showed significant differences 
when compared to controls, though the average numbers were similar.  A likely explanation may 
be a negative role played by the transfection reagent in multiple dosing. However, comparisons 
between three serial transfections of non-targeting siRNA and RANK siRNA showed significant 
differences in osteoclast number, which confirms the inhibition effects on osteoclast differentiation 
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by specific siRNA transfection. Though the average osteoclast number in three serially RANK 
siRNA transfected cell cultures was lower than that for single-dose groups, there was no significant 
difference within the 7 culture days, indicating that osteoclast formation is sensitive to RANK 
expression level and a single transfection at culture initiation is sufficient to inhibit both osteoclast 
formation and activity for a cycle of osteoclast formation in RAW cells. Hence, single doses of 
siRNA were applied for evaluation of effects on osteoclast bone-resorption activity. Similar results 
were obtained in primary BMC cultures; a single dose of RANK siRNA leads to a significant 
reduction in numbers of TRAP-positive cells. Furthermore, we have established that RANK siRNA 
is a potent inhibitor of osteoclast-mediated bone resorption, resulting in significant reduction of 
bone resorption pit number. Bone resorption activity was largely inhibited by RANK siRNA in both 
cultures. We attribute this in part to fewer osteoclasts formed, demonstrated by TRAP assay 
results, consistent with RANK mRNA and protein knockdown specific to siRNA introduction in 
monocyte-macrophage precursor and mature osteoclast serum-based cultures. All experiments 
with primary cells duplicated the results and conclusions from RAW cell cultures, confirming the 
general knockdown effect of RANK siRNA in these cell types in serum-based culture. 
In summary, we conclude that siRNA can be successfully used to specifically inhibit RANK 
expression both in RAW and primary macrophage cell cultures, and also in osteoclast precursors 
and mature osteoclasts in serum-based transfections. Since RANK is an essential receptor in the 
membranes of both osteoclast precursors and osteoclasts and plays a key role in osteoclast 
formation and function, control of RANK has important fundamental and translational implications. 
The experimental results follow theoretical predictions: formation of osteoclasts is strongly 
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suppressed after siRNA treatment and the bone resorption pit numbers are largely reduced as well. 
In addition, our analysis demonstrates that a single dose of RANK siRNA is sufficient to inhibit both 
osteoclast formation and activity for a cycle of osteoclast formation. These data suggest that 
siRNA against RANK could be a powerful tool for inhibiting osteoclast-mediated bone resorption 
and improving bone mass maintenance. Extensions of this concept to treatment of osteoporosis or 
low bone mass using siRNA administration could be interesting if reasonably RANK control at 
desired locations could be achieved.  
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SMALL INTERFERING RNA KNOCKS DOWN THE MOLECULAR TARGET  
OF ALENDRONATE, FARNESYL PYROPHOSPHATE SYNTHASE,  
IN OSTEOCLAST AND OSTEOBLAST CULTURES 
Reprinted with permission from Wang, Y; Buffington, A; Grainger,  
D.W. Mol. Pharmaceutics, 2011, 8(4), 1016-24 
Abstract 
Farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway, is the 
inhibition target of alendronate, a potent FDA-approved nitrogen-containing bisphosphonate 
(N-BP) drug, at the molecular level. Alendronate not only inhibits osteoclasts, but also has been 
reported to positively affect osteoblasts. This study assesses the knockdown effects of siRNA 
targeting FPPS compared with alendronate in both osteoclast and osteoblast cultures. Primary 
murine bone marrow cell-induced osteoclasts and the preosteoblast MC3T3-E1 cell line were used 
to assess effects of anti-FPPS siRNA compared with alendronate. Results show that both FPPS 
mRNA message and protein knockdown in serum-based culture is correlated with reduced 
osteoclast viability. FPPS siRNA is more potent than 10µM alendronate, but less potent than 50µM 
alendronate on reducing osteoclast viability. Despite FPPS knockdown, no significant changes 
were observed in osteoblast proliferation. FPPS knockdown promotes osteoblast differentiation 
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significantly but not cell mineral deposition. However, compared with 50µM alendronate dosing, 
FPPS siRNA does not exhibit cytotoxic effects on osteoblasts while producing significant effects on 
ostoblast differentiation. Both siRNA and alendronate at tested concentrations do not have 
significant effects on cultured osteoblast mineralization. Overall, results indicate that FPPS siRNA 
could be useful for selectively inhibiting osteoclast-mediated bone resorption and improving bone 
mass maintenance by influencing both osteoclasts and osteoblasts in distinct ways. 
Introduction 
Osteoporosis, a metabolic bone disease and leading cause of osteoporotic fragility fractures 
in both men and women, is rapidly becoming a global healthcare crisis as average life expectancy 
increases worldwide. It is defined as a disorder of calcium and phosphate metabolism 
characterized by low bone mass and micro-architectural deterioration.1 With decades of clinical 
experience, bisphosphonates are the most used pharmacological approach to treat osteoporosis 
currently,2 due to their significant inhibition of osteoclast-mediated bone resorption. 
Nitrogen-containing bisphosphonates (N-BPs) are more potent than their non-nitrogen-containing 
bisphosphonate analogs in suppressing osteoclast activity. However, since “avascular 
osteonecrosis” in patients receiving pamidronate (N-BP) therapy was first described by Marx in 
2003,3 their general side effects, including gastrointestinal irritation, bone/joint pain and jaw 
osteonecrosis,3-5 and their long half-life 6 have clouded their therapeutic efficacy. Furthermore, due 
to their severe suppression of bone turnover,7, 8 long-term bisphosphonate therapy can increase 
the risk of fractures, such as atypical fracture as a potential complication which was first reported 
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in 2005.9, 10 Therefore, designing an improved therapeutic that retains N-BPs’ inhibition of bone 
resorption with significant reductions in its side effects will be highly significant.  
The major intracellular target of alendronate, one of the most potent N-BPs, is farnesyl 
pyrophosphate (FPP) synthase (FPPS), a key enzyme in the mevalonate pathway.11-15 The 
mevalonate pathway is ubiquitous in mammalian cells, producing essential lipids including 
cholesterol and isoprenoids that are critical for posttranslational prenylation of proteins regulating 
cell apoptosis, such as Ras and Rho.16, 17 FPPS catalyzes the synthesis of the C15 metabolite 
farnesyl pyrophosphate (FPP) through the sequential condensation of isopentenyl pyrophosphate 
(IPP), starting with dimethylallyl pyrophosphate (DMAPP) and then with the resultant geranyl 
pyrophosphate (GPP). FPP is also used as the substrate to produce the C20 isoprenoid 
geranylgeranyl pyrophosphate (GGPP). Both FPP and GGPP are required for posttranslational 
prenylation of small GTPases. FPP is therefore an essential isoprenoid intermediate in the 
mevalonate pathway required for the posttranslational prenylation of essential GTPase signaling 
proteins.18 Crystallography studies reveal that as potent inhibitors of osteoclastic activity, 
alendronate competitively binds with FPPS in the GPP/DMAPP binding site and the 
FPPS/alendronate complex can be further stabilized by binding with IPP.13, 15 Down-regulation of 
posttranslational prenylation of GTP-binding proteins results in perturbed cell activity and the 
induction of osteoclast apoptosis.19 However, interestingly, increasing evidence suggests that 
these bisphosphonates also have an anabolic effect on osteoblasts. Specifically, N-BPs were 
shown to induce human osteoblast differentiation and mineralization in culture by inhibiting the 
mevalonate pathway.20 Therefore, a therapeutic that avoids known side effects for N-BPs but 
  
99 
reliably suppresses FPPS to inhibit the mevalonate pathway in both osteoclasts and osteoblasts 
could increase bone formation in the control of osteoporosis.  
RNAi is a potent therapeutic gene silencing tool to transiently knock down gene-specific 
mRNA expression levels by exploiting a natural intracellular cytoplasmic mRNA regulatory 
phenomenon in mammalian species.21-23 Gene silencing using short interfering RNAs (siRNAs) 
has many potential therapeutic applications.24 We therefore examined the potential of 
administering small interfering RNA (siRNA) to suppress N-BP’s molecular target, FPPS, in both 
osteoclasts and osteoblasts in vitro and compared its effects with the clinically familiar N-BP, 
alendronate. Ostoclasts were obtained from murine primary bone marrow monocytes.25, 26 The 
preosteoblastic cell line MC3T3-E1 was used since it has been widely exploited as a culture model 
for osteoblast differentiation.27 Expression levels of FPPS message and protein are monitored 
after siRNA transfections. Osteoclast viability and osteoblast proliferation, differentiation and 
mineral deposition posttransfections in serum culture were evaluated.  
Materials and Methods 
In vitro experimental data 
Primary murine cell harvest and differentiation.  C57BL/6 male mice (6-8-week-old, Jackson 
Labs) were maintained in a specific pathogen-free facility at the University of Utah. All procedures 
were performed as approved by the Institutional Animal Care and Use Committee of University of 
Utah. Bone marrow cells (BMCs) were harvested from murine tibias and femurs of C57BL/6 male 
mice and differentiated into osteoclast precursors using previously described methods.25, 26, 28 
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Briefly, BMCs were cultured in α-MEM (Gibco) containing 10% heat-inactivated fetal bovine serum 
(FBS, Hyclone®, UT) and 1% penicillin-streptomycin (Gibco) overnight at a density of 1×106 
cells/ml, defined for all cell cultures as “complete media”. Nonadherent cells were harvested the 
next day and immediately seeded into 24-well tissue culture plates in complete media with 30 
ng/ml M-CSF (R&D Systems) at a density of 1×106 cells per well. After 2 days of culture, adherent 
cells were used as osteoclast precursors. To generate osteoclasts, these precursor cells were 
incubated in 200ng/ml RANKL and 30ng/ml M-CSF (R&D Systems) in complete media, refreshed 
every other day. RANKL working concentrations to reliably generate osteoclasts from primary cell 
cultures in serum media were experimentally determined. Mature osteoclasts, distinguished by 
multinucleated, large cell bodies were purified essentially as described elsewhere by gently 
washing with PBS without Ca2+ and Mg2+ (Gibco).26, 29 It usually took 5 days incubation for at least 
80% of the plate remains to be covered with osteoclasts. By tapping the plate, most mononuclear 
cells were detached and removed, while multinucleated osteoclasts remained on the plate. 
Osteoblast culture.  The immature osteoblast-like cell line MC3T3-E1 (subclone 4, ATCC, 
USA) cells were cultured at 4×104 cells/well in 24-well plates. To induce differentiation, cells were 
maintained in complete media with 50µg/ml ascorbic acid (AA, Sigma) and 10mM 
β-glycerophosphate (Sigma).30 Media was refreshed every other day.  
sRANKL expression.  A glutathione-S-transferase (GST)-tagged sRANKL construct was 
generated by cloning the murine sRANKL SalI/NotI fragment, coding 470-951 nucleotides, into the 
plasmid pGEX-4T-1 (a generous gift of Dr. M. F. Manolson, University of Toronto). The expressed 
protein was harvested as previously described.25, 31, 32 GST-tagged sRANKL was purified by 
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Glutathione Sepharose 4B affinity resin (Amersham Pharmacia Biotech), dialyzed against 
phosphate buffered saline (PBS, Gibco) and concentrated using Amicon Ultra centrifuge tubes 
(Millipore). Protein concentration was determined by a BCA protein assay kit (Pierce). 
siRNA transfection of osteoclasts and osteoblasts.  Four ON-TARGETplus siRNAs all 
designed to target murine FPPS, (Target sequences: siRNA1, 5’-GUC AAG UAC AAG ACG 
GCUU-3’; siRNA2, 5’-GAA AAG AGG UAC AAA UCGA-3’; siRNA3, 5’-AGA AAG UGA CCC CGG 
AAUU-3’; siRNA4, 5’-CCU AGA GUA CAA UGC CUUA-3’), and a non-targeting control siRNA 
(sense: 5’-UAG CGA CUA AAC ACA UCA AUU-3’, antisense: 5’-UUA UCG CUG AUU UGU GUA 
GUU-3’) were purchased from Dharmacon (USA). DharmaFECT 4 (DF4, Dharmacon) was used 
as the cationic lipid cell transfection reagent in complete media. Mature osteoclasts were prepared 
as described above, residual monocytes were removed from culture, and siRNA transfection was 
immediately performed. Transfection reagent DF4 and siRNA were prepared according to 
manufacturer’s instructions (Dharmacon). Final dosing concentrations of all siRNAs provided to 
each well were 125nM in a total volume of 1.0 microliter DF4. Cell uptake of siRNA complexes was 
performed by incubating cells with siRNA complexes in complete media with 30ng/ml M-CSF and 
200ng/ml RANKL at 37°C with 5% CO 2. Nonspecific knockdown from DF4 transfection was 
assessed by using non-targeting siRNA dosed under identical conditions. Multiple repeated siRNA 
cell transfections were performed on alternating days as specified in each figure legend. 
MC3T3-E1 cells were cultured at 4×104 cells/well in 24-well plates in complete media 
overnight. Transfections were performed early the next day. Final dosing concentrations of all 
siRNAs provided to each well were identical to osteoclasts. Cell uptake of siRNA complexes was 
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performed by incubating the cells with siRNA complexes in complete media with 50µg/ml AA and 
10mM β-glycerophosphate at 37°C with 5% CO 2. 
Reverse transcriptase-polymerase chain reaction (RT-PCR).  Total cellular RNA was isolated 
from each well at different time points after siRNA transfection using an RNeasy Mini Kit (Qiagen). 
Up to 4 micrograms of RNA were used to make cDNA with the SuperScript III 1st strand RT kit for 
PCR (Invitrogen). PCR primers were designed for FPPS (5’-TGC TGG TAT CAG AAG CCA GGC 
ATA-3’, 5’-TGC TGG TAT CAG AAG CCA GGC ATA-3’) and cyclophilin B (housekeeping control, 
5’- AGC GCT TCC CAG ATG AGA ACT TCA-3’, 5’-GCA ATG GCA AAG GGT TTC TCC ACT-3’) 
using Primerquest software and purchased from Integrated DNA Technologies (IDT). PCR was 
performed by routine methods described previously.33 
Western immunoblot assay.  The assay was performed as described previously.33 Briefly, 
cells were lysed and protein concentration was measured using a BCA protein assay kit (Pierce). 
Heat-denatured samples were separated on 4-12% SDS-polyacrylamide gels (Invitrogen) and 
blotted on PVDF filters (Bio-Rad). The filter was incubated overnight in primary antibody human 
antimouse FPPS (HCA012, AbD SeroTec) in 5% BSA/TBST. Then the membrane was incubated 
with goat antihuman IgG (0500-0099, AbD SeroTec). The housekeeping control was detected with 
antibody against cyclophilin B (PA1-027; Affinity BioReagents) and HRP-conjugated donkey 
antirabbit antibody (SA1-200, Affinity BioReagents). Secondary antibodies were detected with 
chemiluminescence reagent (Santa Cruz Biotechnology) and band images were captured using a 
Molecular Imager Gel Doc XR System (Bio-Rad). 
Cell viability.  The relative number of viable osteoclasts or osteoblasts in each well was 
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determined using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega, WI, 
USA). To terminate culture, media was replaced with 300µl/well of fresh complete media with the 
addition of 60µl of Cell Titer 96 Aqueous One Solution, including three wells containing only media 
for background subtraction. Cells were then incubated at 37°C with 5% CO 2 for 2 hours and optical 
absorbance at 490nm was then determined using a plate reader (TECAN GENIOS Plus).  
Alkaline phosphatase activity.  To evaluate the differentiation of MC3T3-E1 cells, alkaline 
phosphatase (ALP) activity was determined. MC3T3-E1 cells were seeded at 4×104 cells/well in 
24-well plate and transfected with siRNA or incubated with complete media containing various 
concentrations of alendronate (gift from Prof. J. Kopecek, University of Utah). ALP activity was 
determined using a QuantiChromTM Alkaline Phosphatase Assay Kit (BioAssay Systems, CA). 
Alkaline phosphatase activity values were normalized to the relative number of viable cells as 
determined directly using the above-mentioned cell proliferation assay. 
Cell mineralization.  The degree of mineralization of cultured MC3T3-E1 cells was 
determined using Alizarin red staining,20 sensitive to the identification of cell calcification in vitro. 
Briefly, media was aspirated and the cells were rinsed twice with PBS. Then cells were fixed with 
ice-cold 70% (v/v) ethanol for 1 hour. Ethanol was removed and the cells were then stained with 
2% Alizarin Red S (Sigma) in deionized water (pH 4.2) for half an hour at room temperature. The 
staining solution was removed and the cells were rinsed five times with deionized water. After 
removing the water, cells were incubated in PBS for 15 minutes at room temperature on a shaker. 
After PBS was removed, the cells were rinsed with PBS again. Dye destaining was performed by 
incubating the cells with 10% (w/v) cetylpyridinium chloride in 10mM sodium phosphate (pH 7) 
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washing buffer at room temperature. The washing buffer was then transferred to a 96-well plate 
and the optical absorbance at 562 nm was measured using a plate reader (TECAN GENIOS Plus). 
The concentration of Alizarin Red S in the wash buffer was determined according to Alizarin Red S 
standards. Mineralization values were normalized to the relative number of viable cells determined 
by using Cell Titer 96 Aqueous One Solution Cell Proliferation Assay as described above. 
Mineralization produced in culture after triplicate serial siRNA transfections was measured the day 
following the last transfection. 
Statistical analysis.  MTT, ALP and mineralization results are reported as mean ± standard 
deviation relative to control. Significance is determined using the two-tailed Student’s t-test with 
Bonferroni corrections. All experiments were repeated three times. 
Results 
In vitro knockdown effects 
 Successful FPPS message and protein knockdown in both osteoclast and osteoblast cultures.  
Since this study’s focus was not on assessing transfection efficiency but rather on assessing 
posttransfection knockdown of target, the established commercial cationic cell transfection 
surfactant, DharmaFECT 4 (DF4), was used for siRNA transfection based on its frequency of 
successful use and manufacturer’s instructions claiming it “appropriate” for mouse and rat cell 
lines. Importantly, siRNA transfections were all performed in serum-containing media to avoid 
serum-free media-induced cell stress. Each siRNA sequence was tested individually for 
effectiveness to knock down FPPS expression in osteoclasts in complete media. siRNA-2 
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produced the greatest overall knockdown effect from the commercial library, and therefore, was 
used for all further siRNA transfections of both osteoclast and osteoblast cultures. Nonspecific 
knockdown of FPPS target by DF4, evaluated using non-targeting siRNA and DF4 in both cultures, 
is not significant by PCR analysis (Figure 3.1). Significant down-regulation of FPPS gene and 
protein expression was observed in osteoclast cultures (Figure 3.1A,C). Since all assays on 
osteoblasts were performed 5 days posttransfection, gene and protein expression levels were 
monitored prior to this on Days 2 to 5. Treatment of osteoblasts with FPPS siRNA-2 also 
significantly suppressed FPPS message expression in cultures until Day 4 when cell assays were 
performed, compared to untreated and non-targeting siRNA-transfected osteoblasts (Figure 3.1B). 
Figure 3.1 Successful FPPS message and protein knockdown in both osteoclast and 
osteoblast cultures. FPPS message knockdown by FPPS siRNA in (A) osteoclast culture 48 hours 
posttransfection and (B) osteoblast culture 48 to 96 hours postsingle transfection compared with 
untreated cells and cells transfected with non-targeting siRNA. Inhibition of target FPPS gene 
expression at the mRNA level is shown by PCR. FPPS protein knockdown by FPPS siRNA in (C) 
osteoclast 3 days postsingle transfection and (D) osteoblast cultures 3 to 5 days posttransfection 
compared with untreated cells and cells transfected with non-targeting siRNA. Protein expression 





Significantly, sustained down-regulation of FPPS protein expression was also observed 5 days 
posttransfection (Figure 3.1D).  
 Comparison of FPPS siRNA and alendronate on osteoclast cytotoxicity.  Osteoclast viability 
assays were performed 3 days after siRNA transfections in serum-based cultures. Osteoclasts 
numbers were significantly reduced in FPPS siRNA-treated groups compared with control groups 
(70.3% of the control, *p=0.03, Figure 3.2A). Compared with non-targeting siRNA which showed 
98.4% viability of the untreated control, FPPS siRNA significantly suppressed viability (*p=0.015), 
indicating that reduced cell viability results from specific FPPS gene knockdown, but not from 
nonspecific effects of siRNA or transfection reagent dosing. Osteoclasts were treated with 
alendronate at two different concentrations (10µM and 50µM). After 3-day culture, (the same 
duration as siRNA transfection), cell viability was reduced to 95.5% (*p=0.025) in the 10µM 
 
Figure 3.2 Both FPPS siRNA and alendronate reduce osteoclast cell viability. Cytotoxicity 
was determined using the Cell Titer 96 Aqueous One Solution Cell Proliferation assay. (A) Cultured 
osteoclast viability comparing non-targeting siRNA and FPPS siRNA 3 days posttransfection. (B) 
osteoclast viability compared for 10µM and 50µM alendronate 3 days postdosing to cultures (p 




alendronate-treated group and to 40.3% (**p=0.009) in the 50µM alendronate-treated group. Both 
cell viability decreases are significant compared with control (Figure 3.2B). 
 Comparison of FPPS siRNA and alendronate treatments on MC3T3-E1 preosteoblast cell 
proliferation.  FPPS siRNA and alendronate effects on MC3T3-E1 preosteoblast cell proliferation 
were compared 5 days posttreatment. As shown in Figure 3.3A, FPPS siRNA had little effect on 
cell proliferation (95.9% of the control) compared with nontreated control groups, as well as 
non-targeting siRNA-treated groups (103.7% of the control). Furthermore, there is no significant 
difference between FPPS siRNA and non-targeting siRNA groups (p=0.55). For alendronate, three 
different concentrations (10µM, 50µM and 100µM) were initially used. The 100µM alendronate 
dose showed significant evidence of cell death (>90%), a likely result of bisphosphonate toxicity, 
 
Figure 3.3 FPPS siRNA is not as potent as alendronate (50µM) on reducing cultured 
MC3T3-E1 pre-osteoblast cell proliferation. Cell proliferation was determined using the Cell Titer 
96 Aqueous One Solution Cell Proliferation assay. (A) osteoblast viability comparing non-targeting 
siRNA and FPPS siRNA 5 days postsingle transfection in serum-based cultures. (B) The 
comparison of osteoblast viability compared for 10µM and 50µM alendronate 5 days postdosing to 
cultures. (p values shown are obtained by comparing each group with controls, n=3). 
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and this concentration was not continued. Compared with nontreated controls, there is no 
significant inhibition of cell proliferation at 10µM (Figure 3.3B, p=0.908), but when alendronate’s 
concentration increased to 50µM, cell viability is reduced to 54% compared to control (Figure 3.3B, 
***p<0.001). There is also a significant difference in cell viability between the 50µM and 10µM 
groups (***p<0.001). 
 Comparison of FPPS siRNA and alendronate treatments on MC3T3-E1 preosteoblast cell 
differentiation and mineralization.  MC3T3-E1 pre-osteoblast cell differentiation was detected by 
measuring ALP activity. After 5-day culture, the effects of non-targeting siRNA, FPPS siRNA and 
alendronate (10µM and 50µM) on MC3T3 cell differentiation were compared. As shown in Figure 
3.4A, non-targeting siRNA had no effect on osteoblastic differentiation compared with control 
(99.5%, p=0.977). However, FPPS siRNA treatment increased cell ALP activity and showed a 
 
Figure 3.4 Both FPPS siRNA and alendronate (50µM) significantly increase ALP activity 
during MC3T3-E1 pre-osteoblast differentation. Cell differentiation was monitored by measuring 
ALP activity. (A) osteoblast ALP activity compared for non-targeting siRNA and FPPS siRNA 5 days 
postsingle transfection in serum-containing cultures. (B) osteoblast ALP activity compared for 10µM 
and 50µM alendronate 5 days postdosing to cultures (p values shown are obtained by comparing 
each group to controls, (n=3). 
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significant 21% increase compared to nontreated control groups (*p=0.049). When alendronate 
concentration was 10µM, cell ALP activity was reduced to 85.9% compared to control, but was not 
significant (p=0.12). However, 50µM alendronate treatment significantly increased cell ALP activity 
to 164% (*p=0.017). 
Full comparison of these effects on cell mineralization among non-targeting siRNA, FPPS 
siRNA and alendronate (10µM and 50µM) is summarized in Figure 3.5. Non-targeting siRNA 
 
Figure 3.5 Neither FPPS siRNA nor alendronate significantly affect MC3T3-E1 pre-osteoblast 
cell mineralization. (A) osteoblast mineral deposition compared for non-targeting siRNA and 
FPPS siRNA 5 days postsingle transfection, and (C) posttriple transfections in serum-based 
cultures; (B) osteoblast mineral deposition compared for 10µM and 50µM alendronate 5 days 
postdosing to cultures. (D) osteoblast proliferation after triplicate non-targeting and FPPS siRNA 





reduced MC3T3 cell mineralization to 81% of control (p=0.081). FPPS siRNA of single dose had 
no significant effect on cell mineralization (99.5%, p=0.758) after 5-day culture compared with 
control (p value between non-targeting siRNA and FPPS siRNA groups is 0.078). There is no 
significant influence of 10µM alendronate on cell mineralization (95.3%, p=0.318). However, 50µM 
alendronate increased cell mineralization to 155.5% compared to controls (p=0.058). Cell 
mineralization under triplicate FPPS siRNA transfections on every other day showed 9.98% 
increase compared with control (not significantly different). Triplicate non-targeting siRNA 
transfection showed only 0.51% increase compared with control (Figure 3.5C). In addition, both 
non-targeting and FPPS siRNA (single and triple dosing) have no observed influence on 
osteoblast proliferation (Figure 3.5D). 
Discussion 
Bisphosphonates are potent inhibitors of bone resorption and widely used in clinic to treat 
postmenopausal osteoporosis. However, more attention has been drawn recently to their side 
effects, such as bisphosphonate-associated osteonecrosis and their long half-life that complicates 
fracture healing.7 Inhibition of FPPS in the mevalonate pathway has been implicated as the 
mechanism of action for select N-BPs at the molecular level in both osteoclasts and 
osteoblasts.11-13, 20, 34 Osteoclasts and osteoblasts are closely correlated with each other; therefore, 
in our study, use of siRNA to knock down FPPS expression in both osteoclasts and osteoblasts 
was examined and compared with N-BP alendronate. Alendronate is one of the most potent 
FDA-approved N-BPs,35 commonly prescribed for the treatment and prevention of osteoporosis. 
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Actual dosing ranges of alendronate to which bone cells are exposed under pharmacological 
conditions are unknown. Many studies have shown that bisphosphonate affects cells in a 
dose-dependent manner in cultures.20, 36, 37 We therefore employed three alendronate 
concentrations (10µM, 50µM and 100µM) in cell cultures. Alendronate at 100µM concentration 
significantly reduced cell viability in both cell types, consistent with the observation of Im et al.38 
who showed inhibited cellular proliferation when alendronate was used at 100µM. We chose 
alendronate working concentration within the range of 10-100µM since significant effects on cells 
have been observed in other studies.20, 36, 37, 39 
FPPS siRNA-2 provides the highest knockdown of FPPS mRNA in primary BMC cultures in 
our preliminary studies (data not shown) and was used for all experiments. A dose of 125nM 
siRNA and the commercial cationic lipid transfection reagent, DF4, demonstrated successful 
inhibition of both the target FPPS gene and protein expression 48 hours and 72 hours, respectively, 
after transfection in serum-based culture for osteoclasts. In osteoblast cultures, successfully 
sustained gene and protein knockdown were obtained up to 5 days posttransfections. In addition, 
evidence indicates that FPPS message knockdown is not caused by the transfection reagent, as 
there was no significant reduction of FPPS mRNA or protein expression in cells transfected with 
non-targeting siRNA/DF4 complexes.  
Classically, the majority of reports regarding bisphosphonates have been focused on their 
effects on reducing osteoclast bone resorbing activities.40-45 A variety of modes of drug action on 
osteoclasts have been explored. The present study focused on cytotoxic depletion of osteoclasts 
since both in vitro and in vivo studies provide evidence that bisphosphonates reduce osteoclast 
  
112 
numbers and activity.43 FPPS siRNA showed significant inhibition on growth of cultured murine 
bone marrow cell-induced osteoclasts. This suppression is stronger than that from 10µM 
alendronate, but not as potent as that from alendronate at 50µM. Cell viability can be reduced to 
40% by alendronate at 50µM compared with the nontreated control. FPPS siRNA effects on cell 
viability are less than expected based on the substantial mRNA and protein knockdown results, 
exhibiting about 30% reduction compared with control. A possible explanation for this could be 
intrinsic disproportionate relationships between cell viability and FPPS enzyme activity. Unlike 
other functional cell proteins, e.g., cell receptors where decreased protein expression leads to 
proportionate decreases in functions, enzymatic turn-over activity can remain significant despite 
relative knock-down, distinguishing functional differences between knockdown and knockout. 
Inhibition of the mevalonate pathway has been linked to bisphosphonate-induced apoptosis in 
macrophages and human myeloma cells in vitro.46, 47 These reports suggest that reduced 
osteoclast viability results from FPPS siRNA-induced cell apoptosis by preventing protein 
prenylation in osteoclasts.  
Except for the effect of bisphosphonate on osteoclast apoptosis, it was also reported to be 
able to inhibit osteoclast formation in long-term human marrow culture alone40 or by acting on 
osteoblastic cells.48 In addition, mevalonate pathway is essential for producing DMAPP and IPP 
which are involved in the biosynthesis of molecules for cell memebrane maintenance. Taken 
together, it would be interesting to further investigate the effects of FPPS siRNA on 
osteoclastogenesis and osteoclast podosome assembly and actin ring formation which play a 
critical role of osteoclastic bone resorption. 
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Increasing evidence showing that N-BPs directly affect osteoblast proliferation, differentiation 
and mineralization 37, 49, 50 in ways distinct from those of osteoclasts prompted study of the role of 
FPPS siRNA on the mevalonate pathway in MC3T3-E1 pre-osteoblast cells cultures. Changes in 
MC3T3-E1 cell viability in response to FPPS siRNA addition to cultures was compared to single 
alendronate treatments. As expected, non-targeting siRNA does not significantly influence cultured 
cell proliferation compared with controls without any treatment. However, FPPS siRNA addition 
does not significantly change cell proliferation compared with both control and non-targeting 
siRNA. This suggests that FPPS knockdown is not sufficient to influence MC3T3-E1 viability within 
5 days. No difference is observed on cell viability between cells without any treatment and those 
treated with 10µM alendronate. However, when alendronate concentration increases to 50µM, cell 
viability was inhibited dramatically. During culture, significant numbers of dead cells were not 
evident, suggesting that the decreased cell viability results from suppression of cell proliferation, 
but not cytotoxicity. This observation is not surprising since similar alendronate inhibition of cell 
proliferation is also reported with human fetal osteoblast cells,37 osteoclasts 43, 51 and primary 
osteoblasts.50, 52 Though some opposing effects have been reported,38, 53, 54 this may be due to 
variations in experiments, including cell types, culture duration, bisphosphonate analogue 
chemistries and concentrations applied. 
While FPPS siRNA did not influence osteoblast viability significantly, it increases total alkaline 
phosphatase activity significantly compared with controls lacking any treatment. These 
observations indicate that FPPS knockdown enhances osteoblast differentiation without affecting 
cell proliferation. Stronger induction of alkaline phosphatase activity was obtained by treating these 
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cells with 50µM alendronate. These findings concur with those of a previous study suggesting that 
bisphosphonates enhance osteoblast progression from the proliferation stage to the matrix 
maturation stage.37 However, culture mineralization was increased in MC3T3 cells treated with 
50µM alendronate by 55.5%, nearly significant compared with control (p=0.058) and correlates 
with previous reports20 showing increased human fetal osteoblast cell mineralization by 
pamidronate and zoledronate. Thus, N-BP alendronate augments cultured cell mineralization 
within 5 days posttreatment. In contrast, for osteoblasts treated with siRNA, there is no significant 
difference in mineralization between the control and non-targeting siRNA or FPPS siRNA after 
single transfections. To investigate the possibility for disproportionate functional knockdown of cell 
enzyme (ALP) activity, triplicate siRNA transfections dosed every other day were performed to 
minimize FPPS expression during the subsequent cell assay period. While triplicate dosing of 
non-targeting siRNA produces no observable effects on cell mineralization, multiple FPPS 
transfections generate about 10% increase of cell mineralization compared with control. This 
observed increase may suggest some small cell mineralization enhancement from FPPS 
knockdown.  However, FPPS knockdown did not enhance cell mineralization compared with 
50µM alendronate. Although alendronate at 50µM can promote cell mineralization by 56%, this 
effect is obscured by its severe suppression of cell proliferation. Cell mineral deposition by 50µM 
alendronate in term of percentage of cell proliferation (mineralization%×proliferation%) is 84% 
compared to the controls, while mineralization from FPPS single transfection is 95% and by triple 
transfections is 101.7% of the controls. Overall, the effect of FPPS knockdown on cell 
mineralization is not significant. Based on the siRNA results, the direct effect of FPPS changes on 
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cell mineralization is not clear. Osteoclasts and osteoblasts closely communicate and interact with 
each other in vivo to regulate bone remodeling. Bisphosphonates can act indirectly on osteoclasts 
through their action on osteoblast lineage cells.39, 55-58 Therefore, further study is required to 
determine whether FPPS siRNA effects on osteoblasts seen in this study indirectly influence 
osteoclasts. 
In summary, single-dose FPPS siRNA, unlike results obtained from osteoclast cultures, did 
not show any significant cytotoxicity in MC3T3-E1 preosteoblasts. Compared with 50µM 
alendronate which exhibits potent inhibition of cell viability, FPPS siRNA has much milder effects 
on cell proliferation. Both FPPS siRNA and 50µM alendronate can promote cell differentiation 
significantly, but FPPS siRNA increases ALP activity without significantly inhibiting cell proliferation. 
Within 5 days posttreatment, FPPS siRNA did not evidence an influence on cell mineral 
deposition.  
Conclusions 
Significantly, to the best of our knowledge, this is the first report to knock down the molecular 
target of clinically common nitrogen-containing bisphosphonates using siRNA, and comparing 
these effects to alendronate, both on osteoclasts and osteoblasts in similar cultures. Results from 
both the culture of primary murine bone marrow cell-induced osteoclasts and MC3T3-E1 
preosteoblast cells showed that FPPS siRNA suppresses osteoclast viability significantly, but with 
less potency than alendronate at 50µM. There is no observed effect of FPPS siRNA on osteoblast 
proliferation. However, osteoblast differentiation can be significantly increased by FPPS siRNA. 
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Both FPPS siRNA and alendronate show no significant effects on osteoblast mineral deposition. In 
summary, siRNA targeting FPPS has a beneficial effect at the cellular level of inhibiting excessive 
bone resorption and increasing overall bone mass maintenance by its effects on both osteoblasts 
and osteoclasts and suggest that it has clinical potential.  
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LOCAL DELIVERY OF RANK SIRNA TO BONE USING INJECTABLE PLGA 
MICROSPHERE/CALCIUM PHOSPHATE CEMENT  
AUGMENTATION BIOMATERIALS 
Abstract 
This chapter describes design of a new delivery strategy for RNA interfering technology to 
knock down RANK and inhibit osteoclast formation and function. For this purpose, well-known 
resorbable polyester (PLGA) microparticles were utilized as a carrier to deliver RANK siRNA to 
both osteoclast precursors and osteoclasts. As natural phagocytes, osteoclast and osteoclast 
precursors should selectively internalize micron-sized particles versus most other non-targeted 
cells, producing a natural osteoclast and phagocyte cell targeting capability. PLGA-siRNA particles 
were dispersed into clinical-grade injectable calcium-based injectable bone cement, a clinically 
familiar biomaterial used in osteoporosis bone augmentation and fragility fracture fixation. SiRNA 
released from this formulation in vitro retains bioactivity against RANK in cultured osteoclast 
precursor cells, inhibiting their progression toward the osteoclastic phenotype without killing them. 
These data support the proof-of-concept to utilize a clinically relevant approach to improve fragility 
fracture healing in the context of osteoporosis by delivering functional siRNA directly to sites of 




Osteoporosis is a disease characterized by low bone density and quality, with a primary 
clinical presentation of hip, wrist and spine fractures, severely impairing patients’ quality of life.1 
Such fragility fractures affect thousands of patients annually.2 Most osteoporotic fractures require 
operative reduction and stabilization. Fracture healing processes in the context of ongoing 
osteoporosis pathology are especially difficult. Specifically, osteoporotic bone loss is a strong 
setback in healing prognosis. Low bone quality and excessive bone resorption decrease the 
mechanical strength necessary for acceptable, durable fracture healing.  Fracture fixation is 
therefore employed with surgically implanted hardware and bone augmentation materials in 
osteoporotic fracture sites, and augmentation is increasingly used prophylactically at high-risk 
sites of potential fracture. Nonetheless, loosening occurs commonly around such implants, 
producing hardware “cut out”, mandating fixation tooling removal and retarding fracture healing. 
After implantation, large numbers of differentiating osteoclast precursors in the form of monocyte 
macrophages are recruited to the peri-implant area, especially at the bone-implant interface.3, 4 
Their presence often correlates with enhanced bone resorption and osteoclastogenic activities. 
This reduced bone-implant interface area results in aseptic loosening and finally prosthetic failure.  
Two cytokines -- RANK ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) -- 
are essential for the process of osteoclastogenesis.5, 6 RANKL is the key cytokine for promoting 
osteoclastogenesis. Interactions between RANKL and RANK receptor on the surface of osteoclast 
precursors are essential for expression of osteoclast-specific genes,7 bone resorption and survival 
of mature osteoclasts.8 Osteoclastogenesis is negatively regulated by osteoprotegerin (OPG), 
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which is also expressed by stromal cells and osteoblasts.9 OPG is a decoy receptor that competes 
with RANK for binding RANKL.10 In this RANKL/RANK/OPG axis, positive regulator RANKL and 
negative regulator OPG are coordinated through interaction with RANK on osteoclast precursor 
cells in bone sites to regulate normal bone formation and degradation. 
  Clinical approaches to improving bone quality in osteoporosis fixation include reinforcement 
of porous, weakened bones prior to fracture or device implantation (i.e., prophylaxis) by direct 
augmentation of bone around the fracture and fixation hardware using injected prosthetic bulking 
materials.11-15 Bone augmentation using bone cement has already been investigated and widely 
used with vertebral fractures,16 femur fractures,17 humerus fractures,18 and calcaneum fractures.19 
The technique utilizes various biomaterials, including polymethylmethacrylate (PMMA), calcium 
phosphate substitutes (as bone cements, shaped blocks, coatings), various bone grafts, and 
modified implants.20 PMMA is commonly clinically used and shows acceptable compressive 
strength. However, recognized problems with PMMA hinder its applications.  These include 
excessive heat generation during in situ polymerization, lack of quality control during in situ 
preparation, dense nondegrading foreign body, poor control of antibiotic release when drug-loaded 
and poor removal during revision surgeries.21, 22  Studies show that often less than 50% of a drug 
load is bioavailable from PMMA injected in and around bone.23, 24 Compared to PMMA, calcium 
phosphate cements (CPC) have several unique properties for bone, including intrinsic 
osteoconductivity (degradable by osteoclasts), osteoinductivity (infiltrated by osteoblasts and 
replaced with new bone), deployment as viscous setting fluid matrices by local injection and 
acceptable in situ biocompatibility.25-27 Due to its relatively poor mechanical properties, CPC is 
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FDA-approved for treatment of nonloaded bone defects (i.e., generally craniomaxilofacial). In vivo 
degradation of CPC-based cements can vary widely depending on formulation and chemistry, 
induced by both passive physiologic dissolution and active cell-mediated phagocytosis.28 
Individual CPC degradation rate depends on patients’ metabolic health, anatomic site, age and 
sex, as well as cement’s chemistry, density, formulation, porosity, Powder/Liquid (P/L) ratio 
(loading) and resulting particle size. The self-setting ability of CPC within the bone cavity enables it 
to be used in an injectable formulation, which largely expands its utility.29, 30 To date, substantial 
experience supports the feasibility and value of using CPC as a drug carrier in bone augmentation. 
Pharmacologically active molecules of diverse chemistries are readily distributed within the liquid 
bone cement formulation prior to setting, making CPC a controlled drug release medium. Several 
drugs have formulated for release from CPC, such as antibiotics to decrease postsurgical 
infections,31, 32 anticancer drugs to reduce tumorogenesis33 and growth factors to promote bone 
healing.34 However, release rates of encapsulated drugs are limited since most CPC formulations 
are dense monoliths and its in vivo resorption is very slow. To enhance release and CPC 
degradation, soluble poragens can be incorporated into the CPC to more rapidly dissolve and 
enhance CPC porosity and dissolution.35 Additionally, degradable poly(lactic-co-glycolic acid) 
(PLGA) particles are also used within the cement to deliberately introduce large macropores upon 
their degradation, facilitating further active and passive in vivo degradation of cement and 
enhancing bone in-growth at surgical sites.25, 36 Furthermore, the resultant changes of CPC 
handling properties and cement setting are maintained within desired workable ranges.25 This 
provides an opportunity to load both the CPC matrix and encapsulated PLGA particles with drug 
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loads for controlled release strategies from the injectable hybrid biomaterial. 
PLGA is a well-studied degradable polymer long FDA-approved in microsphere and 
microparticle formulations for delivery of several human drugs.37 Bioactive molecule 
microencapsulation in both animals and humans and versatile capacity for sustaining long-term 
controlled drug release in these systems is well-established.38, 39 As a dual-use drug delivery 
medium, PLGA particles have also been tested in combination with CPC to deliver protein bone 
growth factors (rhBMP-2) while also acting as a poragen.40 Historically, PLGA has been widely 
investigated as a delivery vehicle of small molecule drugs41 and proteins,42 and with some promise 
as a delivery vehicle for nucleic acids, including plasmid DNA43 and siRNA.43, 44 Significantly, 
PLGA particles 3-6 µm in diameter are selectively scavenged by host phagocytic cells, providing a 
particle size-selective cell-specific drug targeting and dosing mechanism.45 Therefore, specific 
osteoclast and phagocyte cell uptake can be achieved by controlling PLGA particle sizes to those 
internalized by professional phagocytes while avoiding other cell types in the tissue bed. 
RNA interference (RNAi) is a powerful tool to down-regulate specific mRNA/protein 
expression utilizing a natural intracellular regulatory mechanism in mammalian species.  Gene 
silencing using siRNA has many potential therapeutic applications due to several advantages 
intrinsic to RNAi.46 SiRNAs are well known for their very short circulating half-lives in vivo,47 and 
current challenges in systemic targeting from parenteral siRNA formulations. These unresolved 
issues have produced the current emphasis on local delivery of therapeutic siRNA as a more direct 
clinical goal.48 We have shown recently that siRNA against RANK provides potent in vitro inhibition 
of osteoclast-mediated bone resorption.49 Here we describe a novel strategy to deliver RANK 
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siRNA locally to bone in an injectable CPC matrix, loaded within PLGA microspheres for local 
uptake by bone-resident osteoclast precursors. PLGA particles served to limit siRNA degradation 
and facilitate phagocyte cell-targeted delivery, demonstrating in vitro efficacy in knocking down 
RANK target in osteoclastic cell cultures from a protective osteoclast-targeted siRNA delivery 
carrier released from injectable calcium-based cement reservoir.  
Materials and Methods 
Materials 
 Reagents.  PLGA (50:50 monomer ratio, molecular weight (mw) 57kDa) with lauryl ester end 
groups was purchased from Lakeshore Biomaterials (AL, USA). Branched polyethylenimine (bPEI) 
(mw: 25kDa) and poly(vinyl alcohol) (PVA, average mw 30,000-70,000) were bought from 
Sigma-Aldrich (USA). RNase-free water was prepared using diethyl pyrocarbonate (DEPC) 
(Sigma-Aldrich). RANK siRNA (sense 5’-GCGCAGACUUCACUCCAUAUU-3’, antisense 5’-UAU 
GGAGUGAAGUCUGCGCUU-3’) and RNase-free siRNA buffer were purchased from Dharmacon 
(CO, USA). RANK siRNA’s DNA analogues (5’-GCGCAGACTTCACTCCATATT-3’, 5’-TATGGAG 
TGAAGTCTGCGCTT-3’) were purchased from Integrated DNA Technologies (IA, USA).  
Methods 
 Primary murine cell harvesting and differentiation.  C57BL/6 male mice (6-8-week-old, 
Jackson Labs, ME, USA) were maintained in a specific pathogen-free facility at the University of 
Utah. All procedures were performed as approved by the Institutional Animal Care and Use 
Committee, University of Utah. Bone marrow cells (BMC) were harvested from murine tibias and 
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femurs of C57BL/6 male mice and differentiated into osteoclast precursors using previously 
described methods.49 Briefly, BMCs were cultured in α-MEM (Gibco) containing 10% FBS and 1% 
penicillin-streptomycin (defined for all cell cultures as “complete media”) overnight at a density of 
1×106 cells/ml. Nonadherent cells were harvested the next day and immediately seeded into 
24-well tissue culture plates in complete media with 30 ng/ml M-CSF (R&D Systems) at a density 
of 1×106 cells per well. After 2 days of culture, attached cells were used as osteoclast precursors. 
To generate osteoclasts, precursor cells were incubated in 200ng/ml RANKL and 30ng/ml M-CSF 
(R&D Systems) in complete media (defined as “osteoclast-specific media”), refreshed every other 
day.45 RANKL was expressed using a previously described detailed procedure.49 
 Reverse transcriptase-polymerase chain reaction (RT-PCR).  Total RNA was isolated using 
an RNeasy Mini Kit (Qiagen). Up to 4 micrograms of RNA were used to make cDNA with the 
SuperScript III 1st strand RT kit for PCR (Invitrogen). PCR primers were designed for RANK 
(5’-AGATGTGGTCTGCAGCTCTTCCAT-3’, 5’-ACACACTTCTTGCTGACTGGAGGT -3’) and 
cyclophilin B (housekeeping control, 5’-AGCGCTTCCCAGATGAGAACTTCA-3’, 5’-GCAATGG 
CAAAGGGTTTCTCCACT-3’) using Primerquest software purchased from Integrated DNA 
Technologies (USA). PCR was performed with iTaq DNA polymerase (Bio-Rad, USA), 1.5 mM 
magnesium chloride, 200 µM each of dNTPs, 500 nM of each primer and 2 µL of the cDNA. 
Reactions were performed using the following protocol: 95oC melt, 60oC anneal and 72oC 
extension in the iCycler Thermal cycler (Bio-Rad). PCR products were analyzed on ethidium 
bromide-stained TBE-based 2% agarose gels run at 100V for 30 min and visualized with UV light. 
 Preparation of siRNA/bPEI complexes and siRNA transfection in vitro.  To prepare 
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siRNA/bPEI complexes at various anion/cation charge (NP) ratios, 2µl of 10µM RANK siRNA 
aqueous solution was mixed with 2µl of bPEI solutions of different concentrations (0.016-0.16µg). 
The complex mixed solutions were kept at room temperature for 20 minutes. Then, 4µl of each 
mixture was electrophoresed using ethidium bromide-stained TBE-based 2% agarose gels run at 
100V for 20 minutes, followed by visualization with UV light to assess the siRNA-bPEI complex 
formation. Cell transfections with siRNA/bPEI complexes at fixed NP ratios in complete media 
were performed subsequently. siRNA/bPEI complexes for each well are prepared by mixing 2.5ul 
of 20µM siRNA aqueous solution with 1.6µl, 1.2µl, 0.8µl and 0µl (NP 20, 15, 10 and 0) of 1mg/ml 
bPEI, respectively, in a total volume of 20µl with RNase-free water. After incubation at room 
temperature for 20 minutes, complete media was added to achieve the final volume of 1ml, 
yielding a final amount of siRNA in each well of 1.675µg. The dose was determined based on our 
published results.49 Cell siRNA transfections were always performed in complete media. After 
24-hour incubation at 37oC under 5% CO2, culture media was refreshed with 1ml complete media 
and the transfected cells were further incubated. RNA was harvested 2 days later and RANK 
expression was analyzed by PCR. 
 PLGA microparticle preparation.  Microparticles of PLGA were prepared using a known 
double-emulsion solvent evaporation technique.50 In brief, siRNA or DNA analog/bPEI complexes 
were prepared by mixing equal volumes of 33.5µg of siRNA/DNA analog and 1mg/ml bPEI in 
RNase-free siRNA buffer. Complex-containing PLGA microspheres were prepared by dispersing 
the siRNA/bPEI aqueous solution into a solution of 50mg PLGA dissolved in 2ml methylene 
chloride with intense probe sonication (Biologics, Inc. Ultrasonic 3000, 20s sonication with 10s 
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pause). Then, the w/o dispersion was added into an aqueous 4% PVA solution while vortexing. 
The solvent was extracted by transferring the final w/o/w emulsion into a beaker containing 
aqueous 0.6% PVA solution and stirred for 3~4 hours at room temperature. The solidified 
microspheres were washed using RNase-free water three times followed by lyophilization.  
Particle size distribution, zeta potential and surface morphology.  Particle size distribution 
and zeta potential (surface charge) of PLGA microparticles with siRNA was determined using a 
Malvern Instruments Zetasizer Nano ZS (Westborough, USA) in 10mM NaCl at pH 7.4. To further 
confirm measured particle sizes and surface morphology, scanning electron microscopy (SEM) 
was performed. PLGA microspheres were attached to a metal stub using conductive tape and 
coated with gold in a sputter coater. SEM images of coated samples were captured on Hitachi 
S2460N. 
siRNA loading and encapsulation efficiency.  Following a previously described procedure,38 
3-5 mg PLGA particles were dissolved in DMSO.  The siRNA was extracted by adding equal 
volumes of Tris-EDTA buffer (10mM Tris-HCl containing 1mM EDTA, pH 7.4).  Aqueous layers 
were removed, and siRNA concentration was measured using the QuantlTTM PicoGreenTM assay 
(Invitrogen, USA). Encapsulation efficiency is calculated as the percent of the PLGA-extracted 
siRNA versus the initial feed siRNA amount. The siRNA was then precipitated from the aqueous 
solution by adding 0.3M sodium acetate and 70% (v/v) ethanol. After 30 min incubation at -20oC, 
the solution was centrifuged at 12,000 rpm at 4oC for 30 min. The pellet was dried and analyzed on 
a 2% agarose gel.  
Evaluation of in vitro siRNA controlled release.  DNA analog loaded PLGA particles (1 mg) 
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were suspended in 1ml RNase-free siRNA buffer (pH 7.4), and kept at 37oC under constant gentle 
shaking for 4 weeks. To collect the supernatant, the suspension was centrifuged at 12,000 rpm for 
15 minutes, and supernatant was removed for analysis followed by replacement with the same 
volume of fresh buffer. The siRNA content in supernatant was measured using the QuantlTTM 
PicoGreenTM assay. 
Cytotoxicity assay.  Murine bone marrow cells were cultured in osteoclast-specific media 
with 1 mg PLGA particles loaded with either RANK siRNA or the DNA analogue negative control.  
After 3-day incubation in 37oC, cytotoxicity was measured using CellTiter-Blue Cell Viability Assay 
kit (Promega, USA). 
Particle intracellular degradation studies and RANK knockdown efficiency in culture.  
Fluorescently labeled PLGA particles were prepared by adding 0.5% (weight percentage vs. PLGA) 
6-coumarin dye to methylene chloride.51 Murine bone marrow cells were seeded at 1×106 cells/well 
and incubated with 1 mg fluorescently-labeled PLGA particles in a 24-well plate in complete media 
containing M-CSF and RANKL at 37oC. Particle intracellular degradation studies were performed 
using fluorescence microscopy. Culture media was refreshed every other day. Disappearance of 
punctate fluorescence indicates particle degradation. Murine bone marrow cells were incubated 
with PLGA particles in 24-well plates in osteoclast-specific media. The dose of siRNA per well (125 
nM) was determined using previous published results.49  The RANK siRNA-loaded PLGA 
particle-treated groups were compared with control groups treated with PLGA particles without 
siRNA, and also with DNA analogue-loaded PLGA particle-treated groups. PLGA particles was 
diluted in 1 ml osteoclast-specific media and added to cultures. Total RNA was isolated 4 days 
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posttransfection using an RNeasy Mini Kit (Qiagen). PCR products were analyzed on ethidium 
bromide-stained TBE-based 2% agarose gels and visualized under UV light. 
Loading of siRNA-containing PLGA particles into CPC.  A commercially available injectable 
CPC (62.5 wt% tricalcium phosphate (α-TCP), 26.8 wt% dicalcium phosphate anhydrous (DCPA), 
8.9 wt% calcium carbonate (CaCO3), and 1.8 wt% hydroxyapatite (HAP)) was a gift from BioMet 
Osteobiologics (NJ, USA). Pure CPC cement was prepared according to the manufacturer’s 
instructions and used as the control. PLGA microparticles were loaded into dry CPC powder at 
10% (w/w). This mixture was added into a 5-ml syringes (Becton Dickinson, NJ) filled with 
aqueous solution provided in the kit to achieve the liquid/powder ratio of 0.35 ml/g.25 Subsequently, 
thorough mixing required manual stirring within the syringe barrel for 60 seconds. The resulting 
CPC suspension containing PLGA microparticles was then injected into a clean rubber mold 
(circular cylinder shape: 6 mm diameter, 6 mm height) to cure CPC samples.  
Characterization of the PLGA-modified CP cement.  The total porosity of PLGA 
microparticle-loaded CPC was determined by heating CPC specimens at 650oC for 2 hours to 
pyrolyze the PLGA particles. CPC sample weight is measured before and after pyrolysis. Total 
porosity and macroporosity is calculated from the following equations52: 
<1>;      <2> 
                           
 Equation <1> calculates macropores produced by PLGA particles. Equation <2> yields the 























where mburnt is the weight of samples after PLGA removal by heating, v (cm3) is the volume of the 
sample, mpureCPC is the weight of pure CPC sample, and ρHAP (g/cm3) is the density of 
hydroxyapatite (3.156 g/cm3).53  
 CPC mechanical testing.  CPC samples were vacuum-dried overnight. Compression 
strength was measured using an Instron (Instron TT-CM; Instron, Canton, Massachusetts). 
Samples were placed in the mechanical testing bench and compressive strength was measured at 
a crosshead speed of 0.5 mm/min. Mechanical stiffness was determined and compared between 
CPC alone and 10:90 PLGA/CPC samples. 
 CPC composite matrix morphology.  Cross-sections of CPC samples (vacuum dried 
overnight) were visualized for porosity and morphology by SEM.  
 RANK knockdown efficacy by siRNA released from modified cement in vitro.  In order to 
fabricate CPC composite wafers to deploy into 24-well plate cell cultures for siRNA release and 
bioactivity assays in cell culture, 1 mg PLGA microparticles carrying 1.675µg were mixed 
thoroughly with 9 mg CPC powder (10:90) on a sterilized plastic weighing plate, and dissolved in 
aqueous solution to reach the same liquid/powder ratio of 0.35 ml/g as used for mechanical 
samples. A flat medicine spoon was used to mold the CPC mixture into a flat disc. After curing the 
CPC into a hard wafer, a razor blade was used to cut and remove pieces of the plate to fit into 
wells of 24-well culture plate. Murine bone marrow cells were then seeded onto these CPC wafers 
at 1×106 per well in the wells. Cells were then incubated with 30 ng/ml M-CSF in complete media 
for the first 2 days and followed by incubation with osteoclast-specific media. Cell RNA was 
harvested 8 days posttreatment and subject to RT-PCR. PCR products were analyzed on ethidium 
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bromide-stained TBE-based 2% agarose gels run at 100V for 30 min and visualized with UV light. 
 Cell imaging and statistical analysis.  Fluorescent images of adherent cells in culture were 
captured using a Coolsnap color CCD camera attached to a Nikon E600 microscope using Image 
Pro Plus 4.0 software. All images were captured using the same exposure time period and 
corrected for unequal field illumination. Analysis of variance (ANOVA) followed by two-tailed 
student’s t-test was used for statistical analysis. All experiments were repeated three times. Error 
bars represent the standard error of the mean. Statistically significant was considered if p < 0.05. 
Results 
Particle preparation 
 Optimization of RANK siRNA/bPEI complexes.  To determine the NP threshold for stable 
siRNA polyplex formation, different amounts of bPEI were mixed with 0.14nmol RANK siRNA at 
NP ratios of 0, 0.5, 1, 2 and 5. Figure 4.1A shows migration of siRNA/bPEI complexes by gel 
electrophoresis. With NP ratios of 0, 0.5 and 1, siRNA bands migrate separately on the gel, 
indicating uncomplexed, excess siRNA. When the NP ratio is equal to 2, the density of the siRNA 
band is substantially weaker. When the NP ratio is 5, no siRNA migrates freely in the gel, indicating 
that all siRNA molecules are initially entrapped in bPEI complexes through electrostatic 
interactions. Knowing that an NP value of 5 is the threshold, RANK expression was assayed after 
cells were incubated with NP 10, 15 and 20 for 2 days. RANK gene expression starts to decrease 
when NP is 15, and significant down-regulation was shown when NP is 20 (Figure 4.1B). 
Therefore, NP 20 was used for the following delivery experiments. 
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 Characterization of PLGA microspheres.  PLGA SEM images (Figure 4.2A) revealed that 
microspheres display the expected spherical morphology with an average size of 5.45 ± 0.88 µm 
as detetmined from light scattering particle size analysis. PLGA microparticle surface charge was 
-21.07 ± 1.42 mV. The siRNA encapsulation efficiency in these PLGA particles using the 
double-emlusion method is 80.75 ± 4.1%. (n=3) 
 RANK knockdown effects, cytotoxicity and intracellular degradation of PLGA microspheres.  
Cytotoxicity from PLGA microparticle exposure in culture was determined: no significant cell 
toxicity differences were observed between controls without treatment and cells treated with 
particles (Figure 4.2B). Gel electrophoresis showed that the charge and molecular weight of RANK 
siRNA extracted from PLGA particles was similar to the control stock siRNA (Figure 4.2C). RNA 
harvested from murine-derived primary bone marrow cells incubated with microparticles for 4 days 
was subject to RT-PCR. Cells incubated with RANK-siRNA-loaded PLGA particles showed 
significant down-regulation of RANK expression, compared with controls without microparticle 
incubation and cells treated with microparticles loaded with dummy DNA analogues as controls 
 
Figure 4.1 siRNA polyplex preparation. (A) Gel migration of RANK siRNA/bPEI complexes at 
different NP ratios (0-5). (B) RANK expression in BMC cultures 3 days post-BMC treatment with 




Figure 4.2 Physicochemical and functional properties of siRNA encapsulated in PLGA 
microparticles. (A) SEM image of PLGA particles. (B) Murine BMC cell cytotoxicity of RANK 
siRNA/bPEI complexes incorporated in PLGA particles in serum-based cultures after 3 days. 
(C) Gel electrophoresis comparison of the RANK siRNA extracted from PLGA particles versus 
control stock siRNA. (D) Significant down-regulation of RANK in murine BMC cultures by 
siRNA-loaded PLGA particles. RANK siRNA DNA analogue-loaded PLGA particles served as 
negative control. (E) Degradation of fluorescent-labeled PLGA particles in BMC over time. (F) 
PLGA particles were phagocytosed by BMCs compared to nonphagocytic cells. (a) No particle 




(Figure 4.2D).  Efficient cell phagocytosis of PLGA microspheres was also confirmed. Particles 
were readily taken up by cells and started to degrade after particle uptake. After 11 days in culture, 
microspheres disappeared and the enclosed fluorescence marker was distributed evenly 
throughout the cell volume (Figure 4.2E). Figure 4.2F shows PLGA particles were selective 
phagocytosed by BMCs compared to nonphagocytic cell cultures. 
 In vitro release of DNA analogues of RANK siRNA from PLGA microparticles.  Murine RANK 
DNA analogue-loaded PLGA microparticles were used (Figure 4.3) to evaluate the in vitro release 
profile of siRNA from microparticles due to its similar physical chemistry and structure, higher 
stability and lower cost compared to siRNA. There was little or no release from the PLGA particles 
over 50 days in culture media alone.  
Preparation of PLGA/CPC composite 
 Characterization of PLGA microparticle/CPC composite matrix.  Table 4.1 shows calculated 
































Figure 4.3 Release kinetics of RANK siRNA analogue DNA from PLGA microparticles. 1mg 




CPC samples had a porosity of 55%, while the PLGA-loaded CPC samples (10% w/w particle load) 
displayed a higher porosity of 63%. The macroporosity introduced by PLGA particles is 35%. 
 CPC morphology and mechanical characteristics.  Figures 4.4A and 4.4B show SEM images 
of the cross-sections of pure CPC and PLGA particles within the cured 10:90 PLGA/CPC matrix, 
respectively. PLGA microparticles are shown distributed homogeneously within the CPC matrix 
(Figure 4.4B). CPC matrix stiffness is expressed as maximum compressive load (N) versus 
maximum compressive extension (mm). Control samples (CPC alone) showed a stiffness of 251.8 
±27.14 N/mm. The 10% PLGA incorporated CPC samples had an average value of 200.5±9.57 
N/mm. No significant difference in stiffness was observed between the CPC alone and the 10:90 
CPC samples (Figure 4.4C).  
 Down-regulation of RANK gene expression by RANK siRNA-loaded PLGA/CPC composite 
microparticles.  Murine BMC RNA was harvested 8 days after these cells were seeded on CPC 
wafers. PCR results shows significant suppression of RANK expression in cells incubated with 
RANK siRNA-loaded PLGA/CPC compared with control without particle treatments and DNA 
analogue-loaded PLGA/CPC matrices (Figure 4.4D). 
 





Increasing incidence of osteoporotic fragility fractures and their prolonged healing 
requirements postfixation constitute major clinical challenges that require better clinical solutions 
to improve osteoporosis patient outcomes. Though bisphosphonate drugs are effective against 
generalized osteoporosis, their severe suppression of bone turnover largely inhibits fracture 
healing.54, 55 Currently, no therapy has yet produced significant improvements in osteoporotic bone 
augmentation for improved fragility fracture healing. RNA interference is a new promising drug 
 
 
Figure 4.4 Characteristics of CPC matrices: morphology, mechanical and functional 
properties. (A) SEM of cross-section of pure CPC, (B) SEM of cross-section of PLGA/CPC 
composite, (C) Comparison of mechanical stiffness between CPC alone and 10:90 PLGA/CPC 
samples. (D) significantly reduced RANK expression in murine BMC cultures by treatment with 
RANK siRNA-PLGA particle-loaded CPC matrices for 8 days. RANK siRNA DNA 




class with unique mechanisms to selectively target pathological pathways. Yet, effective siRNA 
delivery to target tissues is difficult, mandating primarily local or topical routing to produce 
therapeutic efficacy to date. Importantly, siRNA has not yet been studied to ameliorate 
osteoclast-mediated bone loss in the context of fragility fractures and fixation tooling.  This 
opportunity is explored in this study with in vitro assays of siRNA delivery using injectable bone 
augmentation biomaterials (CPC) clinically applied in osteoporosis as delivery matrices.  
As RANK is recognized to play an essential role in regulating osteoclastogenesis, it is a 
natural target for siRNA bioactivity in the context of osteoporosis therapy.56 Activation of RANK by 
its ligand, RANKL, is required for the formation and activation of osteoclasts.57, 58 Our previous 
RANK siRNA delivery methods show specific siRNA silencing of RANK in both macrophage-like 
secondary cell line cultures (RAW264.7) and primary murine bone marrow cultures to inhibit 
osteoclast formation and bone resorption in vitro, and collectively support proof-of-concept to 
deliver therapeutic RANK siRNA to osteoclasts locally.49 Therefore, this current study continues 
the development of this concept for locally delivered siRNA targeting RANK from bone cement, 
assessing in vitro siRNA delivery and RANK knockdown efficacy from PLGA particles within CPC 
bone augmentation materials to target osteoclasts and osteoclast precursors and suppress 
osteoclast-mediated bone resorption.  
To increase the stability and loading efficiency of siRNA in PLGA microparticles, RANK siRNA 
was complexed with bPEI at different NP ratios (i.e., NP ~ 0-5) because of bPEI’s known utility as 
a nonviral nucleic acid delivery vector.59-61 The siRNA/bPEI migration assay demonstrates that 
siRNA forms stable complexes with bPEI when the NP ratio ≥ 5. Transfection of RANK siRNA in 
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mouse bone marrow cells in serum-based cultures with these polyplexes showed produced RANK 
gene silencing monitored by PCR 2 days posttransfection. Compared to controls without treatment, 
RANK gene expression in BMC cultures shows no significant gene expression reduction when the 
NP ratio was 10, but begins to decrease when the NP ratio equals 15. Significant RANK gene 
silencing is achieved when the NP ratio reached 20, indicating that siRNA specifically 
down-regulates RANK message RNA expression in BMCs. Therefore, NP 20 was used for the 
following experiments. RANK knockdown effect is comparable with using DharmaFECT 4 
transfection reagent in our previous published results.49 
The established double emulsion method was used to prepare all PLGA microspheres. For 
maximum particle loading and protection of siRNA payloads from nucleases, 4% (w/v) PVA was 
used for microparticle preparation.50, 62 With modifications of the fabrication process, including the 
time and power of sonication, microparticle size was controlled within the range of 1~10 µm, to 
selectively target particle uptake exclusively by professional phagocytosis.45 PEI has been proven 
previously to increase oligoDNA encapsulation in PLGA particles at least 2-fold relative to that 
without PEI, especially for preformed PEI-oligoDNA polyplexes, and to increase cellular 
accumulation of nanoparticles.63 For this study, use of bPEI improves the siRNA PLGA particle 
encapsulation efficiency to 81%, which is comparable with previous published encapsulation 
efficiency of preformed siRNA-PEI in PLGA particles. Cytotoxicity from siRNA-loaded PLGA 
particles was analyzed by culturing BMCs with PLGA particles in serum-containing complete 
media at minimum effective dose determined before.49 No significant cytotoxicity was observed. 
Electrophoresis results showed that the extracted siRNA from these particles maintained a similar 
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charge, migration and molecular weight as the uncomplexed siRNA. Microparticles were readily 
phagocytosed by BMCs compared to nonphagocytic cell cultures, establishing this particle 
size-dependent targeting mode, and gradual intracellular particle degradation was observed using 
fluorescence imaging. Complete microparticle degradation was achieved in 11 days of incubation 
in cell cultures. 
In vitro release profiles of DNA from PLGA microparticles have been shown to be dependent 
on the molecular mass of the PLGA; increasing PLGA molecular weight reduced the encapsulated 
DNA release rate.64 Little or no release of DNA from PLGA particles was shown from PLGA 
microspheres where the PLGA molecular weight was greater than 30kDa.65  OligoDNA release 
results from polyplexes in PLGA microparticls are consistent with this previous report. Only 3% of 
loaded oligoDNA, as a stable siRNA analogue for this study, was released from the PLGA particles 
of molecular weight 57kDa over 7 weeks in siRNA buffer. High molecular weight PLGA particles 
protect encapsulated DNA and maintain the particle integrity until particles are released from CPC 
to target cell candidates by phagocytosis.  Clearly, there is a difference between particle 
degradation to release the nucleic acid payload within cells (i.e., 11 days, Figure 4.2D) versus to 
water (negligible release after 50 days to water, Figure 4.3).  OligoDNA analogue/bPEI 
polyplex-loaded PLGA particles posses similar polyplex charge as RANK siRNA and the same 
particle surface charge when loaded into PLGA particles (Table 4.1). However, as expected, the 
actual siRNA/bPEI PLGA particles effectively reduced RANK expression in BMC cultures, 
compared with control oligoDNA analogue/bPEI-loaded PLGA particles, indicating that decreased 
RANK expression is due to specific siRNA taken up by phagocytes and subsequent gene 
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sequence-specific knockdown. The retention of physicochemical and functional integrity of RANK 
siRNA during the encapsulation also suggests that the polyplex polymer effectively protects siRNA 
during particle fabrication. Taken together, these results support the utility of siRNA/bPEI-loaded 
PLGA microparticles for specific suppression of RANK expression in osteoclast precursors in 
serum-based cultures of NP ratios of 20. 
CPC has been used by the orthopaedic community for osteoporotic fracture healing.66, 67 
Similarly, PLGA particles have been previously loaded into CPC as drug delivery vehicles and as 
an additive to increase CPC macropore-mediated bone integration.  Extending this concept to 
PLGA microparticles encapsulating RANK siRNA as CPC injectable composite structural and drug 
delivery materials with dosing and bioactivity sufficient to suppress osteoclast formation and 
function and increase the periprosthetic bone density was the goal of this study.  The design calls 
for particle-selective delivery to professional host-resident phagocytes responsible for bone loss in 
osteoporosis, and application of the CPC matrix as a bone augmentation material adjunct to 
fixation.  
PLGA particles formulated into injectable clinical-grade CPC are known to increase total CPC 
porosity and function as a delivery vehicle.35 Addition of 10% or 20% (w/w) PLGA in CPC retains 
all CPC physical parameters within surgically workable ranges, but 20% (w/w) PLGA particle 
loading is the maximum loading to maintain composite cement injectability.36, 40, 68, 69 CPC 
containing 10% PLGA microspheres has similar properties with CPC alone.25 Therefore, the 10% 
(w/w) PLGA particle/CPC composite formulations were selected for siRNA delivery in this study. 
After cement curing and setting, the PLGA/CPC formulation formed a rigid scaffold with 
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homogeneously distributed PLGA microspheres. Addition of these PLGA microparticles 
significantly increased the porosity of the cement (Table 4.1), implying the improvement of 
interconnectivity in the cement. Significantly, as long as pore interconnectivity is obtained, PLGA 
particle release will not be dependent on slow CPC degradation or dissolution kinetics, yielding a 
versatile sustained release system. In addition, such interconnectivity also can accelerate overall 
aqueous access, penetration and degradation of CPC.  
Matrix mechanical properties could also be compromised with higher PLGA particle 
incorporation. Based on mechanical testing results from the 10% formulations of PLGA-loaded 
CPC, no significant differences are observable in stiffness between CPC alone and PLGA/CPC 
composites at their as-cured initial stage. A previous published study showed significant 
differences in compression strength after 3 days of the matrix degradation time.35 
For cell cultures, thin, flat CPC wafers were used to accelerate PLGA particle release to 
produce an experimentally accessible cell culture period.  Successful knockdown of RANK gene 
by incubating osteoclast precursor phagocytic cells with RANK siRNA/PEI PLGA 
particle-incorporated CPC proves the facility of this bone targeting delivery system.  Unchanged 
RANK expression observed from DNA analogue/bPEI PLGA-incorporated CPC and blank CPC 
control cell cultures implies the desired specific knockdown by the released siRNA sequences in 
cell culture. We have previously shown specific siRNA-induced suppression of RANK expression 
and significant inhibition of osteoclast formation and bone resorption in both secondary RAW264.7 
and primary cultures.49 PLGA particle release must start with the particles exposed on the CPC 
matrix surface and newly generated CPC pores can then increase their interconnectivity over time 
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to facilitate further particle release and make cement more porous and susceptible for further 
degradation. However, this in vitro release profile will be very different from in vivo kinetics, due to 
body fluid transport, bone mechanical stress influences and individual pathological conditions. In 
vitro studies have shown that the overall pH of the medium around 10:90 PLGA/CPC samples 
decreased to 4.4 after 12 weeks’ incubation from PLGA acid by-product production and the 
significant pH decrease started to show after week 4.35 In vivo, however, the local tissue system 
may be buffered sufficiently, depending on the deployed CPC volume and the CPC-PLGA intrinsic 
acid-base interactions.  
Future in vivo studies will exploit local siRNA delivery to bone from bone augmentation 
devices and injected liquid depots. This strategy seeks to provide a novel, clinically relevant 
approach to improve osteoporotic fragility fracture healing using current clinical bone 
augmentation strategies in osteoporosis, while also remaining amenable to local siRNA 
therapeutic drug delivery directly from bone defects and common fracture fixation hardware. 
Conclusions 
We have shown that siRNA can be encapsulated within PLGA microspheres without 
significantly impairing its functional integrity. As a result, targeted phagocytic cell-specific delivery 
can be achieved by controlling particle sizes within the microrange. This study supports the 
concept of applying the unique combination of bone augmenting CPC and local siRNA 
cell-targeted particle delivery achieved by PLGA-encapsulation of siRNA molecules and siRNA cell 
uptake targeted from CPC matrices injected into bone augmentation sites. RANK-targeted 
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knockdown in osteoclasts and their precursor phagocytic cells can be achieved by particle 
size-cell phagocyte discrimination. This selectively targets osteoclastic phenotypes in 
augmentation zones where osteoporosis has produced low bone density and allowed CPC 
injection. PLGA particle release and degradation produces CPC macropores known to facilitate 
further particle release, and promote bone in-growth, simultaneously, with suppression of bone 
resorption in peri-implant areas needed to facilitate healing and mechanical stabilization 
processes. 
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SUMMARY AND PROPOSED FUTURE WORK 
This dissertation research focuses on the development of a novel clinically relevant approach 
to improve osteoporotic fragility fracture healing using locally delivered small interfering RNA 
(siRNA) to osteoporotic sites using clinically familiar interventional technology. Two cellular targets 
have been investigated for their efficacy in inhibiting osteoclast-mediated excessive bone 
resorption. A combination device strategy has been designed to introduce siRNA as a therapeutic 
approach locally to bone. 
Major Accomplishments of This Dissertation Research 
○ Both osteoclast precursors and mature osteoclasts can be successfully transfected by 
siRNA in serum cultures without toxicity; both the RANK gene and protein expression can 
be successfully knocked down by RANK siRNA; both osteoclast formation and specific 
functions can be significantly suppressed without toxicity in vitro. Significantly, our in vitro 
studies support RANK as a potent and attractive target for siRNA control in osteoporosis 
fracture healing. 
○ We first reported the knockdown of the molecular target of clinically common 
nitrogen-containing bisphosphonates, farnesyl pyrophosphate synthase (FPPS) using 
siRNA, and compared these effects to alendronate, both on osteoclasts and osteoblasts in 
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similar cultures. Results from both the culture of primary murine bone marrow cell-induced 
osteoclasts and MC3T3-E1 preosteoblast cells showed that siRNA targeting FPPS has 
substantial effects at the cellular level of inhibiting excessive cell-based bone resorption 
and increasing overall bone mass maintenance by its effects on both osteoblasts and 
osteoclasts, suggesting clinical potential.  
○ We have designed a novel strategy to deliver anti-RANK siRNA-incorporated PLGA 
particles from injectable calcium phosphate cement (CPC) carriers to demonstrate their 
efficacy in inhibiting osteoclast-mediated bone resorption in vitro. 
Proposed Future Work 
With several important in vitro studies accomplished as significant proof-of-concept, the next 
step moves to critical in vivo evaluations of the designed PLGA/CPC system using an animal 
model of osteoporosis. Two ovariectomized rat bone defect models are proposed for this 
extension. The objective of this in vivo work is to show biological transformations in osteoporotic 
bone from this therapeutics approach. Expected deliverables include proof of concept of the local 
siRNA delivery approach for reversal of surgically imposed osteopenia and loss of bone mineral 
density in an animal model, and dose-response evaluations to permit extrapolation to human bone 
therapies.  
Human osteoporosis is defined by World Health Organization as BMD showing 2.5 standard 
deviations (SD) below the average value of healthy adults (T-score). Laboratory animals models 
for osteopenia include rodents (rats, mice, rabbits), dogs, nonhuman primates (monkeys, large 
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apes), and ruminants (sheep). Each species exhibits strengths and weaknesses in modeling this 
disease, and each species has limited appropriate characteristics for modeling certain aspects of 
bone demineralization diseases. As osteoporosis is a hormonally induced disease occurring late in 
life, most animals do not experience osteoporosis as they die soon after their reproductive maturity 
is finished.  Since the advent of improved healthcare and nutrition in most societies in the 20th 
century, most humans are an exception to this rule, living decades after their reproductive potential 
is completed.  Only the larger apes can manifest osteopenia at advanced ages, such as 
monkeys.1  BMD decreases are difficult to compare among different species due to different 
methods and equipments used in studies. However, BMD reduction by ovariectomy and 
calcium-restricted diet in animals is lower than osteoporotic humans.1 In addition, human 
osteoporotic vertebral bodies are quite different from animal species. Interspecies differences in 
bone architecture result from different anatomical features and weight bearing, and site-specific 
differences should be carefully considered. Hence, use of animal models for a strictly human 
disease is always difficult. Ovariectomized rats have been studied most as approximate 
osteoporotic models. Estrogen deficiency-induced rat skeletal bone loss mimics postmenopausal 
cancellous bone loss.  However, the absence of a Haversian system in cortical bone and different 
bone remodeling in young rats largely limit its application.2 Nonhuman primates, naturally 
developing osteoporosis when living to advanced age, are closer to human physiological 
conditions.  Ovariectomy can result in a bone loss of -1.4SD compared with control animals.3 
Monkeys can develop age-related osteopenia,4 but monkeys must be over 30 years old, which 
largely restricts the practical application of this experimental model.5  This nonhuman primate 
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model was pivotal for Mercks’ approval of bisphosphonate drugs to allow them to proceed to 
human trials. However, problems of cost, handling and ethics largely restrict use of this nonhuman 
primate model.  Using sheep, decreases in BMD or bone mass were reported at distal femur and 
spine in ovariectomized sheep model.1 Additionally, sheep have intrinsic advantages in their ease 
of maintenance and more human-relevant bone size and anatomy/physiology compared with other 
large animal models.6 A major problem in using the sheep for disease models requiring genetic 
monitoring is that its genome database is not as well-developed as other species. Dog models are 
more appropriate for intracortical bone remodeling compared to other animal models and 
well-established.5 However, ovariectomy does not change BMD values in dogs.1 Compared to 
other species, rats and mice are much less expensive and easy to maintain, and widely available 
both as in-bred wildtypes and numerous mutant knockouts and knockins. Some transgenic mouse 
models, such as OPG knockout mutants, exhibit osteoporosis. Among various osteopenia models, 
the well-established ovariectomized (OVX) wildtype (Wistar) rat model is the most commonly used 
due to its pathologic reproducibility and relative efficiency.5 Ovariectomy in rats was reported to 
reduce mean BMD by about 7% compared to controls in the femur and 16% reduction in bone 
mechanical properties at the femoral neck.1  Moreover, the rat is a well-established model for 
bone cement use, fracture healing and bone implantation with a relatively short lifespan and 
well-characterized skeleton.1 Substantial published data available for this OVX rat model make it 
preferred for preliminary in vivo therapy studies in experimental therapies. After important 
proof-of-concept in rodentia, a large animal model is better justified but not simple to accomplish. 
Future work to evaluate locally injected RANK siRNA-encapsulated PLGA particle delivery in 
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CPC carriers to improve healing of large segmental bone defects in osteoporotic rat femurs under 
external fixation. The large segmental femoral defect model is well-established7-9 and used to 
evaluate bone healing in long bone osteoporosis under external fixation. The AO Foundation’s 
Rat-Fix™ commercial external fixator tooling kit also makes this the model of choice for fragility 
fracture modeling under human-relevant orthopedic fixation conditions. The objective of this in vivo 
work is to test the improvement of large segmental bone defect healing by our modified CPC.  
A significant 40% reduction in the cross-sectional area of fracture callus was found in 
osteoporotic rats, and 23% reduction in bone mineral density (BMD) in their bone healing was 
reported between the osteotomized and wildtype rat femurs.10 Reduced rates of fracture callus are 
induced by ovariectomy in rats.11 A study of ovariectomized sheep showed a dramatic 33% 
decrease in torsional stiffness in healed osteoporotic fractured animals.12 Osteoporosis bone 
mineral density is expected 6 weeks after the ovariectomy in the rat as a concomitant 60% 
reduction in femur bone mineral density was reported.13 Therefore, 6-week postovariectomy is 
chosen as the starting point for in vivo surgery models. 
The large segmental rodent defect model has been extensively used for evaluating bone 
grafting materials 7, 8, 14, 15 and hence chosen to test our modified CPC for bone regeneration in the 
context of rat osteoporosis fragility fracture. A 5 mm mid-diaphyseal segmental defect will be 
created, since published data show 100% femoral nonunion at 5 mm after 9 weeks in the rat.7, 8 
Furthermore, it has been shown that 9 weeks are sufficient to show formation of bone shell and 
significant bone healing in the model treated with rhBMP-2.8 Therefore, 5 mm excision and 9 week 
experimental duration are initially chosen for our studies. However, we realize that longer periods 
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might be required to differentiate significantly from controls since callus and shell are not mature 
bone healing modes. Bone healing efficacy using the proposed CPC formulation with siRNA/PLGA 
particles will be compared to 1) CPC alone, 2) CPC with unloaded PLGA particles, and 3) CPC 
with two siRNA incorporation levels (see Table 5.1). Rats will be assigned (n=42/cohort, see 
Section 2.3) to each group: nine rats for histological examination/cohort (3 rats per time point at 
three time points (3-, 6- and 9-week sacrifice endpoints),7, 8 and 33 rats for all other analyses. 
Group sample size was determined from power analysis based on torsional strength analyses 
from a previously study using the same rat model.8 This power analysis determined that, with a 
significant difference of torsional strength between rats without treatment and CPC alone-treated 
groups, and the alpha set at 0.05, 28 animals per group provided a power above 80%. An 
additional 20% increase (5 rats) is included to account for pilot studies, inevitable animal loss due 
to infection, transport and other unforeseen complications.  
Methods 
PLGA/CPC composite preparation.  PLGA microparticles prepared as described in Chapter 
4 (Materials and Methods-PLGA particle preparation) will be sterilized by ethylene oxide, assayed 
TABLE 5.1 LARGE SEGMENTAL DEFECT OVARIECTOMIZED RAT COHORT DESIGNS 
FOR SIRNA DELIVERY FROM CPC MATRICES 
Group 1 Sham control 
Segmental defect created but the segmental bone is 
replaced into the defect site 
Group 2 Control A Defect with 100% CPC implant alone 
Group 3 Control B 
Defect with CPC implant with 15% w/w nonloaded 5µm 
PLGA particles 
Group 4 Treated/high dose Defect with CPC with 20% w/w 5µm siRNA/PLGA particles 




for LPS contamination, tested for siRNA bioactivity in vitro as established on osteoclast cultures 
and reconstituted with CPC powders for injection as described in D.2.A. A glass mold of 4 mm 
(diameter) × 5 mm (height) with a central hole of 1.5 mm will be used for cement cylinder 
preparation.   
Animal model preparation.  Osteoporotic female Wistar rats (n=210 total, ~250g) will be used, 
ovariectomized at the age of 5 months. A bilateral ovariectomy using a dorsal approach will be 
performed following well-established protocols.16 Briefly, after anaesthesia, a 1 cm incision will be 
made on the rat’s back.  Both ovaries will be excised and fallopian tubes ligated using absorbable 
suture material. The peritoneum and muscle will be sutured and the skin closed with wound clips. 
Osteopenia is expected 6 weeks postovariectomy as a reduction in femur bone mineral density of 
60% assessed in-house by dual-energy x-ray absorptiometry (DEXA, Hologic QDR-1000/W).13 
Bone surgeries to establish defects and to place various CPC implants will be performed (see 
below) after that time point. All rats will be housed individually in cages in the University of 
Utah-approved animal facilities and have access to standard medical care, calcium-deficient chow 
and water ad libitum. 
Femoral defect surgical protocols.  One day before surgery, all rats will undergo dual-energy 
X-ray absorptiometry (Core facility, University of Utah) of both femurs and basal bone mineral 
density will be recorded. Each rat will receive one implant in the right femur with external fixation. 
The entire surgical protocol will be performed as routinely described.7-9, 14 Rats will be anesthetized 
by intraperitoneal injection of sodium pentobarbital (50 mg/kg) prior to the operation. A 3 to 4 cm 
longitudinal incision will be made along the right femoral axis.  An external fixator six-hole 1.2 mm 
  
161 
LC-DCP mini-plate (Mouse-Fix™, AO/ASIF Synthes, PA, USA, see Figure 5.1) will be fixed to the 
anterior portion of the femur with four threaded Kirchner pins 1.2 mm in diameter (Zimmer). A 5 
mm middiaphyseal segmental defect will then be created using a dental burr. The operating field 
will be irrigated thoroughly, the cement cylinder implants inserted into the defect and the wound 
closed with sutures.  
Evaluation of siRNA-mediated bone defect healing 
Radiographic evaluation.  At 3, 6 and 9 weeks postsurgery, rats will be anesthetized and live 
radiographs and microCT scans of the right femur will be collected (School of Medicine Core 
facilities, University of Utah). The criterion of a united defect is the observation of continuity of 
femurs restored by a bone shell or bridging callus formed from radiographs and 3-D CT imaging. 
The number of united femurs in each group at each time point will be recorded. 
 Explant histology/histomorphometry: At each experimental time point (3, 6 and 9 weeks 
postsurgery), three rats will be sacrificed and tissue from the area of the defect and the adjacent 
bone will be removed and preserved using a well-established procedure: fixation in formalin, serial 






Figure 5.1: (A) Concept of femoral large segmental rat defect model with the RatFix™ 
LC-DCP plate external fixation stabilizer and implanted siRNA-loaded CPC bone cement 
device and (B) MouseFix™ plate on explanted murine femur. (C) AO Foundation’s 




alcohol dehydration and polymerization in MMA. Sections with 500 µm thickness will be cut 
parallel to the long axis of the bone and further polished to 10 µm (ARUP, University of Utah) for 
histochemistry. Three sections will be made for each implant from central sections, and some 
stained with hematoxylin and eosin for general histological analysis. Others will be immediately 
stained with methylene blue/basic fuchsin for identification of cement line.17 Specifically, thin 
sections will be first incubated in mouse antirat RANK for 1 hour followed by peroxidase 
conjugated rabbit antimouse IgG incubation for half an hour. Then 3,3’-diaminobenzidine 
tetrahydrochloride will produce a brownish color by reaction with peroxidase. Methylene blue/basic 
fuchsin will then be stained. After washing in PBS, sections will be subjected to TRAP assay 
(marker for osteoclasts). All sections will be investigated by light microscopy to analyze bone 
formation, RANK expression (immunohistochemistry) and osteoclast numbers (staining and 
antibody markers) in the periprosthetic and defect areas. Ten images from each section will be 
averaged for numbers of osteoclasts per image. 
Dual energy x-ray absorptiometry.  At week 9, 33 rats from each group will be sacrificed. 
Both femurs will be harvested, wrapped in saline-saturated filter paper and stored in sealed plastic 
bags at 4oC until testing.7 The surrounding soft tissue and the fixation plates together with pins will 
be removed. The harvested femurs will be subjected to dual energy x-ray absorptiometry (Hologic 
QDR-1000/W, School of Medicine Core facility, University of Utah). Bone specimens will be 
oriented with the anterior-posterior plane along the scanner beam axis. A constant area of 5×10 
mm, including the defect region, will be scanned and analyzed. Data of BMD and area of bone 
formation (BA) will be obtained by software analysis. 
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 microCT determination of bone defect healing quality.  Postmortem µCT at final 
postmortem follow-up (General Electric EVS-RS9 micro-CT, Utah School of Medicine Core facility, 
or S. Miller lab) will be used to produce a cross-sectional area of callus relative to bone and 
high-resolution (36 micron voxel) images of bridging callus, defect site mineralization and polar 
moment of inertia in femurs. The micro-CT data will be analyzed with imaging software (Northern 
Eclipse, PA) to determine any differences in defect sizes and bone mineralization amounts.18, 19 
Explanted femur mechanical testing.  Following absorptiometry and microCT analyses, 
femurs will be mechanically tested. Both bone ends of each femur will be placed in purpose-built 
aluminum potting fixtures with a height of 10 mm each. The fixtures will then be filled with plastic 
padding (Bondo), so that the bone ends became immovably embedded, leaving the remaining 
section of the femurs between the fixtures free for testing. A custom jig will be used to ensure 
correct alignment of the bone axis along the loading axis of the testing machine. All specimens will 
be tested to failure in torsion at room temperature on an electromechanical testing machine 
(MZ500S, Maruto Instrument Co., Japan) at a rate of 6°/sec, with no axial load during the testing. 
Values for angulation and torque will be collected 50 times per second until failure, using 
commercially available software (LabVIEW, National Instruments, Texas). The collected data will 
be digitally stored and will include the variables of time, angulation and torque.  Based on the data 
collected, maximum torque, torsion at failure (angulation at failure) and torsional stiffness will be 
calculated. The torsional rigidity will be calculated by using the angulation and torque data to 
define a slope, from which the tangent of the maximal slope for each sample will be used to define 
the torsional stiffness. The mechanical properties of the right femurs will be first compared with 
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their contralateral left femurs to reduce the effect of animal variation in treated groups and then 
compared with the right femurs from the other groups.  
Future work to deliver PLGA microparticles containing RANK siRNA from calcium phosphate 
cement (CPC) in an in vivo rat bone hole osteopenia model.  The potential issue with femoral 
large segmental defect model is that bone defect is generated at the diaphysis which is composed 
largely of cortical bone.  This dense bone may not show significant bone loss in this area during 
experimental period, even after ovariectomization as cancellous bone is the primary issue in 
osteoporosis. Therefore, another rat model with bone defect at a cancellous bone area that can be 
resorbed rapidly is proposed as an alternative. Protocols for preparing ovariectomized rats, animal 
grouping and postsurgery evaluation will be the same as femoral large segmental rat defect 
model. 
Surgical protocol.  The bone mineral density (BMD), CT scans and x-rays of all experimental 
rats’ right femurs will be recorded by DEXA and CT scanner (GE EVS-RS9, Core facility, University 
of Utah) before surgery. The surgical protocol has already been described in detail.20 Rats will be 
anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg) prior to the operation. 
Each rat will receive one cement injection in the right femur. The untreated left femur will be used 
as control. The midline of the rat right knee will be cut, and patella will be lifted. A drill with 1.8 mm 
diameter will be used to remove the medulla ossium from the intercondylar area to expose the 
intertrochanteric area. At the same time, CPC will be prepared. TSK Surecut Biopsy Needles 
(TochigiSeiko, Japan) will be used for injection. After the injection of the cement composite, the 
wound will be closed with sutures. DEXA and CT scan will be performed on the next day of surgery 
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for rats’ implanted femur. Six months after implantation, all rat right femurs will be scanned by 
DEXA and CT again for BMD and sacrificed by CO2 asphyxiation.  Both femurs will be harvested 
and all soft tissues removed. All specimens will be wrapped in saline-saturated filter paper and 
stored in sealed plastic bags at -20oC until testing.  
Animal grouping.  Group sample size was determined from power analysis based on 
torsional strength analyses from a previously study using the same rat model.8 This power 
analysis determined that, with a significant difference of torsional strength between rats without 
treatment and CPC alone-treated groups, and the alpha set at 0.05, 28 animals per group 
provided a power above 80%. An additional 20% increase (5 rats) is included to account for pilot 
studies, inevitable animal loss due to infection, transport and other unforeseen complications. CPC 
without modification will serve as control. 
Anticipated results.  The successful local siRNA bone delivery system is anticipated to show: 
(1) resorption of the CPC matrix, and 2) newly formed bone around the cement implant at 3 or 6 
weeks in siRNA-treated groups. In case of the first model mentioned, a large bone shell forms 
(microCT) to bridge these defects; in contrast, fracture nonunions should be significant in control A 
and B groups, (3) treated groups should show significantly higher BMD and/or bone formation than 
the other groups, (4) a significant resorption of the cement and incorporation of the remaining 
matrix into the bone tissue is expected in both models, (5) a significantly reduced expression of 
RANK and number of osteoclasts should be evident in the periprosthetic areas, and (6) treated 
femurs in treated groups are expected to show a higher maximum torque, failure torque and 
torsional stiffness than the other groups.  Should CPC not provide sufficient dosing or release 
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kinetics in vivo, alternative siRNA injectable carriers will be studied.  
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Abstract 
 Fibrous encapsulation of surgically implanted devices is associated with elevated proliferation 
and activation of fibroblasts in tissues surrounding these implants, frequently causing foreign body 
complications. Here we test the hypothesis that inhibition of the expression of mammalian target of 
rapamycin (mTOR) in fibroblasts can mitigate the soft tissue implant foreign body response by 
suppressing fibrotic responses around implants. In this study, mTOR was knocked down using 
small interfering RNA conjugated with branched cationic polyethylenimine (bPEI) in fibroblastic 
lineage cells in serum-based cell culture as shown by both gene and protein analysis. This mTOR 
knockdown led to an inhibition in fibroblast proliferation by 70% and simultaneous down-regulation 
in the expression of type I collagen in fibroblasts in vitro. These siRNA/bPEI complexes were 
released from poly(ethylene glycol) (PEG)-based hydrogel coatings surrounding model polymer 
implants in a subcutaneous rodent model in vivo. No significant reduction in fibrous capsule 
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thickness and mTOR expression in the foreign body capsules was observed. Observed siRNA 
inefficacy in this in vivo implant model was attributed to siRNA dosing limitations in the gel delivery 
system, and lack of targeting ability of the siRNA complex specifically to fibroblasts. While in vitro 
data supported mTOR knockdown in fibroblast cultures, in vivo siRNA delivery must be further 
improved to produce clinically relevant effects on fibrotic encapsulation around implants. 
Introduction 
 The foreign body reaction (FBR) at the tissue/material interface commonly contributes to 
abnormal inflammation, wound healing responses and tissue fibrosis without effective mitigation.1, 
2
 In general, monocytes/macrophages are activated at implant surfaces and modulate local host 
fibroblast function, contributing to often-excessive deposition of collagen matrix around implanted 
materials (fibrotic capsule), a component of the FBR.1, 3 Recent work 4 demonstrated that 
macrophage fusion observed around implants alone does not necessarily produce implant fibrotic 
encapsulation. Instead, an alternative hypothesis is that fibro-proliferation is regulated by growth 
factors secreted by activated macrophages.3, 5, 6 Fibrogenesis induced by implants is characterized 
by macrophage activation and associated elevated proliferation and activation of fibroblasts that 
up-regulate collagen production. Therefore, control of inflammation around implants by locally 
released drugs to reduce cell activation and limit collagen encapsulation of implanted biomaterials 
has been reported.7-9 
 Mammalian target of rapamycin (mTOR) plays a critical role in cell cycle regulation. 
Rapamycin, a known inhibitor for mTOR,10 can inactivate mTOR specifically. Because mTOR 
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regulates cell proliferation, it has been extensively investigated as a potent target for both 
anticancer 11 and antirestenotic 12 therapies. Inhibition of mTOR in fibroblasts influences not only 
proliferation but also collagen production.13, 14 Rapamycin and its analogues are reported to 
effectively prevent cardiac and pulmonary fibrosis in vivo. 15, 16  These previous reports describing 
modulation of mTOR in fibroblasts indicate that mTOR could also be a potent target to prevent 
implant-induced fibrosis in the context of the FBR.  
 RNAi is a powerful tool to knock down specific mRNA expression levels by exploiting a natural 
intracellular regulatory phenomenon in mammalian species.17-19 Gene silencing using siRNAs has 
many potential therapeutic applications.20 However, RNAi technology has not yet been used 
clinically largely due to challenges in dosing and effective targeted siRNA delivery systems. Local 
or topical siRNA therapeutics have been most actively investigated and successful delivery 
approaches include ocular delivery, respiratory delivery, CNS delivery, skin delivery and vaginal 
delivery where local delivery accesses cell target populations directly.21-25 One unexplored and 
promising delivery route is via combination implantable devices for local drug delivery.26 We 
therefore demonstrate device-based local delivery of siRNA, testing the hypothesis that delivery of 
mTOR siRNA from poly(ethylene glycol) (PEG)-based hydrogel-coated biomaterials can suppress 
collagen encapsulation elicited from a soft tissue implant FBR.  
Materials and Methods 
 Branched polyethylenimine (bPEI) (m.w..: 25,000) and dithiothreitol (DTT) were obtained from 
Sigma-Aldrich (USA). Poly(ethylene glycol) dimethacrylate (PEGDM; m.w.: 7500) was synthesized 
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as reported previously.27 RNase-free water was prepared using diethyl pyrocarbonate (DEPC) 
(Sigma-Aldrich). All siRNA molecules were purchased from Dharmacon (CO, USA).  
Methods 
 Preparation of siRNA/bPEI complexes.  To prepare siRNA/bPEI complexes at various 
anion/cation charge (NP) ratios, 2 µl of 10 µM mTOR siRNA aqueous solution (sense: GCG GAU 
GGC UCC UGA CUA UUU, antisense: AUA GUC AGG AGC CAU CCG CUU) was mixed with 2 µl 
of bPEI solutions of different concentrations (0.016-0.64 µg). The complex mixed solutions were 
kept at room temperature for 20 minutes. Then 4 µl of each mixture was electrophoresed using 
ethidium bromide-stained TBE-based 2% agarose gels run at 80V for 20 minutes, followed by 
visualization with UV light to assess the siRNA-bPEI complex formation. 
 Cell culture and siRNA transfection in vitro.  Murine NIH 3T3 fibroblasts (American Type 
Culture Collection, ATCC) were plated at 3×104 cells/well in a 12-well plate in Dulbecco’s modified 
Eagle’s medium (DMEM, GIBCO) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS, Hyclone®, USA) and 1% penicillin-streptomycin (GIBCO), defined for all cell cultures as 
“complete media”, at 37oC with 5% CO2 overnight. Cell transfections with siRNA/bPEI complexes 
at fixed NP ratios in complete media were performed subsequently. siRNA/bPEI complexes for 
each well are prepared by mixing 7 ul of 20 µM siRNA aqueous solution with 4.48 µl, 2.24 µl, 1.12 
µl and 0 µl (NP 20, 10, 5 and 0) of 1mg/ml bPEI, respectively, in a total volume of 18 µl with 
RNase-free water. After incubation at room temperature for 20 minutes, complete media was 
added to achieve the final volume of 1ml, yielding a final concentration of siRNA in each well of 
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140nM. Cell siRNA transfections were always performed in complete media. After 24 hours 
incubation at 37oC under 5% CO2, culture media was refreshed with 1ml complete media and the 
transfected cells were further incubated.  
 Cell cytotoxicity and proliferation.  3T3 murine fibroblasts were seeded at 3×103 cells/well in 
96-well plates in complete media. After overnight incubation, cells were transfected with mTOR 
siRNA/bPEI complexes at different NP ratios (1, 2, 5, 10, 20 and 40 prepared as described above) 
in complete media, maintaining siRNA concentration at 140nM. Cytotoxicity of the siRNA/bPEI 
complexes was determined at 24 hours after initial transfection using the CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega, USA). Media for each well was replaced with 
100µl fresh complete media containing 20µl of Cell Titer 96 Aqueous One Solution including three 
wells without cells for background subtraction. Cells were then incubated at 37oC for 2 hours and 
optical absorbance at 490nm was then determined using a plate reader (TECAN GENIOS Plus). 
To evaluate mTOR siRNA effects on cell proliferation, cells were plated at 3×104 cells/well in 6-well 
plates and transfected with mTOR siRNA/bPEI complexes at an NP ratio of 20 in complete media. 
Non-targeting siRNA/bPEI complexes with the same NP ratio were used as control. Cultures were 
refreshed with complete media 24 hours later. After incubation at 37oC for 5 days, relative numbers 
of cells in each well were determined using the Cell Proliferation Assay (Promega, USA). CellTiter 
96 solution-containing media was transferred to 96-well plates for optical reading at 490 nm. In 
addition, cultured cells were imaged at Day 5 with phase contrast microscopy prior to this assay. 
 Western immunoblotting.  Cells were lysed by using M-PER Mammalian Protein Extraction 
reagent (Pierce, USA) with 1X HaltTM protease inhibitor cocktail (Pierce). Insoluble material was 
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removed by centrifuging at 15,000 rpm at 4oC for 5 minutes after 20 minutes on ice. Protein 
concentrations were measured with the Bio-Rad protein assay system (Bio-Rad, USA). 
Heat-denatured protein samples (8µg) were separated on 4-12% SDS-polyacrylamide gels 
(Invitrogen) and blotted onto cellulose membranes (Bio-Rad). After blocking with bovine serum 
albumin (BSA) in phosphate-buffered saline containing 0.5% Tween 20 (PBST) for 1 hour at RT, 
the filter was incubated overnight with antibody against murine mTOR (2983, Cell Signaling) in 5% 
BSA/PBST with constant shaking. After three washes with PBST, the membrane was incubated 
with horseradish peroxidase (HRP)-conjugated antirabbit IgG (SA1-200, Affinity BioReagents). 
Housekeeping controls were detected with an antibody against mouse cyclophilin B (PA1-027, 
Affinity BioReagents) and HRP-conjugated antirabbit IgG. Chemiluminescence was produced with 
western blotting luminol reagent (Santa Cruz Biotechnology) and gel images captured using a 
Molecular Imager Gel Doc XR System (Bio-Rad). 
 Reverse transcript polymerase chain reaction (RT-PCR).  Total RNA harvests from 
transfected cells were isolated 48 hours after siRNA transfection using an RNeasy Mini Kit 
(Qiagen). Up to 0.5 µg of RNA was converted to cDNA with the SuperScript III 1st strand RT kit for 
PCR (Invitrogen). PCR primers were designed for mTOR (forward: 5’-AGC GTA TTG TTG AGG 
ACT GGC AGA-3’, reverse: 5’-ATC CTG GAG GTT GTT GCC TCT TGA-3’), cyclophilin B 
(housekeeping control, forward: 5’-GCA ATG GCA AAG GGT TTC TCC ACT-3’, reverse: 5’-AGC 
GCT TCC CAG ATG AGA ACT TCA-3’), and collagen type 1 alpha 1 (COL1A1) (forward: 5’-AAG 
AAT GGC GAT CGT GGT GAG ACT-3’, reverse: 5’-TTG AGT CCG TCT TTG CCA GGA GAA-3’) 
using Primerquest software from Integrated DNA Technologies (IDT, USA). PCR was performed 
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with iTaq DNA polymerase (Bio-Rad), 1.5 mM magnesium chloride, 200 µM each of dNTPs, 500 
nM of each primer, and 2 µl of the cDNA. PCR reaction for mTOR was 95oC for 3 minutes, 
followed by 25 cycles with 95oC for 30 seconds, 63.9oC for 30 seconds, and finally at 72oC for 1 
minute. PCR reactions for cyclophilin B and COL1A1 were 95oC for 3 minutes, followed by 30 
cycles with 95oC for 30 seconds, 60oC for 30 seconds, and finally at 72oC for 1 minute. PCR 
products were collected for all three genes and electrophoresed using ethidium bromide-stained 
TBE-based 2% agarose gels run at 100V for 30 minutes. 
 Preparation of PEG-based hydrogel release matrix and in vitro controlled release of 
siRNA/bPEI complexes to cultured cells.  Crosslinked hydrogels releasing siRNA were prepared 
using PEGDM and DTT at a 1:1 stoichiometric ratio of thiols to acrylates by Michael-type addition 
reactions.28, 29 FITC-labeled siRNA (FITC-siRNA, siGLO® Green, Dharmacon) was used for 
determining siRNA release kinetics from the PEG-based hydrogels. To encapsulate siRNA in the 
hydrogels, 2 µg of siRNA and 4.77 µl of 1 mg/ml bPEI (NP = 20) were mixed first and incubated at 
room temperature for 15 minutes. Volumes of stock solutions equal to either 4.25 or 8.5 mg of 
PEGDM and 0.09 or 0.18 mg of DTT in RNase-free water were added respectively to the 
siRNA/bPEI complex mixtures successively in a circular plastic mold with a parafilm bottom (6 mm) 
diameter. Final polymerization volume was adjusted to 20 µl with RNase-free water. After 5 hours 
incubations at 37oC, the resulting hydrogels were used for releasing study after washes with PBS 
at least three times to remove free siRNA and unreacted reagents.  
 The siRNA-containing hydrogels were immersed in 1ml of PBS buffer for 14 days, and the 
supernatant was collected and refreshed at different time points for fluorescence intensity 
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measurements using a plate reader (TECAN GENIOS Plus, excitation 485 nm/emission 528 nm). 
The standard curve was prepared by using FITC-labeled siRNA PBS solutions (0, 0.0125, 0.25, 
0.5, 1 and 2 µg/ml). 
 To further confirm that siRNA can be released as intact polyplexes, delivery of siRNA/bPEI 
complexes to cells was evaluated by incubating fibroblast cultures with hydrogel-released 
siRNA/bPEI complexes. Hydrogels were incubated in 1ml complete media at 37oC. The complex 
suspension was collected at several time intervals over 15 days. At each sampling time except the 
last one, supernatant (1 ml) was removed and an equivolume of fresh media was replaced for 
continued collection.  Cells were plated at 3×104 cells/well in a 12-well plate and then treated with 
the collected media. Protein harvested 3 days later was followed by Western blotting. 
 In vivo subcutaneous siRNA-releasing device implantation.  All procedures were conducted 
as approved by the Institutional Animal Care and Use Committee of the University of Utah. 
C57/BL-6 female mice (12-week-old, 20-25 g, Jackson Laboratories) were maintained in a 
pathogen-free facility at the University of Utah. Circular Millipore filters (mixed cellulose ester, pore 
size: 0.45 µm, diameter: 4 mm) were coated with siRNA-containing PEG-based hydrogel under 
sterile conditions in a cell culture hood. PEGDM, DTT and siRNA/bPEI were mixed in a circular 
plastic mold with a parafilm bottom (6 mm diameter) and then one filter was placed into the middle 
of the viscous solution. After incubation at 37oC for 5 hours, the resulting hydrogel (6 mm diameter, 
0.7 mm thickness) containing the embedded filter was used for implantation. Mice were 
anesthetized by intraperitoneal injection of ketamine/xylazine mixture (ketamine: 75 mg/kg, 
xylazine: 25 mg/kg). Their backs were shaved and cleaned. Dorsal incisions about 1 cm long were 
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made perpendicularly to the longitudinal axis at the same level as the diaphragm with sterilized 
surgical scissors. Subcutaneous pockets on both sides of the incision were created by blunt 
curved forceps and the hydrogel-coated filters were implanted subcutaneously into the dorsal 
region of mice essentially as described previously.4 Identical filter pieces covered with 
PEG-hydrogel without siRNA were used as negative controls. Hydrogels with siRNAs targeting 
TGF-β1 (sense: GCA ACA ACG CCA UCU AUG AdTdT, antisense: UCA UAG AUG GCG UUG 
UUG CdTdT) were used as positive controls (sequence sourced from Dr. M. Gonzalez-Juarrero, 
Colorado State University, showing significant TGF-β1 knockdown efficacy in a chronic pulmonary 
tuberculosis murine model, unpublished data). Cellulosic (filter paper) circular discs coated with 
polymer hydrogels containing mTOR-specific siRNAs were compared to both controls. For mTOR 
siRNA delivery, two doses, 2 µg and 10 µg per implant, were tested, while a single control TGF-β1 
siRNA dose (10 µg) was used. After implantation, each surgical incision was closed with standard 
4-0 silk sutures. Each mouse received two bilateral implants dorsally of different siRNA doses, 
providing 4 implants per siRNA per dose. All subjects were euthanized after 2 weeks and 
surrounding tissues with implants were harvested by necropsy and fixed in 10% neutralized 
formalin for histological analysis as described below.  
 Histological analyses and immunohistochemistry.  Tissue samples were embedded in 
paraffin and cut into 5 µm sections after 24 hours’ fixation in 10% formalin. Three longitudinal 
ground sections were generated per sample and were stained with Hematoxylin and eosin (H&E) 
for cell nuclei and Masson’s trichrome (MTS) for collagen encapsulation assessments (conducted 
at ARUP, University of Utah).8, 30 Capsule thickness for each section was estimated 
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microscopically as the average thickness at six different random locations, and was determined 
per filter implant as the average thickness of 3 sections per filter explant.  
 Immunohistochemical staining was performed by ARUP Laboratories (Salt Lake City, UT). 
Briefly, slides were cut at 4 µm, then melted at 55oC to 60oC for 30 minutes, deparaffinized and 
rehydrated in graded alcohols (100% × 2, 95% × 2, 70% × 1) for 1 minute each. The following 
steps were performed on the Ventana XT (Ventana Medical Systems, Tucson, AZ) at 37°C.  
Slides were deparaffinized with EZ Prep solution on the XT, and pretreated with CC1 solution for 
30 minutes (TGF beta) or 60 minutes (m-TOR) on the XT. Primary mTOR antibody were applied 
for 2 hours (m-TOR 1:300), followed by the secondary antibody for 32 minutes (antirabbit IgG, 
Sigma 1:100). Detection was done by staining with Alkaline Phosphatase Red, and the 
counterstain was hematoxylin (Ventana) for 4 minutes. Slides were then dehydrated through 
graded alcohols (70% × 1, 95% × 2, 100% × 2) for 30 seconds each, dipped in 4 changes of 
xylene, and covered with a coverslip. Negative controls included sections treated with hydrogel 
without siRNA loading. Microscopic analysis of the FBR was performed independently by two 
investigators who were not aware of the identity of the samples. 
 Cell imaging.  Live adherent cells and histological images were captured using a Nikon 
Eclipse TE 2000-U microscope with Photometrics Coolsnap ES camera (Roper Scientific). 
 Statistical analysis.  ANOVA followed by two-tailed student’s t-test was used to evaluate 
significant differences among groups. All in vitro experiments were repeated three times. Error 




In vitro experimental data 
 Optimization of mTOR siRNA/bPEI complexes and their cytotoxicity.  To determine the NP 
threshold for stable siRNA complex formation, different amounts of bPEI were mixed with 0.14 
nmol mTOR siRNA at NP ratios of 0, 0.5, 1, 2, 5, 10 and 20. Figure 6.1a shows migration of 
siRNA/bPEI complexes by gel electrophoresis. With NP ratios of 0, 0.5 and 1, siRNA bands 
migrate separately on the gel, indicating uncomplexed excess siRNA. When the NP ratio is equal 
to 2, the density of the siRNA band is substantially weaker. When the NP ratios are ≥ 5, no siRNA 
migrates freely in the gel, indicating that all siRNA molecules are initially entrapped in bPEI 
complexes through electrostatic interactions. Therefore, the complex at NP > 5 should be 
appropriate for siRNA transfection. 
 
 
Figure 6.1. Gel migration and cytotoxicity assays of mTOR siRNA/bPEI complexes. (a) 
Gel migration of mTOR siRNA/bPEI complexes at different NP ratios (1-40). (b) Cell 
cytotoxicity of mTOR siRNA/bPEI complexes in 3T3 fibroblast in serum-based media. Assay 
was performed 24 hours posttransfection. (*p=0.0004, compared with cultures without 
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 Cytotoxicity from the siRNA complexes in serum-cultured fibroblasts in vitro was compared 
among the different NP ratios (NP = 0-40). As shown in Figure 6.1b, compared with cells without 
any treatment, cytotoxicity of the siRNA complexes is negligible when NP ratios are at or less than 
20 (p = 0.18). In addition, there is no significant difference among the groups for NP ratios ≤ 20. 
 In vitro mTOR knockdown by siRNA/bPEI complexes on fibroblast cultures.  3T3 Fibroblasts 
transfected with siRNA/bPEI complexes of different NP ratios (0, 5, 10 and 20) were assayed for 
mTOR expression. Total protein was harvested 3 days after siRNA treatment. Western blot results 
showed significant reductions of mTOR expression by siRNA when the NP ratio was 20 (Figure 
6.2a). Furthermore, an NP ratio of 20 is sufficient to knock down mTOR expression in fibroblasts in 
vitro using serum-based transfections. Therefore, the effect of mTOR siRNA/bPEI complexes on 
cellular mTOR gene expression was only evaluated by RT-PCR for NP = 20. Non-targeting 
 
 
Figure 6.2. RNA message knockdown in 3T3 fibroblast cultures in serum-based media. 
(a) Western blot analysis for mTOR expression after mTOR siRNA/bPEI exposure. Cellular 
mRNA levels of (b) mTOR and (c) COL1A1 in cells treated with non-targeting siRNA (control) 
and mTOR siRNA/bPEI complexes were analyzed by RT-PCR. Cyclophilin B (housekeeping 
gene) mRNA was used as a control. 
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siRNA/bPEI complexes with the same NP ratio were used as controls. Compared to controls, 
mTOR siRNA complexed with bPEI reduces mTOR mRNA expression dramatically (Figure 6.2b) 
in 3T3 fibroblast cultures in vitro.  
 Since mTOR positively regulates collagen type I production,13 COL1A1 mRNA levels were 
also assayed after mTOR siRNA transfection. Compared with non-targeting siRNA transfection, 
COL1A1 mRNA levels were significantly suppressed by mTOR siRNA treatment in vitro (Figure 
6.2c). 
 Cell proliferation assays were performed 5 days after siRNA transfections in serum-based 
cultures. As shown in Figure 6.3c, cell numbers in mTOR siRNA groups under NP ratio 20 are 
much less than that for control siRNA transfection groups (<30%, *p = 0.028). Its representative 
microscopic images of fibroblasts for control (Figure 6.3a) and treated (Figure 6.3b) groups also 
demonstrate significant differences in cell density. PEG-based hydrogels were made with 
published methods 29 by reacting aqueous solutions of PEGDM and DTT. Within a 20 µl total 
 
Figure 6.3. Microscopic images of fibroblast serum-based cultures (a) treated with 
non-targeting siRNA, (b) mTOR siRNA at NP ratio 20, and (c) cell proliferation in the 
siRNA-treated cells (NP 20, *p = 0.028), scale bar = 250µm. Images were taken 5 days after 
siRNA transfection. Numbers of cells treated with non-targeting siRNA was normalized to 100%.  
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reaction volume and an NP ratio of siRNA/bPEI equal to 20, 10 µg of siRNA is found to be the 
maximum loading for successful in situ gelation with Michael addition network chemistry. Release 
profiles for siRNA within the PEG-based hydrogels for two different siRNA/PEG gel formulations 
were analyzed (Figure 6.4a). In Formulation 1 (PEGDM: 4.25 mg, DTT: 0.09 mg), approximately 
50% of the siRNA was released from the gel within the first 24 hours incubation, and 80% of the 
siRNA was released within 3 days. In Formulation 2 (PEGDM: 8.5 mg, DTT: 0.18 mg), 
approximately 80% of the siRNA was released by day 7.  A prolonged protein knockdown effect 
 
 
Figure 6.4. Release of siRNA/bPEI complex from PEG-based hydrogels in vitro. (a) Cumulative 
siRNA release profiles in PBS media sink conditions. NP ratio of the siRNA/bPEI complex was 20. 
Release profiles in Formulation 1 (PEGDM: 4.25mg, DTT: 0.09mg) and Formulation 2 (PEGDM: 
8.5mg, DTT: 0.18mg) are indicated by the solid line and dash-dotted line, respectively. (b) Western 
blot analysis for mTOR expression in fibroblasts after incubating cells with hydrogel-released 
siRNA/bPEI complexes. Cell lysis was harvested after 3-day culture in this media. Numbers of days 
shown reflect the hydrogel release time prior to media collection and cell culture. 
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(up to 1 week) was also obtained by siRNA Formulation 2 compared with Formulation 1 (3 days), 
which was also supported by Western blot results (Figure 6.4b). Formulation 2 provides longer 
sustained release kinetics and protein expression suppression, and therefore was used for gel 
preparations for in vivo studies in subdermal implant-based siRNA release in mice. Tissue 
harvests surrounding hydrogel-coated filter implants were stained with MTC to identify collagen 
capsules (blue color). Collagen capsule thicknesses were calculated and compared among 
negative controls (hydrogels without siRNA: 71.95 ± 7.39 µm), positive controls (hydrogels loaded 
with TGF β1-specific siRNA: 66.82 ± 10.46 µm) and treated groups (hydrogels loaded with 
mTOR-specific siRNA: 2 µg dose, 96.60 ± 19.80 µm; 10µg dose, 63.22 ± 5.95 µm). Collagen 
capsule structure and thickness were evaluated from microscopic images (see Figure 6.5, foreign 
 
Figure 6.5. Comparison of in vivo collagen capsule thickness for murine subdermal 
hydrogel-coated implants explanted after 2 weeks for (a) negative control, no siRNA loaded, 
(b) 2µg mTOR siRNA loaded, (c) 10µg mTOR siRNA loaded and (d) positive control, 10 µg TGF-β 
siRNA loaded. Localization of fibrous capsule is marked by white arrows (scale bar = 100µm). (e) 
Summary of collagen capsule thickness data. P values for each individual group vs. negative 
control without siRNA treatment are: 0.3112 (2µg mTOR siRNA), 0.3954 (10µg mTOR siRNA), 
and 0.7045 (10µg TGF-β siRNA).  
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body capsules are demarcated with arrows). However, no significant difference in capsule 
thickness or structure between these three groups was evident. In addition, H&E staining images 
indicate that mTOR siRNA does not significantly influence fibroblast density around these implants. 
To further investigate whether mTOR inhibition modulates the fibrotic response, tissue mTOR 
expression was evaluated by immunohistochemistry. Immunostaining of mTOR in tissues adjacent 
to the capsule (2 µg and 10 µg siRNA dosing cohorts) indicated no significant differences in mTOR 
expression in foreign body capsules between siRNA-treated mice and the mice treated with blank 
gel.  As shown in Figure 6.6, foreign body capsules contain fibroblasts, inflammatory cells and 
ECM. After 2-week implantations, no significant foreign body giant cells (FBGC) are observed 
around the implants. Numbers of macrophages were recruited to the interface, but there were no 
significant differences in numbers of macrophages around the implants among the groups. 
Therefore, despite in vitro knockdown success, it was concluded that mTOR siRNA treatments 
produced no significant reductions in FBR capsule thickness and protein knockdown in vivo.  
 
 
Figure 6.6 Immunostains of mTOR protein expression in foreign body capsules from 
murine histological sections. Tissue samples surrounding implants (I) were harvested from 
mice 2-week postimplantation. Immunohistochemical staining for mTOR in foreign body capsules 
around filter paper from (a) negative control group (no siRNA loaded), (b) 2µg mTOR 
siRNA-treated group, and (c) 10µg mTOR siRNA-treated group. Sections were stained with 
mTOR antibody, and counterstaining was done with hematoxylin. These treatments stain target 
proteins red and cell nuclei dark (blue). Arrows denote fibroblasts (scale bar = 125µm). 
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Discussion 
 siRNA is of substantial current interest as a sequence-specific posttranscriptional gene 
silencing tool for the genetic analysis and, significantly, for translational, therapeutic applications in 
various mammalian cells.31, 32 In order to overcome several delivery challenges for siRNA in 
therapeutics, several approaches have been used, including conjugating siRNA with cholesterol 33, 
and delivery using cationic liposomes 34 and polymer carriers.35 Some have also been successfully 
utilized for systemic siRNA delivery in mice.34, 36 Viral vectors have been described for siRNA 
delivery as well.37-39 Nevertheless, overcoming viral vector oncogenicity and immunogenicity 
remains a significant barrier for viral-based siRNA delivery. In general, efficiently targeting siRNA 
to systemic disease sites remains a significant problem. To overcome this, lipid or polymer-based 
siRNA delivery systems have been successfully used for local siRNA (e.g., topical) delivery, 
particularly to ophthalmic, vaginal, dermal, liver, neural, pulmonary and tumor targets.21, 23-25, 40-44 
Therefore, locally delivered siRNA from the surface of implantable subcutaneous devices was 
assessed for efficacy in targeting a major clinical complication of the foreign body response – 
implant-associated fibrosis. 
 To facilitate released siRNA internalization by mammalian cells in serum, mTOR siRNA was 
complexed with bPEI at different NP ratios (0-20) because of its known utility as a nonviral nucleic 
acid delivery vector.45-47 The siRNA/bPEI migration assay (Figure 6.1a) demonstrates that siRNA 
forms stable complexes with bPEI when the NP ratio ≥ 5. Cytotoxicity from siRNA complexes was 
analyzed by culturing fibroblasts with siRNA complexes with different NP ratios up to 40 in serum 
complete media. Significant cytotoxicity was observed only when the NP ratio approached 40. 
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Taken together, these results indicate that siRNA/bPEI complexes can be used for specific 
suppression of mTOR expression in fibroblast serum-based cultures for NP ratios from 5 to 20. 
 Transfection of mTOR siRNA in 3T3 fibroblasts in serum-based cultures produced mTOR 
gene silencing monitored by Western blotting 3 days posttransfection. Knockdown of mTOR 
occurs only when the NP ratio was 20, indicating that siRNA specifically knocked down mTOR 
message RNA in fibroblasts. To further exclude the possibility of nonspecific knockdown of mTOR 
by the transfection reagent (bPEI), target gene expression was compared between non-targeting 
siRNA and mTOR siRNA in cells. Compared to non-targeting siRNA complexes, mTOR siRNA 
complexes reduced mTOR mRNA expression in fibroblasts dramatically as shown in Figure 6.2b. 
Thus, these data confirm that mTOR siRNA suppressed the targeted gene specifically through the 
RNAi mechanism.  
 In previous studies, mTOR was demonstrated to be essential for activating expression of the 
collagen type I gene (COL1A1) in dermal fibroblasts.13, 48 A dramatic decrease (75%) in COL1A1 
mRNA expression was induced by down-regulating mTOR expression level to 56%.13 Hence, it is 
not surprising that mTOR siRNA also down-regulates COL1A1 mRNA expression by decreasing 
mTOR expression (Figure 6.2c). This supports the hypothesis that collagen production by 
fibroblasts would be blocked by mTOR siRNA transfection. 
 A significant role for mTOR is also promoting cell growth and proliferation by regulating 
protein synthesis. 49, 50 It is therefore conceivable that mTOR knockdown may also control or alter 
cell proliferation to some extent. Suppression of cell proliferation is shown after fibroblast 
transfection with mTOR siRNA in cultures (Figure 6.3). Nearly 70% decrease in cell number after 
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mTOR siRNA treatment is observed compared to non-targeting siRNA transfections, supporting 
that mTOR function specifically, not cytotoxicity, was successfully suppressed by the specific 
siRNA delivery to fibroblast cultures in serum. 
 These in vitro findings support siRNA targeting of mTOR to modulate collagen production and 
implant encapsulation, analogous to rapamycin’s use against mTOR as an antifibrotic agent.51-54 
To move this in vivo, a local delivery strategy using release from an implant surface as a 
combination device model was used. PEG-based hydrogels were exploited for this in vivo delivery 
system since the Michael addition chemistry in water allows mild in situ polymerization at 
physiological temperatures and pH in the presence of siRNA/bPEI complexes, control of both 
loading and release rates, and in situ polymerization on or around an implant.28, 29 To facilitate 
siRNA entry into cells,  bPEI is used as a known complexing agent for nucleic acid delivery.45, 46 
SiRNA/bPEI complexes were loaded into and released from the swollen and degrading 
PEG-based hydrogel networks. Two different siRNA diffusion profiles were obtained from PEG 
hydrogels of two formulations, showing that encapsulated siRNA dosing release depends on 
hydrogel cross-linking. The higher cross-linked PEG hydrogels showed sustained release of 
siRNA to 14 days in vitro (Figure 6.4a). In addition, the sustained siRNA release resulted in 
prolonged protein knock-down to 7 days. Furthermore, this successful knockdown confirms that 
the released siRNA is active and complexed with PEI. Therefore, siRNA formulation 2 was 
selected for our in vivo studies.  
 Since encapsulated siRNA molecules exhibit both sustained release from PEG-based 
hydrogels and effective mTOR and collagen knockdown in the presence of serum in vitro, the 
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siRNA hydrogels were applied to a model soft tissue implant to reduce collagen expression and 
fibroblast proliferation in the context of the FBR. Based on in vitro release data showing complete 
siRNA release after 2 weeks, implants were harvested 2 weeks postsurgery. The thickness of the 
collagen fibrous capsule was evaluated for model circular membrane devices coated with PEG 
hydrogels in mice. As shown in Figure 6.5, no significant differences in collagen capsule formation 
were found among the three groups. Compared to negative controls, both mTOR and control 
TGF-β siRNA-releasing material groups exhibited no detectable antifibrotic activity in vivo. The 
capsule thickness for negative control groups is comparable to the published data for the same 
cellulose implants harvested 4 weeks postsurgery in the same animal model, (i.e., 63 ± 25µm in 
Ref 4, and 79 ± 40µm in Ref 55). Previous studies have demonstrated that TGF-β is a potent target 
for antifibrotic therapy. 56-59 These studies show antifibrotic efficacy of TGF-β siRNA to prevent 
fibrosis in vivo using different delivery systems. However, TGF-β siRNA showed no detectable 
antifibrotic activity as collagen capsule thickness was unaffected by the TGF-β siRNA in the 
murine implant model. Possible explanations for these nondistinguishing results include 
insufficient siRNA dosing, inefficient cellular uptake by the target fibroblasts around the implant 
and siRNA scavenging by cells other than fibroblasts at the implant site. A limitation of this design 
is that PEG hydrogel gelation is inhibited when siRNA complex loading exceeds 10µg per 
polymerization. siRNA device-based dose loading cannot be increased in this formulation to 
address the dosing issue in vivo. Effective gene silencing dose of siRNA in many applications in 
vivo is 1-2.5mg/kg.21 Here, our study administered 0.4~0.5mg/kg. Thus, inefficient silencing 
produced by the siRNA was due partially to low dosing.  As bPEI also has mild nucleophilicity and 
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some Michael addition capability with PEG acrylate,60 increasing bPEI concentrations in the 
gelation step could alter polymerization and also affect bPEI participation as a cell transfection 
agent.  
 In situ tissue slice histology immunostaining for mTOR protein was performed to monitor in 
vivo knockdown effects. In both 10µg and 2µg mTOR siRNA dose-treated groups, siRNA 
treatment is unable to inhibit mTOR protein expression in the capsule. Therefore, similar capsule 
thickness results from unchanged mTOR expression level in fibroblasts. For subcutaneous filter 
paper implantation in our case, FBGCs were difficult to find at the implant interface with tissue 
2-week postimplantation. Plenty of macrophages were recruited to the interface. However, there is 
no significant difference of the number of macrophages at the implant and capsule interface 
between siRNA treated groups and controls. Immunoreactivity appears comparable in all groups 
and the addition of siRNA does not elicit significant changes in the FBR. In the early stage of the 
FBR, macrophages recruited to the implant site fuse to form FBGCs. They adhere to the surface of 
the hydrogel-coated implant and release several chemicals that affect the implant surface. In this 
microenvironment, the hydrogel was also susceptible to degradation. Some fraction of siRNA/PEI 
complexes are likely taken up by active capsule-associated cell endo- and phagocytosis 
mechanisms, followed by their degradation in phagolysosomes where pH remains as low as 4.61 
Hydrogel-released siRNA/PEI complexes escaping active cell phagocytosis must penetrate the 
dense tissue extracellular matrix in the capsule to approach and enter target cells and then 
successfully escape endosomes to produce siRNA bioactivity.  Hence, despite local siRNA 
dosing and direct release into the fibrous implant-associated capsule, siRNA polyplex dosing has 
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low percentage success in producing efficacy for mTOR knockdown in vivo. The apparent 
absence of protein knockdown in vivo is a testimony to the difficulty in getting sufficient siRNA from 
the implant to nearby fibroblast cells in the capsule. For device-based local siRNA delivery, the 
drug release system must overcome nonspecific macrophage/FBGC capture and degradation, 
unless these cells are specific targets for therapies. Therefore, device-based local siRNA delivery 
seeking to target collagen-producing local fibroblasts, but lacking specific cell-targeting features for 
fibroblasts, exhibits poor in vivo subcutaneous performance despite promising in vitro knockdown 
and antiproliferative efficacy in serum-based fibroblast monocultures. 
Conclusions 
 In vitro cell culture results support siRNA targeting of mTOR to effectively suppress fibroblast 
proliferation and down-regulate type I collagen mRNA expression in serum-based fibroblast 
cultures. Thus, like commonly studied rapamycin, mTOR-targeted siRNA was expected to inhibit 
fibrotic responses around implants in vivo. Nonetheless, subcutaneous in vivo results 
demonstrated little translation of in vitro siRNA activity to alter implant-associated fibrous 
encapsulation using a PEG-based hydrogel-coated implant releasing mTOR siRNA in a murine 
subcutaneous implant model. Though mTOR remains a potent and attractive target for this 
therapeutic purpose, and local device-based delivery is attractive for combination device local 
siRNA delivery, further studies are warranted to improve in vivo efficacy in this application.  These 
include new in vivo siRNA delivery systems, improvements in siRNA cell transfection efficacy, 
degradation-resistant siRNA chemistries, and specific siRNA targeting to fibroblasts under 
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physiological conditions and foreign body responses. 
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STANDARD OPERATING PROCEDURES 
1. PRIMARY OSTEOCLAST DIFFERENTIATION 
Components: Mice, Tissue culture hood, Dissection kit (2 pairs of tweezers and a pair of scissors), 
α-MEM, Ice bucket, 26 gauge needles (All cell culture reagents and tools should be sterilized 
before placing them into the hood or incubator!!!!  All steps should be performed using sterile 
technique!!!!  If you don’t know sterile technique, find someone who does to show you before 
attempting) 
At animal facility: Sacrifice mice 
a. Turn CO2 on low to fill chamber, let run for at least 5 minutes. 
b. Turn CO2 off and let gas sink to bottom of tank for about 5 minutes.  This creates a 1-2 inch 
layer of 95% CO2, and will allow for faster, more humane killing of the mice. 
c. Gently add mice to tank, trying not to disrupt air too much (so the 95% CO2 layer remains 
intact). 
d. Leave mice in tank for at least 2 minutes to ensure that they are all dead. 
e. Bring mice to our lab 
Dissect out femurs and tibias 
a. Place mouse on dissection board on paper towel and soak both with 70% ethanol. 
b. Use tweezers to grab “hands” and pin them to the board so the mouse can be stretched out. 
c. Pick up abdominal skin with tweezers and make a small incision with the scissors, be careful 
not to cut through the abdominal muscles as that will expose more of the mouse than you will 
wish to see. 
d. Use tweezers to gently tear abdominal skin and reveal the lower half of the abdomen. 
e. Remove skin from legs using your fingers, as if “taking off his pants.”   
f. Dislocate the hip and knee by pulling at the ankle while immobilizing the hip. If necessary, 
bend the knee backwards to dislocate (often necessary on older mice). 
g. In younger mice, the femur will “pop” through the muscle if you pull down on the shin while 
pushing up on the thigh.  Remove femur, then clip off foot and tease muscle off of tibia.  In 
older mice, this will not happen.  Clip off foot and tease muscle away from tibia, you may 
need to cut at the knee to remove.  Then use scissors and tweezers to tease away muscle 
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from femur, clip out once you can see the ball of the femur.  Remove as much excess muscle 
as possible and store all bones in incomplete ice cold α-MEM.   
h. Mouse carcasses should be wrapped in a black plastic bag and placed in the necropsy 
freezer located at the far south end of the basement. 
Flush bone marrow cells out of femurs and tibias 
a. Transfer all bones into a Petri dish containing ice cold incomplete α-MEM. 
b. Use tweezers to clean off all bones of excess muscle. 
c. Hold a bone with tweezers, use scissors to clip ends. 
d. Using a 10mL syringe filled with ice cold incomplete α-MEM and a 26 gauge needle, hold 
bone vertically over a 50mL tube and flush marrow out of bones (5~10ml/bone).  Use about 
5mL per bone, and flush from both sides.   
e. Resuspend bone marrow cells using a 5mL pipette, mix at least 20 times with pipette.   
f. Spin down cells at 500g 5minutes. 
g. Resuspend bone marrow cells in α-MEM and plate in 10cm-dish over night.  We usually 
resuspend cells to be at a concentration of 107 cells per mL prior to plating.   
h. Harvest flowing cells the next day. Spin down cells and resuspend cells in complete α-MEM 
with 20ng/ml M-CSF. Seed cells at 1.2 x 106/well into 24-well plate. 
i. Two days later, renew the media with complete α-MEM with 20ng/ml M-CSF and 200ng/ml 
RANKL. The media should be replaced every other day. 
 
Container   Volume  Number of cells 
T-175    50mL   10 x 107 
T-125 flask   35mL    5 x 107 
100mm Petri dish  10mL       107 
6-well plate   4mL        3 x 106 
12-well plate   2mL        2 x 106 
24-well plate   1mL        1 x 106 
 
2. RANKL EXPRESSION 
Components: 
a. Autoclave the 2L flask with LB media (without Amp). Each flask contains 400ml LB (each flask 
contains 10g LB powder).  
After autoclave, prepare AMP solution (water): weight 40mg AMP powder dissolves in 1ml pure 
water (di water + autoclave). Add 0.5ml to each 2L flask. 
b. Using lysis buffer equilibrium the column, which keeps in 4oC. Wash 2.7 ml of the 
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glutathione-Sepharose (from Amersham Pharmacia, Cat. 17-0756-01; in a 75% slurry) with water 
to remove the ethanol, then twice in lysis buffer. Resuspend the Sepharose in 4 ml of lysis buffer, 
and pack the column (Bio-Rad Poly-Prep; 0.8 x 4 cm; #731-1550). 
Bacterial lysates 
a. Start two 3 ml culture (small glass tubes) of the 1~2 GST-OPGL clones in the early morning. 
Grow at 30oC in LBamp, 230rmp. In the evening, add each of them to 400 ml LB-amp 
separately, and grow O/N at 30.4oC. 
b. Next early morning, induce the culture with the addition of 1 mM IPTG for 4 hours. (Prepare 
IPTG right before using: 0.2g into 1ml of water, and 0.5ml into each big flask)  
c. Pellet the cells (7000rpm/6300g, 20 minutes), throw away the supernatant. (The pellet may 
be frozen at -70oC for an extended period of time). Transfer the pellet to the 50ml Nalgene 
high speed centrifuge tube (05-529-1D). 
d. Resuspension the pellet once in 10ml lysis buffer (20 mM Tris pH 8.0; 150 mM NaCl; 1 mM 
EDTA + protease inhibitor cocktail, Pierce). Using spoon to help the dissolving/lysis process 
until all pellet resuspended uniformly.  
e. Centrifuge at 7000 rpm for 20 minutes. Re-suspend the pellet in 10ml of the same buffer. 
Again, using spoon to help dissolving process. 
f. Add lysozyme (10mg dissolved in 0.5ml pure water, prepare right before use) to a final 
concentration of 1 mg/ml, and 10ul of 500mM MgCl2 (1ul/ml), mix up and down gently, and let 
sit at RT for 15 minutes. 
g. Add 100ul Triton X-100 to a final concentration of 1%. Sonicate 1.5 minutes, 30 seconds each 
time, resting 10~20 seconds between, on ice (low setting-be careful not to generate froth). 
Add 10ul DNAase I (keep in the blue rack in -20oC) to a final concentration of 10 ug/ml. Leave 
on ice for 20-30 minutes. 
h. Spin at 14,000-20,000rpm/25100-51300g for 20 minutes at 4oC and save the supernatant. 
The sup should be yellow, not clear. If it is clear, lysis was not complete. Load the entire sup 
on the top of the column, seal the column top and bottom with paraframe tightly. Rolling the 
column on the shaker in the refrigerator in chemical site O/N. Or the sup can be save O/N at 
4oC. 
Glutathione column 
a. Wash the column with 2 x 10 ml of lysis buffer. 
b. Wash the column with 2 x 10 ml of lysis buffer that lacks NaCl (20 mM Tris pH 
c. 8.0, 1 mM EDTA).Using the blue color reagent (5X dilution before using) to check whether 
there is still protein in the flow through (If solution change to blue, means there is protein). If 
not, start elution. 
d. Prepare reduced glutathione washing buffer: 30.7 mg reduced glutathione dissolve in 10ml 
lysis buffer with lacking NaCl. 
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e. Add 4 ml of fresh (or frozen) 10 mM reduced glutathione (Sigma, Cat. No is G-4251) in 20 mM 
Tris pH 8.0, 1 mM EDTA to column. Cap the column, and leave it rocking O/N in cold room or 
rolling for 2 hours in 4oC. 
f. To elute, let the column sit at RT for 10 minutes first! Then collect 2 ml fractions by gravity 
flow. After that collect next 2 ml. During this process, use the blue color reagent (5X dilution 
before use) checking the protein containing amount. 
g. Add 2 more ml of the elution buffer. Collect flow through total reach to 5~6ml. 
h. Using Millipore concentration tubes to concentrate and desalting. First pour all flow through in 
the tube, centrifuge at highest speed for 20 minutes. Then after finishing, add 2ml of pure 
water to the tube, centrifuge again. At last, after finishing, add 2ml of PBS with 0.1% sodium 
azide again. After finishing this time, collect the concentrated sample (be careful do not tough 
the membrane).  
i. Using pure water clean the concentrated tube and pour 20% ethanol into the tube which can 
totally immerse the membrane. 
j. Please follow Amersham Pharmacia’s instruction to clean and store the column. 
k. Measure protein concentration. 
Buffers: 
For 500 ml lysis buffer (20 mM Tris pH 8.0; 150 mM NaCl; 1 mM EDTA)-- 
10 ml 1 M Tris pH 8.0 
15 ml 5 M NaCl 
1 ml 0.5 M EDTA 
For 200 ml lysis buffer lacking NaCl— 
4 ml 1 M Tris pH 8.0 
0.4 ml 0.5 M EDTA 
3. PLGA PARTICLE PREPARATION 
Components: prepare everything in RNase-free environment 
a) siRNA/bPEI solution in 160 ul Rnase-free buffer 
b) PLGA solution: dissolve 50 mg PLGA polymer (-20C freezer) into 2 ml methylene chloride 
(CH2Cl2) in a glass test tube. Wrap with foil paper and parafilm to prevent evaporation. Takes 
overnight to dissolve; also, methylene chloride evaporates quickly so on day of use, add 
additional methylene chloride if needed. 
c) Polyvinyl alcohol (PVA) solution: 5% stock PVA solution stored in 4oC fridge. Dilute to 4% 
before use. 
Supplies: Beaker, magnetic stirrer, stir bar, vortex mixer and sonicator, glass culture tubes, ice 
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a. Add 160 ul siRNA/bPEI solution into 2 ml PLGA solution in CH2Cl2 drop-wise while vortexing 
and sonicate for 10 seconds at 10% output. Pause 10 seconds. Repeat sonication. This is 
emulsion 1. 
b. (Add 2 ml 4% PVA drop-wise and slowly while vortexing. Sonicate for 10 seconds at 20% 
power output. Pause 10 seconds. Repeat sonication. This is emulsion 2 (this step is to make 
the PLGA solution easier to pour from the glass tube without losing PLGA polymer).) 
c. Pour emulsion 2 into 6 ml 4% PVA in a 50 ml falcon tube while vortexing.  (Sonicate for 10 
seconds at output 7. Pause 10 seconds. Repeat sonication. This is emulsion 3.) 
d. Pour emulsion 3 to 4 ml 0.06% PVA solution in a glass beaker while stirring.  
e. Stir for 3-4 hours to completely evaporate methylene chloride and allow PLGA particles to 
harden. 
f. Collect particles and aliquot 1 ml into centrifuge tubes. But be sure to write the total volume 
and aliquot volume. Store the aliquots at -20 or -80 freezer. 
g. Wash the particles 3 times with cold Milli-Q water for further analysis. 
h. Perform steps shown in the parentheses can generate nanoscale particles 
i. SEM preparation is subjected to different equipments. Dilute concentrated sample 100 times 
and dry 1~2 sample drops on the sample presenting matrix in the hood overnight. 
4. PLGA/CPC PREPARATION 
Components: Dried PLGA particles in powder, calcium phosphate cement (CPC) kit (BioMed) 
Mixing 
a. Add aqueous solution provided in the kit into a syringe at 0.35 g/ml of the PLGA/CPC. 
b. Add weight percentage of 10% or 20% PLGA particles into CPC powder. Mix two powder 
using spoon provided in the kit and vertex. Transfer the mixture into the syringe. 
c. Use spoon help dissolving process for 1minute. 
d. Inject the mixture into mode provided in the kit. 
e. The sitting reaction lasts 20 minutes. Be sure finishing injection within 15 minutes. 
